≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Small cell lung cancer

DOID Endpoint Browser

C3_SCLC

non-small cell lung carcinoma: A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

  • HLP_C3_SCLC
1134

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cause of death: ICD-10 — C34
  • Cause of death: ICD-9 — 162
  • Cause of death: ICD-8 — 162
  • Cancer registry: Topography ICD-O-3 — C34
  • Cancer registry: Morphology ICD-O-3 — 8041
  • Cancer registry: Behaviour codes — 3

2 out of 7 registries used, show all original rules.

1134

4. Check minimum number of events

None

1134

5. Include endpoints

1134

6. Filter based on genotype QC (FinnGen only)

1098

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE
Control conditions
not HLP_C3_SCLC

Extra metadata

Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF8

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 1098 270 828
Unadjusted period prevalence (%) 0.31 0.10 0.38
Median age at first event (years) 70.99 69.12 71.61

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
1134
Matched controls
11340
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L01CB01
ATC
etoposide; systemic
+∞
307.7
314
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
16.8
307.7
456
437
C34.16
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary microcellular carcinoma
+∞
307.7
337
*
8041/3-C34.9
ICD-O-3
Small cell carcinoma, NOS, of lung, NOS
+∞
307.7
697
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
12.0
307.7
459
606
A04AA01
ATC
ondansetron; systemic, rectal
49.0
307.7
293
80
C34.1
ICD-10 Finland
Malignant neoplasm: Upper lobe, bronchus or lung
+∞
307.7
310
*
A03FA01
ATC
metoclopramide; systemic, rectal
19.1
307.7
604
638
130
Kela drug reimbursment
Malignant tumour
+∞
307.7
647
*
H02AB02
ATC
dexamethasone; systemic
161.5
307.7
489
53
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
58.1
307.7
278
63
Z51.5
ICD-10 Finland
Palliative care
14.3
303.2
314
296
C34.86
ICD-10 Finland
Malignant overall tumor of bronchial and pulmonary microcellular carcinoma
+∞
287.0
263
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
2786.4
253.9
236
*
C34.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bronchus and lung
+∞
248.3
229
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
2576.2
238.1
222
*
8041/3-C34.1
ICD-O-3
Small cell carcinoma, NOS, of upper lobe, lung
+∞
217.9
202
*
C34.36
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung microcellular carcinoma
+∞
210.1
195
*
C34.3
ICD-10 Finland
Malignant neoplasm: Lower lobe, bronchus or lung
+∞
191.2
178
*
XX3DW
NOMESCO Finland
Time consuming IT work
12.5
188.0
200
191
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
169.1
158
*
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
27.6
159.1
110
44
N02AA05
ATC
oxycodone; systemic
5.5
158.2
415
1071
C34.9
ICD-10 Finland
Malignant neoplasm: Bronchus or lung, unspecified
1757.0
158.2
150
*
C34.90
ICD-10 Finland
Malignant tumor in unspecified location in bronchus and lung without histology
+∞
154.8
145
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
391.2
141.2
139
*
A04AA02
ATC
granisetron; systemic, transdermal
743.7
136.7
132
*
8041/3-C34.3
ICD-O-3
Small cell carcinoma, NOS, of lower lobe, lung
+∞
135.2
127
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
134.1
126
*
WF002
NOMESCO Finland
Radical radiotherapy
250.8
132.0
133
6
C34.96
ICD-10 Finland
Malignant tumor in unspecified localization in bronchial and pulmonary microcellular carcinoma
+∞
130.8
123
*
L03AA13
ATC
pegfilgrastim; parenteral
667.8
123.8
120
*
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
+∞
123.2
116
*
JN4AD
NOMESCO Finland
Body CT examination
7.1
121.5
203
336
JN4BD
NOMESCO Finland
Extensive body CT
8.2
112.8
161
223
C34.06
ICD-10 Finland
Malignant tumor of the main bronchial microcellular carcinoma
+∞
110.2
104
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
9.4
97.5
122
143
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
998.7
95.4
92
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
986.9
94.3
91
*
C34.99
ICD-10 Finland
Malignant tumor in unspecified localization in bronchial and pulmonary other or unspecified histology
+∞
94.1
89
*
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
51.5
93.4
54
11
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
93.0
88
*
C34.0
ICD-10 Finland
Malignant neoplasm: Main bronchus
+∞
93.0
88
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
93.0
88
*
C34.10
ICD-10 Finland
Malignant tumor of the upper lobe, bronchus or lung without histology
+∞
89.8
85
*
GD5AD
NOMESCO Finland
Thorax and upper abdomen combined CT examination of
17.5
79.4
66
40
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
+∞
75.9
72
*
C34.80
ICD-10 Finland
Malignant overall tumor of bronchus and lung without histology
+∞
70.6
67
*
AA1BD
NOMESCO Finland
Extensive CT of head and brain
12.1
70.4
72
63
C34.19
ICD-10 Finland
Malignant tumor of the upper lobe, bronchus or lung other or unspecified histology
+∞
66.3
63
*
XGX32
NOMESCO Finland
Bronchoscopic ultrasonography
104.9
63.6
69
7
C34.00
ICD-10 Finland
Malignant tumor of the main bronchus without histology
+∞
62.0
59
*
C34.30
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung without histology
+∞
61.0
58
*
8041/3-C34.0
ICD-O-3
Small cell carcinoma, NOS, of main bronchus
+∞
61.0
58
*
TGD00
NOMESCO Finland
Needle biopsy of lung
214.7
59.7
61
*
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
18.1
57.8
47
27
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
57.8
55
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
158.2
57.5
60
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
149.9
54.4
57
*
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
2.9
53.6
333
1419
R84
ICPC
Malignant neoplasm bronchus/lung
284.1
53.6
54
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
53.6
51
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
542.3
52.9
52
*
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
14.3
52.2
48
35
C34.2
ICD-10 Finland
Malignant neoplasm: Middle lobe, bronchus or lung
+∞
51.4
49
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
5.5
51.1
105
208
N02AA01
ATC
morphine; systemic, rectal
8.5
50.8
67
83
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
266.9
50.5
51
*
C34.26
ICD-10 Finland
Malignant tumor of the middle lobe, bronchus or lung microcellular carcinoma
+∞
50.4
48
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
96.3
50.3
55
6
WW500
NOMESCO Finland
Blood transfusion
8.1
50.2
69
90
C61
ICD-10 Finland
Malignant neoplasm of prostate
177.8
49.3
51
*
WZC00
NOMESCO Finland
Treatment plan or consultation
2.8
49.2
339
1517
GD1AD
NOMESCO Finland
Thorax CT examination
4.8
48.7
116
261
L03AA02
ATC
filgrastim; parenteral
250.3
47.4
48
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
47.2
45
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
130.6
47.2
50
*
8041/3-C34.2
ICD-O-3
Small cell carcinoma, NOS, of middle lobe, lung
+∞
46.2
44
*
YG1CD
NOMESCO Finland
Very extensive CT examination of thorax for dose design of radiotherapy
+∞
45.1
43
*
A06AH03
ATC
naloxegol; oral
18.6
44.8
36
20
A98
ICPC
Health maint/preventive medicine
0.4
42.6
529
7616
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
38.8
37
*
C34.39
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung other or unspecified histology
+∞
37.7
36
*
1623B
ICD-9 Finland
Malignant neoplasm of trachea, bronchus and lung, Upper lobe, bronchus or lung[NEOPL MAL LOB SUPER PULMONIS,CA MICROCELLURE]
+∞
37.7
36
*
UGC18
NOMESCO Finland
Flexible bronchoscopy with biopsy of lung
63.8
37.4
43
7
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
379.3
37.2
37
*
N07BA03
ATC
varenicline; oral
5.5
35.5
70
133
JN4CD
NOMESCO Finland
Very extensive body CT
9.1
34.7
43
49
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
34.6
33
*
A04AD12
ATC
aprepitant; systemic
+∞
32.4
31
*
WW200, ,
SPAT
0.2
31.9
47
2044
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
169.8
31.9
33
*
116
Kela drug reimbursment
Prostate cancer
+∞
31.4
30
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
31.4
30
*
L01XX17
ATC
[U] topotecan
+∞
31.4
30
*
C34.12
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary adenocarcinoma
+∞
29.3
28
*
ZX095
NOMESCO Finland
Combined chemoradiotherapy
+∞
28.2
27
*
R03AL06
ATC
olodaterol and tiotropium bromide; inhalant
5.6
28.1
54
100
C34.89
ICD-10 Finland
Malignant overall tumor of the bronchus and lung other or unspecified histology
+∞
27.2
26
*
Z51.0
ICD-10 Finland
Radiotherapy session
277.4
26.8
27
*
TGE00
NOMESCO Finland
Needle biopsy of mediastinum
74.5
25.9
29
*
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
3.8
25.1
80
223
L01CE01
ATC
topotecan; systemic
+∞
25.1
24
*
H02AB06
ATC
prednisolone; systemic
1.9
24.7
551
3754
1625B
ICD-9 Finland
Malignant neoplasm of trachea, bronchus and lung, Lower lobe, bronchus or lung[NEOPL MAL LOBI INFERIORIS PULMONIS,CA MICROCELLURE]
+∞
24.0
23
*
C34.11
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary epidermoid carcinoma
+∞
24.0
23
*
C79.31
ICD-10 Finland
Secondary malignant tumor of the cerebellum
+∞
24.0
23
*
GD1AT
NOMESCO Finland
Biopsy of the lung with ultrasound guidance
127.7
23.7
25
*
WZC30
NOMESCO Finland
Teaching
2.6
23.5
152
640
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
23.0
22
*
115
Kela drug reimbursment
Breast cancer
+∞
23.0
22
*
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
+∞
23.0
22
*
R03BB04
ATC
tiotropium bromide; inhalant
2.3
22.9
212
1049
N40
ICD-10 Finland
Hyperplasia of prostate
0.4
22.6
145
2979
GAA10
NOMESCO Finland
Intercostal insertion of pleural drainage tube
5.6
22.6
43
79
K03.82
ICD-10 Finland
Split tooth for reasons other than trauma
0.2
21.6
40
1552
A79
ICPC
Malignancy NOS
117.3
21.6
23
*
N06DA02
ATC
donepezil; oral
0.1
21.1
7
718
R03AK03
ATC
[U] fenoterol and ipratropium bromide
2.4
21.1
164
751
Z72.0
ICD-10 Finland
Tobacco use
5.5
21.0
41
77
C34.09
ICD-10 Finland
Malignant tumor of the main bronchus other or unspecified histology
+∞
20.9
20
*
C79.3
ICD-10 Finland
Secondary malignant neoplasm of brain and cerebral meninges
+∞
20.9
20
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
20.9
20
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
19.8
19
*
C77.1
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrathoracic lymph nodes
+∞
19.8
19
*
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
203.4
19.6
20
*
I10
ICD-10 Finland
Essential (primary) hypertension
0.6
19.6
448
6115
D38.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Respiratory organ, unspecified
35.0
18.9
24
7
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
18.8
18
*
N06DX01
ATC
memantine; oral
0.1
18.7
11
974
ZX120
NOMESCO Finland
Intravenous
2.7
18.7
103
399
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
3.1
18.6
83
286
F17.29
ICD-10 Finland
Addiction caused by tobacco UNS
6.1
18.3
32
54
NK6AN
NOMESCO Finland
Total body bone isotope imaging
53.4
18.0
21
*
PJ2AT
NOMESCO Finland
Biopsy of lymphnode with ultrasound guidance
53.4
18.0
21
*
D38.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Mediastinum
53.4
18.0
21
*
L02AE02
ATC
leuprorelin; implant, parenteral
67.7
17.8
20
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
17.8
17
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.0
17.6
82
290
EB4VA, ,
NOMESCO Finland
0.1
17.3
6
599
C34.20
ICD-10 Finland
Malignant tumor of the middle lobe, bronchus or lung without histology
+∞
16.7
16
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
28.0
16.5
22
8
SFA20
NOMESCO Finland
Two-surface restoration
0.5
16.4
203
3382
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.7
16.4
441
3070
R04.2
ICD-10 Finland
Haemoptysis
3.1
16.3
70
236
P20
ICPC
Memory disturbance
0.3
16.3
48
1448
G04CA02
ATC
tamsulosin; oral
0.5
16.1
188
3196
SAA02
NOMESCO Finland
Basic examination of mouth
0.5
16.0
247
3855
WF090
NOMESCO Finland
Profylactic radiotherapy
+∞
15.7
15
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
15.7
15
*
TQW40, ,
SPAT
0.1
14.9
*
461
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
14.6
14
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
14.6
14
*
1628B
ICD-9 Finland
Malignant neoplasm of trachea, bronchus and lung, Other parts of bronchus or lung[NEOPL MAL PULMONIS LOCO MULTIPLICI,CA MICROCELLURE]
+∞
14.6
14
*
C34.15
ICD-10 Finland
Malignant tumor of the anterior, bronchial or lung other non-microcellular carcinoma
+∞
14.6
14
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
4.9
14.5
32
67
GD5CD
NOMESCO Finland
Thorax and upper abdomen combined very extensive CT examination of
15.6
14.4
23
15
C10AA05
ATC
atorvastatin; oral
0.6
14.2
256
3863
M79.6
ICD-10 Finland
Pain in limb
0.5
14.1
162
2791
J01MA12
ATC
levofloxacin; systemic
1.8
14.0
227
1356
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
16.0
14.0
22
14
1240
FHL
Bronchoscopy
4.4
13.9
35
82
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
5.1
13.9
29
58
OAB44, ,
SPAT
0.1
13.8
5
480
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
20.3
13.8
20
10
SAA01
NOMESCO Finland
Simple examination of mouth
0.6
13.8
314
4463
G30.1
ICD-10 Finland
Alzheimer disease with late onset
0.2
13.7
13
805
SFA10
NOMESCO Finland
One-surface restoration
0.5
13.7
201
3220
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.6
13.7
494
3662
SFA30
NOMESCO Finland
Three-surface restoration
0.5
13.6
141
2518
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
13.6
13
*
L02BB03
ATC
bicalutamide; oral
+∞
13.6
13
*
8120/3-C67.9
ICD-O-3
Transitional cell carcinoma, NOS, of bladder, NOS
+∞
13.6
13
*
GDC01
NOMESCO Finland
Thoracoscopic lobectomy of lung
+∞
13.6
13
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
141.6
13.5
14
*
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
141.6
13.5
14
*
M25.5
ICD-10 Finland
Pain in joint
0.4
13.5
80
1754
H25.1
ICD-10 Finland
Senile nuclear cataract
0.5
13.3
186
3028
EB1SA
NOMESCO Finland
Dental X-ray, bite-wing X-ray on one side of the mouth
0.4
13.1
94
1918
J01MA14
ATC
moxifloxacin; systemic
2.2
13.1
114
545
C10AA07
ATC
rosuvastatin; oral
0.5
13.1
133
2394
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
0.5
13.0
175
2885
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
0.6
12.9
238
3594
I87.1
ICD-10 Finland
Compression of vein
50.6
12.9
15
*
C34.35
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung other non-microcellular carcinoma
+∞
12.5
12
*
C34.82
ICD-10 Finland
Malignant overall tumor of bronchial and pulmonary adenocarcinoma
+∞
12.5
12
*
C34.32
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung adenocarcinoma
+∞
12.5
12
*
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
20.3
12.5
18
9
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
5.1
12.5
26
52
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.4
12.4
87
378
G04CA52
ATC
tamsulosin and dutasteride; systemic
0.3
12.2
42
1180
N03AX14
ATC
levetiracetam; systemic
3.5
12.2
42
124
GEA00
NOMESCO Finland
Mediastinoscopy
18.3
12.1
18
10
EB1VA, ,
NOMESCO Finland
0.2
12.0
20
845
H90.3
ICD-10 Finland
Sensorineural hearing loss, bilateral
0.4
11.9
87
1769
Z02.4
ICD-10 Finland
Examination for driving licence
0.5
11.9
152
2560
M01AH05
ATC
etoricoxib; oral
0.6
11.8
270
3880
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
3.0
11.7
53
185
L02BG04
ATC
letrozole; oral
65.6
11.6
13
*
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
11.5
11
*
C34
ICD-10 Finland
Malignant neoplasm of bronchus and lung
+∞
11.5
11
*
A04AA03
ATC
tropisetron; systemic
+∞
11.5
11
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
11.5
11
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
11.5
11
*
C34.29
ICD-10 Finland
Malignant tumor of the middle lobe, bronchus or lung other or unspecified histology
+∞
11.5
11
*
Z87.1
ICD-10 Finland
Personal history of diseases of the digestive system
0.5
11.4
139
2381
N02BE01
ATC
paracetamol; systemic, rectal
0.6
11.3
638
7545
JN6AD
NOMESCO Finland
CT of torso and neck
11.3
11.1
20
18
ZX050
NOMESCO Finland
Stereotactic radiotherapy
43.8
10.9
13
*
J44.9
ICD-10 Finland
Chronic obstructive pulmonary disease, unspecified
2.0
10.9
116
599
G04CB02
ATC
dutasteride; oral
0.3
10.8
25
871
Z76.0
ICD-10 Finland
Issue of repeat prescription
0.4
10.8
65
1429
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
0.4
10.8
72
1519
L17
ICPC
Foot/toe symptom/complaint
0.5
10.8
109
1984
G04CB01
ATC
finasteride; oral
0.5
10.7
82
1644
R4110, ,
SPAT
0.2
10.7
20
787
R85
ICPC
Malignant neopl respiratory other
60.6
10.6
12
*
L08
ICPC
Shoulder symptom/complaint
0.4
10.6
61
1364
D19
ICPC
Teeth/gum symptom/complaint
0.4
10.6
70
1482
Z01.2
ICD-10 Finland
Dental examination
0.5
10.5
146
2414
C34.81
ICD-10 Finland
Malignant overall tumor of bronchial and pulmonary epidermoid carcinoma
+∞
10.4
10
*
1622B
ICD-9 Finland
Malignant neoplasm of trachea, bronchus and lung, Main bronchus[NEOPL MAL BRONCH PRINCIP,CA MICROCELLURE]
+∞
10.4
10
*
C78.1
ICD-10 Finland
Secondary malignant neoplasm of mediastinum
+∞
10.4
10
*
GEA20
NOMESCO Finland
Mediastinoscopy with excision of lesion
+∞
10.4
10
*
WB111
NOMESCO Finland
Multiple neoadjuvant cytostatic therapy
+∞
10.4
10
*
ZX013
NOMESCO Finland
Radiotherapy with large shaped fields - SSD therapy
+∞
10.4
10
*
C80.90
ICD-10 Finland
Malignant tumor without specified localization without histology
+∞
10.4
10
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
10.4
10
*
SDA02
NOMESCO Finland
Periodontal treatment, brief
0.5
10.4
101
1866
GA1AE
NOMESCO Finland
Ultrasound examination of thorax
3.7
10.3
32
88
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
10.7
10.3
19
18
K02.1
ICD-10 Finland
Caries of dentine
0.6
10.3
237
3431
WZC00, ,
SPAT
0.3
10.2
22
797
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
0.3
10.1
38
1027
L15
ICPC
Knee symptom/complaint
0.5
10.0
73
1494
H02
ICPC
Hearing complaint
0.4
9.9
49
1171
SDA03
NOMESCO Finland
Periodontal treatment
0.5
9.9
119
2056
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
0.6
9.9
213
3140
EB1AA
NOMESCO Finland
Intraoral radiographic dental examination
0.6
9.8
224
3259
KCD02
NOMESCO Finland
Transurethral resection of bladder
10.7
9.8
18
17
OAB42, ,
SPAT
0.2
9.8
18
716
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
0.4
9.8
64
1363
SDA01
NOMESCO Finland
Periodontal treatment, very brief
0.4
9.7
65
1374
K03.64
ICD-10 Finland
Dental calculus supragingival
0.4
9.7
67
1399
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
3.1
9.6
40
133
J01FA06
ATC
roxithromycin; oral
1.5
9.5
388
2896
C77.0
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
100.9
9.4
10
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
100.9
9.4
10
*
GCA32
NOMESCO Finland
Endoscopic insertion of stent into bronch
100.9
9.4
10
*
WPB10
NOMESCO Finland
Making a convalescent care decision
17.7
9.4
14
8
WF099
NOMESCO Finland
Other radiotherapy
30.3
9.4
12
*
C79.39
ICD-10 Finland
Secondary malignant tumor of the meninges, ventricle or other part of the brain
+∞
9.4
9
*
C34.91
ICD-10 Finland
Malignant tumor in unspecified localization in bronchial and pulmonary epidermoid carcinoma
+∞
9.4
9
*
C78.2
ICD-10 Finland
Secondary malignant neoplasm of pleura
+∞
9.4
9
*
C34.92
ICD-10 Finland
Malignant tumor in unspecified localization in bronchial and pulmonary adenocarcinoma
+∞
9.4
9
*
1624B
ICD-9 Finland
Malignant neoplasm of trachea, bronchus and lung, Middle lobe, bronchus or lung[NEOPL MAL LOBI MEDII PULMONIS,CA MICROCELLURE]
+∞
9.4
9
*
YX9AW, ,
NOMESCO Finland
+∞
9.4
9
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
9.4
9
*
TGA30
NOMESCO Finland
Thoracocentesis
7.0
9.3
22
32
F00.10*G30.1
ICD-10 Finland
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
0.1
9.3
5
362
HA1AA
NOMESCO Finland
X-ray mammography
3.5
9.2
31
90
L12
ICPC
Hand/finger symptom/complaint
0.3
9.2
34
928
G30.8
ICD-10 Finland
Other Alzheimer disease
0.1
9.1
*
312
307
Kela drug reimbursment
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
0.2
9.0
14
621
HAB40
NOMESCO Finland
Wedge excision of mammary gland
15.7
9.0
14
9
Z71.8
ICD-10 Finland
Other specified counselling
0.5
9.0
104
1824
WPA15
NOMESCO Finland
Palliative care consultation with the patient and loved ones
18.8
8.9
13
7
R03AL01
ATC
fenoterol and ipratropium bromide; inhalant
2.7
8.9
49
190
SPAT1312
SPAT
General health counselling
0.5
8.9
110
1892
I25.1
ICD-10 Finland
Atherosclerotic heart disease
0.6
8.9
229
3256
GA4AT
NOMESCO Finland
Cathetrisation of pleural cavity with ultrasound guidance
6.9
8.9
21
31
WX302
NOMESCO Finland
Thoracal epidural anesthesy
3.7
8.8
27
74
N05CF01
ATC
zopiclone; oral
1.5
8.7
365
2727
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
4.2
8.7
23
56
N02AX02
ATC
tramadol; systemic, rectal
1.5
8.7
417
3202
NGB20
NOMESCO Finland
Primary total prosthetic replacement of knee joint without patellar part
0.3
8.7
24
760
M17.1
ICD-10 Finland
Other primary gonarthrosis
0.5
8.6
83
1547
C10AX09
ATC
ezetimibe; oral
0.4
8.6
59
1237
HA6AA
NOMESCO Finland
Extra corporeal mammography of operated mammary gland
16.4
8.6
13
8
J70.0
ICD-10 Finland
Acute pulmonary manifestations due to radiation
90.7
8.4
9
*
GDC00
NOMESCO Finland
Lobectomy of lung
90.7
8.4
9
*
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
+∞
8.3
8
*
1623X
ICD-9 Finland
Malignant neoplasm of trachea, bronchus and lung, Upper lobe, bronchus or lung[NEOPL MAL LOB SUPER PULMONIS,EI HIST/SYTOL DG]
+∞
8.3
8
*
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
+∞
8.3
8
*
GD004
NOMESCO Finland
Palliative radiotherapy of trachea, bronchi and lungs
+∞
8.3
8
*
C79.7
ICD-10 Finland
Secondary malignant neoplasm of adrenal gland
+∞
8.3
8
*
D82
ICPC
Teeth/gum disease
0.5
8.3
111
1872
Z01.7
ICD-10 Finland
Laboratory examination
0.4
8.3
35
897
B01AF02
ATC
apixaban; oral
0.4
8.3
51
1115
B02AA02
ATC
tranexamic acid; systemic
1.9
8.3
103
562
SPAT1053
SPAT
Memory test
0.5
8.2
70
1358
M17.0
ICD-10 Finland
Primary gonarthrosis, bilateral
0.4
8.1
44
1011
R03AL03
ATC
vilanterol and umeclidinium bromide; inhalant
3.7
8.0
25
69
G04BD12
ATC
mirabegron; oral
0.3
8.0
27
771
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
2.3
8.0
60
270
SPAT1325
SPAT
Vaccination
0.6
8.0
169
2527
M05BX04
ATC
denosumab; parenteral
2.5
7.9
50
208
S18
ICPC
Laceration/cut
0.6
7.8
232
3221
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
0.6
7.8
152
2323
XX1AD
NOMESCO Finland
Other CT-examination
45.3
7.7
9
*
GD2AT
NOMESCO Finland
Cytology of the lungs with ultrasound guidance
45.3
7.7
9
*
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
0.6
7.7
227
3158
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
0.4
7.7
36
884
N05AX08
ATC
risperidone; systemic
0.4
7.7
32
828
2391A
ICD-9 Finland
Neoplasm of unspecified nature, Respiratory system
7.5
7.7
17
23
H13
ICPC
Plugged feeling ear
0.5
7.7
83
1493
L13
ICPC
Hip symptom/complaint
0.5
7.6
63
1238
L28
ICPC
Limited function/disability (L)
0.5
7.6
94
1623
A97
ICPC
No disease
0.5
7.6
61
1210
A07AA02
ATC
nystatin; oral
2.2
7.6
61
283
WZC30, ,
SPAT
0.2
7.5
12
521
G04CA01
ATC
alfuzosin; oral
0.5
7.5
68
1294
SPAT1256
SPAT
Intramuscular and subcutaneous injection
0.6
7.5
204
2887
HAC20
NOMESCO Finland
Total mastectomy
80.6
7.4
8
*
J01DB01
ATC
cefalexin; oral
0.7
7.4
552
6486
H91.1
ICD-10 Finland
Presbycusis
0.3
7.4
18
608
A49.9
ICD-10 Finland
Bacterial infection, unspecified
1.7
7.4
136
836
N17
ICPC
Vertigo/dizziness
0.4
7.3
33
823
C50
ICD-10 Finland
Malignant neoplasm of breast
+∞
7.3
7
*
8070/3-C34.9
ICD-O-3
Squamous cell carcinoma, NOS, of lung, NOS
+∞
7.3
7
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
7.3
7
*
C71.90
ICD-10 Finland
Malignant tumor in unspecified localization in the brain without histology
+∞
7.3
7
*
C38.3
ICD-10 Finland
Malignant neoplasm: Mediastinum, part unspecified
+∞
7.3
7
*
C20.91
ICD-10 Finland
Malignant tumor of the rectum invasive carcinoma
+∞
7.3
7
*
1629X
ICD-9 Finland
Malignant neoplasm of trachea, bronchus and lung, Bronchus and lung, unspecified[NEOPL MAL PULMONIS LOCO ALIO/NUD,EI HIST/SYTOL DG]
+∞
7.3
7
*
C32.0
ICD-10 Finland
Malignant neoplasm: Glottis
+∞
7.3
7
*
C34.14
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary macrocellular anaplastic carcinoma
+∞
7.3
7
*
5826
FHL
Lobectomy or bilobectomy
+∞
7.3
7
*
OAB38
NOMESCO Finland
Psychosocial guidance and counselling
+∞
7.3
7
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
15.9
7.2
11
7
K86.00
ICD-10 Finland
Acute pancreatitis caused by alcohol
4.3
7.2
18
42
TGC00
NOMESCO Finland
Bronchial lavation
2.9
7.2
32
111
N06DA03
ATC
rivastigmine; oral, transdermal
0.2
7.2
11
491
L82
ICD-10 Finland
Seborrhoeic keratosis
0.5
7.2
50
1045
P70
ICPC
Dementia
0.1
7.2
*
235
SCA01
NOMESCO Finland
Preventive oral health care, short
0.5
7.1
71
1313
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
0.6
7.1
133
2058
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
0.7
7.1
224
3082
I50.0
ICD-10 Finland
Congestive heart failure
0.5
7.1
51
1054
G30.9
ICD-10 Finland
Alzheimer disease, unspecified
0.2
7.0
11
484
C09AA05
ATC
ramipril; oral
0.6
7.0
182
2608
F01.9
ICD-10 Finland
Vascular dementia, unspecified
0.0
6.9
*
205
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.0
6.9
74
383
HA4AT
NOMESCO Finland
Labeling mammary gland pathology with ultrasound guidance
13.9
6.9
11
8
PJ3AT
NOMESCO Finland
Cytology of lymphnode with ultrasound guidance
13.9
6.9
11
8
M75.1
ICD-10 Finland
Rotator cuff syndrome
0.6
6.9
100
1653
R42
ICD-10 Finland
Dizziness and giddiness
0.6
6.8
116
1841
PJD41
NOMESCO Finland
Excision of cervical lymph nodes
9.4
6.8
13
14
SAD01
NOMESCO Finland
Assessment of need for oral health care, standard
0.3
6.8
22
639
C09CA01
ATC
losartan; oral
0.6
6.8
134
2046
KMAK, ,
NOMESCO Finland
0.7
6.7
201
2804
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
2.5
6.7
39
157
A69.2
ICD-10 Finland
Lyme disease
0.2
6.6
6
306
M17.9
ICD-10 Finland
Gonarthrosis, unspecified
0.4
6.6
35
814
A02BA02
ATC
ranitidine; systemic
1.5
6.6
229
1637
D01BA02
ATC
terbinafine; oral
0.6
6.6
112
1776
OAB73
NOMESCO Finland
Prevention and treatment of malnutrition
8.8
6.6
13
15
M01AX05
ATC
glucosamine; oral
0.6
6.6
85
1452
C08CA01
ATC
amlodipine; oral
0.7
6.5
264
3474
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
0.6
6.5
123
1902
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
0.5
6.5
78
1363
7931A
ICD-9 Finland
Nonspecific abnormal findings on radiological and other examination of body structure, Lung field
6.2
6.5
16
26
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
0.6
6.5
132
2004
K85
ICPC
Elevated blood pressure
0.5
6.5
65
1199
I50.9
ICD-10 Finland
Heart failure, unspecified
0.6
6.4
130
1979
R23.8
ICD-10 Finland
Other and unspecified skin changes
0.5
6.4
45
940
K05.31
ICD-10 Finland
Periodontitis pronounced
1.7
6.4
106
631
L02BA01
ATC
tamoxifen; oral
70.2
6.4
7
*
UGC02
NOMESCO Finland
Rigid bronchoscopy
70.2
6.4
7
*
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
0.2
6.4
9
358
C09CA06
ATC
candesartan; oral
0.6
6.4
93
1537
K80
ICPC
Cardiac arrhythmia NOS
0.3
6.3
15
512
K05.10
ICD-10 Finland
Gingivitis (chronic) NOS
0.3
6.3
21
600
8041/3-C34.8
ICD-O-3
Small cell carcinoma, NOS, of overlapping lesion of lung
+∞
6.3
6
*
C34.01
ICD-10 Finland
Malignant tumor of the main bronchial epidermoid carcinoma
+∞
6.3
6
*
PJD71
NOMESCO Finland
Extended sparing excision of cervical lymph nodes
+∞
6.3
6
*
C34.21
ICD-10 Finland
Malignant tumor of the middle lobe, bronchus or lung epidermoid carcinoma
+∞
6.3
6
*
C79.0
ICD-10 Finland
Secondary malignant neoplasm of kidney and renal pelvis
+∞
6.3
6
*
OAA41
NOMESCO Finland
Health check based on individual needs
+∞
6.3
6
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
6.3
6
*
YN7AD
NOMESCO Finland
CT examination of spine for dose design of radiotherapy
+∞
6.3
6
*
C34.34
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or hunga macrocellular anaplastic carcinoma
+∞
6.3
6
*
C38.4
ICD-10 Finland
Malignant neoplasm: Pleura
+∞
6.3
6
*
1629B
ICD-9 Finland
Malignant neoplasm of trachea, bronchus and lung, Bronchus and lung, unspecified[NEOPL MAL PULMONIS LOCO ALIO/NUD,CA MICROCELLURE]
+∞
6.3
6
*
C77.8
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of multiple regions
+∞
6.3
6
*
1850A
ICD-9 Finland
Malignant neoplasm of prostate[NEOPLASMA MALIGNUM PROSTATAE]
+∞
6.3
6
*
C34.31
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung epidermoid carcinoma
+∞
6.3
6
*
ZYC01, ,
SPAT
0.3
6.2
15
510
XG410
NOMESCO Finland
Flow-volume spirometry
2.3
6.2
47
213
A06AC01
ATC
ispaghula (psylla seeds); oral
0.6
6.2
126
1917
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
0.4
6.2
26
668
E78.0
ICD-10 Finland
Pure hypercholesterolaemia
0.6
6.1
89
1474
U02
ICPC
Urinary frequency/urgency
0.4
6.1
35
789
SPAT1043
SPAT
Audiometry
0.4
6.1
29
706

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
7.3e-01
9.3e-01
2.7e+00
—
6.6e+00
5.1e+00
3.2e+00
cases:3.18%
controls:1.55%
cases:1.68%
controls:0.67%
cases:1.06%
controls:0.07%
—
—
cases:32.49%
controls:0.06%
cases:47.88%
controls:0.57%
cases:28.71%
controls:1.60%
36
176
1097
11146
19
76
1114
11246
12
8
1121
11314
—
323
7
671
11302
294
63
320
11044
29
145
72
8930
Pulmonary Disease
29 [38004472]
5.5e-01
1.3e+00
4.6e+00
—
5.4e+00
3.8e+00
3.0e+00
cases:18.01%
controls:11.23%
cases:17.65%
controls:5.71%
cases:48.54%
controls:0.90%
—
—
cases:72.23%
controls:1.13%
cases:73.13%
controls:5.99%
cases:75.25%
controls:12.83%
204
1271
929
10051
200
646
933
10676
550
102
583
11220
—
718
128
276
11181
449
665
165
10442
76
1164
25
7911
dexamethasone; oral, parenteral
H02AB02 [21602730]
4.6e-01
8.8e-01
2.5e+00
—
6.0e+00
5.3e+00
2.5e+00
cases:2.29%
controls:1.47%
cases:1.06%
controls:0.44%
cases:1.15%
controls:0.10%
—
—
cases:22.74%
controls:0.07%
cases:47.72%
controls:0.46%
cases:23.76%
controls:2.41%
26
166
1107
11156
12
50
1121
11272
13
11
1120
11311
—
226
8
768
11301
293
51
321
11056
24
219
77
8856
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
3.2e-01
8.3e-01
3.5e+00
—
4.9e+00
3.5e+00
2.6e+00
cases:3.53%
controls:2.59%
cases:2.47%
controls:1.10%
cases:3.09%
controls:0.10%
—
—
cases:14.49%
controls:0.12%
cases:27.36%
controls:1.09%
cases:30.69%
controls:3.13%
40
293
1093
11029
28
124
1105
11198
35
11
1098
11311
—
144
14
850
11295
168
121
446
10986
31
284
70
8791
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
3.2e-01
7.6e-01
3.7e+00
—
4.4e+00
3.2e+00
2.1e+00
cases:12.36%
controls:9.27%
cases:9.09%
controls:4.46%
cases:17.03%
controls:0.50%
—
—
cases:30.78%
controls:0.57%
cases:51.63%
controls:4.31%
cases:56.44%
controls:13.25%
140
1049
993
10273
103
505
1030
10817
193
57
940
11265
—
306
64
688
11245
317
479
297
10628
57
1202
44
7873
FEV1/FVC
19926-5 [3011505]
8.4e-01
1.3e+00
4.5e+00
—
3.5e+00
1.9e+00
2.3e+00
cases:4.77%
controls:2.11%
cases:2.47%
controls:0.67%
cases:6.62%
controls:0.08%
—
—
cases:2.01%
controls:0.06%
cases:3.91%
controls:0.59%
cases:11.88%
controls:1.34%
54
239
1079
11083
28
76
1105
11246
75
9
1058
11313
—
20
7
974
11302
24
65
590
11042
12
122
89
8953
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
8.4e-01
1.3e+00
4.5e+00
—
3.5e+00
1.9e+00
2.3e+00
cases:4.77%
controls:2.11%
cases:2.47%
controls:0.67%
cases:6.62%
controls:0.08%
—
—
cases:2.01%
controls:0.06%
cases:3.91%
controls:0.59%
cases:11.88%
controls:1.34%
54
239
1079
11083
28
76
1105
11246
75
9
1058
11313
—
20
7
974
11302
24
65
590
11042
12
122
89
8953
FEV1
20150-9 [3024653]
8.4e-01
1.3e+00
4.5e+00
—
3.5e+00
1.9e+00
2.3e+00
cases:4.77%
controls:2.11%
cases:2.47%
controls:0.67%
cases:6.62%
controls:0.08%
—
—
cases:2.01%
controls:0.06%
cases:3.91%
controls:0.59%
cases:11.88%
controls:1.34%
54
239
1079
11083
28
76
1105
11246
75
9
1058
11313
—
20
7
974
11302
24
65
590
11042
12
122
89
8953
olodaterol and tiotropium bromide
R03AL06 [1588644]
1.4e+00
1.7e+00
3.3e+00
—
3.2e+00
3.1e+00
2.7e+00
cases:0.79%
controls:0.19%
cases:1.15%
controls:0.20%
cases:1.15%
controls:0.04%
—
—
cases:2.01%
controls:0.08%
cases:4.23%
controls:0.21%
cases:5.94%
controls:0.43%
9
22
1124
11300
13
23
1120
11299
13
5
1120
11317
—
20
9
974
11300
26
23
588
11084
6
39
95
9036
Thorax X-ray examination
GD1AA [2001303617]
5.3e-01
9.8e-01
3.9e+00
—
3.6e+00
2.9e+00
2.0e+00
cases:13.86%
controls:8.61%
cases:8.03%
controls:3.16%
cases:12.97%
controls:0.29%
—
—
cases:11.57%
controls:0.37%
cases:33.22%
controls:2.75%
cases:45.54%
controls:10.35%
157
975
976
10347
91
358
1042
10964
147
33
986
11289
—
115
42
879
11267
204
305
410
10802
46
939
55
8136
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
6.8e-02
6.2e-01
2.9e+00
4.3e+00
3.0e+00
1.7e+00
1.3e+00
cases:29.21%
controls:27.83%
cases:28.33%
controls:17.58%
cases:36.01%
controls:3.04%
cases:10.33%
controls:0.16%
cases:38.23%
controls:3.09%
cases:54.40%
controls:18.29%
cases:68.32%
controls:37.01%
331
3151
802
8171
321
1990
812
9332
408
344
725
10978
117
18
1016
11304
380
349
614
10960
334
2031
280
9076
69
3359
32
5716
Extensive body CT
JN4BD [2001310899]
1.6e+00
2.9e+00
1.0e+50
1.0e+50
1.0e+50
5.3e+00
3.9e+00
cases:2.21%
controls:0.47%
cases:1.41%
controls:0.08%
cases:3.18%
controls:0.00%
cases:0.62%
controls:0.00%
cases:2.31%
controls:0.00%
cases:11.07%
controls:0.06%
cases:16.83%
controls:0.40%
25
53
1108
11269
16
9
1117
11313
36
0
1097
11322
7
0
1126
11322
23
0
971
11309
68
7
546
11100
17
36
84
9039
Inpatient Hospital
21 [8717]
2.9e-01
5.4e-01
3.0e+00
4.4e+00
3.4e+00
2.0e+00
4.4e-01
cases:41.48%
controls:34.65%
cases:21.36%
controls:13.62%
cases:31.07%
controls:2.18%
cases:5.38%
controls:0.07%
cases:39.13%
controls:2.03%
cases:51.30%
controls:12.95%
cases:42.57%
controls:32.28%
470
3923
663
7399
242
1542
891
9780
352
247
781
11075
61
8
1072
11314
389
230
605
11079
315
1438
299
9669
43
2929
58
6146
Supplier / Service Provider
OMOP5117446 [33004]
-1.1e-01
1.1e-01
2.4e+00
—
4.3e+00
3.7e+00
3.1e+00
cases:23.92%
controls:25.97%
cases:8.38%
controls:7.58%
cases:7.77%
controls:0.75%
—
—
cases:5.73%
controls:0.08%
cases:19.87%
controls:0.59%
cases:23.76%
controls:1.34%
271
2940
862
8382
95
858
1038
10464
88
85
1045
11237
—
57
9
937
11300
122
65
492
11042
24
122
77
8953
Emergency Room Visit
ER [9203]
1.4e-01
5.7e-01
3.2e+00
4.1e+00
2.8e+00
1.9e+00
7.3e-01
cases:35.48%
controls:32.39%
cases:19.24%
controls:11.86%
cases:27.98%
controls:1.55%
cases:3.00%
controls:0.05%
cases:19.72%
controls:1.48%
cases:46.09%
controls:11.84%
cases:50.50%
controls:33.02%
402
3667
731
7655
218
1343
915
9979
317
175
816
11147
34
6
1099
11316
196
167
798
11142
283
1315
331
9792
51
2997
50
6078
Outpatient Hospital
22 [8756]
2.1e-01
5.1e-01
2.9e+00
4.5e+00
3.1e+00
1.9e+00
3.5e-01
cases:30.36%
controls:26.05%
cases:12.89%
controls:8.13%
cases:16.95%
controls:1.07%
cases:4.50%
controls:0.05%
cases:17.40%
controls:0.94%
cases:32.90%
controls:6.91%
cases:27.72%
controls:21.25%
344
2949
789
8373
146
920
987
10402
192
121
941
11201
51
6
1082
11316
173
106
821
11203
202
767
412
10340
28
1928
73
7147
Treatment plan or consultation
WZC00 [2001310885]
4.7e-01
8.9e-01
2.0e+00
—
4.9e+00
3.5e+00
1.6e+00
cases:5.38%
controls:3.44%
cases:2.56%
controls:1.07%
cases:1.41%
controls:0.19%
—
—
cases:12.88%
controls:0.11%
cases:28.01%
controls:1.19%
cases:15.84%
controls:3.80%
61
389
1072
10933
29
121
1104
11201
16
22
1117
11300
—
128
13
866
11296
172
132
442
10975
16
345
85
8730
Oncology Clinic/Center
261QX0200X [38004268]
3.0e+00
3.4e+00
1.0e+50
1.0e+50
—
2.9e+00
3.4e+00
cases:6.62%
controls:0.34%
cases:2.65%
controls:0.09%
cases:0.97%
controls:0.00%
cases:99.38%
controls:0.00%
—
—
cases:1.30%
controls:0.07%
cases:7.92%
controls:0.29%
75
39
1058
11283
30
10
1103
11312
11
0
1122
11322
1126
0
7
11322
—
8
8
606
11099
8
26
93
9049
oxycodone; oral, parenteral
N02AA05 [21604260]
3.8e-01
6.8e-01
2.4e+00
1.0e+50
4.0e+00
3.8e+00
2.3e+00
cases:1.94%
controls:1.34%
cases:1.77%
controls:0.90%
cases:2.74%
controls:0.25%
cases:0.71%
controls:0.00%
cases:12.98%
controls:0.27%
cases:30.46%
controls:0.99%
cases:21.78%
controls:2.60%
22
152
1111
11170
20
102
1113
11220
31
28
1102
11294
8
0
1125
11322
129
30
865
11279
187
110
427
10997
22
236
79
8839
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
7.6e-01
9.9e-01
3.8e+00
1.0e+50
3.5e+00
1.5e+00
1.9e+00
cases:3.09%
controls:1.48%
cases:1.68%
controls:0.63%
cases:4.59%
controls:0.11%
cases:1.06%
controls:0.00%
cases:2.92%
controls:0.09%
cases:3.26%
controls:0.71%
cases:11.88%
controls:1.98%
35
167
1098
11155
19
71
1114
11251
52
12
1081
11310
12
0
1121
11322
29
10
965
11299
20
79
594
11028
12
180
89
8895
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
1.4e+00
1.4e+00
3.1e+00
—
3.1e+00
1.9e+00
1.4e+00
cases:12.97%
controls:3.46%
cases:8.83%
controls:2.24%
cases:8.47%
controls:0.43%
—
—
cases:10.26%
controls:0.53%
cases:15.64%
controls:2.66%
cases:21.78%
controls:6.18%
147
392
986
10930
100
254
1033
11068
96
49
1037
11273
—
102
60
892
11249
96
295
518
10812
22
561
79
8514
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
2.6e-01
1.0e+00
3.8e+00
—
3.1e+00
2.7e+00
1.6e+00
cases:2.12%
controls:1.63%
cases:2.56%
controls:0.95%
cases:3.97%
controls:0.10%
—
—
cases:2.92%
controls:0.13%
cases:13.19%
controls:1.04%
cases:19.80%
controls:4.91%
24
185
1109
11137
29
108
1104
11214
45
11
1088
11311
—
29
15
965
11294
81
116
533
10991
20
446
81
8629
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
2.0e-01
1.2e+00
3.9e+00
—
3.1e+00
2.7e+00
1.2e+00
cases:1.32%
controls:1.09%
cases:1.85%
controls:0.59%
cases:2.91%
controls:0.06%
—
—
cases:2.01%
controls:0.09%
cases:9.12%
controls:0.68%
cases:11.88%
controls:3.78%
15
123
1118
11199
21
67
1112
11255
33
7
1100
11315
—
20
10
974
11299
56
75
558
11032
12
343
89
8732
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
1.5e-01
7.3e-01
3.0e+00
1.0e+50
3.9e+00
2.5e+00
2.0e+00
cases:6.35%
controls:5.51%
cases:4.50%
controls:2.22%
cases:5.56%
controls:0.29%
cases:0.62%
controls:0.00%
cases:10.26%
controls:0.24%
cases:23.94%
controls:2.46%
cases:35.64%
controls:7.13%
72
624
1061
10698
51
251
1082
11071
63
33
1070
11289
7
0
1126
11322
102
27
892
11282
147
273
467
10834
36
647
65
8428
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
2.8e-01
8.6e-01
3.0e+00
—
3.6e+00
2.7e+00
1.9e+00
cases:13.24%
controls:10.33%
cases:13.06%
controls:5.97%
cases:19.59%
controls:1.17%
—
—
cases:29.98%
controls:1.15%
cases:48.37%
controls:6.15%
cases:52.48%
controls:14.45%
150
1170
983
10152
148
676
985
10646
222
133
911
11189
—
298
130
696
11179
297
683
317
10424
53
1311
48
7764
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
2.3e-01
1.2e+00
3.8e+00
—
3.0e+00
2.6e+00
1.4e+00
cases:1.41%
controls:1.12%
cases:1.85%
controls:0.59%
cases:2.74%
controls:0.06%
—
—
cases:1.81%
controls:0.09%
cases:8.31%
controls:0.67%
cases:12.87%
controls:3.52%
16
127
1117
11195
21
67
1112
11255
31
7
1102
11315
—
18
10
976
11299
51
74
563
11033
13
319
88
8756
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.6e-02
3.7e-01
2.4e+00
4.4e+00
2.7e+00
1.1e+00
9.5e-01
cases:34.33%
controls:33.76%
cases:33.36%
controls:25.63%
cases:30.89%
controls:3.98%
cases:4.24%
controls:0.05%
cases:37.12%
controls:3.71%
cases:54.23%
controls:27.74%
cases:70.30%
controls:47.69%
389
3822
744
7500
378
2902
755
8420
350
451
783
10871
48
6
1085
11316
369
420
625
10889
333
3081
281
8026
71
4328
30
4747
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
1.4e-01
7.1e-01
3.3e+00
—
3.6e+00
2.3e+00
1.9e+00
cases:19.95%
controls:17.83%
cases:18.62%
controls:10.09%
cases:28.24%
controls:1.37%
—
—
cases:35.01%
controls:1.45%
cases:53.75%
controls:10.03%
cases:68.32%
controls:24.14%
226
2019
907
9303
211
1142
922
10180
320
155
813
11167
—
348
164
646
11145
330
1114
284
9993
69
2191
32
6884
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
-8.3e-02
4.9e-01
3.0e+00
—
4.0e+00
2.6e+00
2.2e+00
cases:2.65%
controls:2.87%
cases:2.12%
controls:1.31%
cases:3.35%
controls:0.18%
—
—
cases:8.35%
controls:0.16%
cases:16.78%
controls:1.44%
cases:29.70%
controls:4.68%
30
325
1103
10997
24
148
1109
11174
38
20
1095
11302
—
83
18
911
11291
103
160
511
10947
30
425
71
8650
pH of Serum or Plasma
2753-2 [3018418]
2.1e-01
9.4e-01
3.2e+00
—
3.6e+00
2.3e+00
1.5e+00
cases:6.35%
controls:5.22%
cases:6.35%
controls:2.59%
cases:8.83%
controls:0.39%
—
—
cases:14.29%
controls:0.43%
cases:23.45%
controls:2.94%
cases:29.70%
controls:8.35%
72
591
1061
10731
72
293
1061
11029
100
44
1033
11278
—
142
49
852
11260
144
326
470
10781
30
758
71
8317
FEV1/FVC --post bronchodilation
69970-2 [42868459]
9.9e-01
1.5e+00
4.8e+00
—
—
2.0e+00
2.3e+00
cases:4.68%
controls:1.78%
cases:2.21%
controls:0.49%
cases:6.18%
controls:0.05%
—
—
—
—
cases:2.93%
controls:0.40%
cases:9.90%
controls:1.13%
53
202
1080
11120
25
56
1108
11266
70
6
1063
11316
—
—
18
44
596
11063
10
103
91
8972
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
9.9e-01
1.5e+00
4.8e+00
—
—
2.0e+00
2.3e+00
cases:4.68%
controls:1.78%
cases:2.21%
controls:0.49%
cases:6.18%
controls:0.05%
—
—
—
—
cases:2.93%
controls:0.40%
cases:9.90%
controls:1.13%
53
202
1080
11120
25
56
1108
11266
70
6
1063
11316
—
—
18
44
596
11063
10
103
91
8972
FEV1 --post bronchodilation
20155-8 [3023550]
9.9e-01
1.5e+00
4.8e+00
—
—
2.0e+00
2.3e+00
cases:4.68%
controls:1.78%
cases:2.21%
controls:0.49%
cases:6.18%
controls:0.05%
—
—
—
—
cases:2.93%
controls:0.40%
cases:9.90%
controls:1.13%
53
202
1080
11120
25
56
1108
11266
70
6
1063
11316
—
—
18
44
596
11063
10
103
91
8972
FVC percent change Respiratory system
69982-7 [42868471]
9.9e-01
1.5e+00
4.8e+00
—
—
2.0e+00
2.3e+00
cases:4.68%
controls:1.78%
cases:2.21%
controls:0.49%
cases:6.18%
controls:0.05%
—
—
—
—
cases:2.93%
controls:0.40%
cases:9.90%
controls:1.13%
53
202
1080
11120
25
56
1108
11266
70
6
1063
11316
—
—
18
44
596
11063
10
103
91
8972
FEV1 percent change
69983-5 [42868472]
9.9e-01
1.5e+00
4.8e+00
—
—
2.0e+00
2.3e+00
cases:4.68%
controls:1.78%
cases:2.21%
controls:0.49%
cases:6.18%
controls:0.05%
—
—
—
—
cases:2.93%
controls:0.40%
cases:9.90%
controls:1.13%
53
202
1080
11120
25
56
1108
11266
70
6
1063
11316
—
—
18
44
596
11063
10
103
91
8972
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
7.2e-01
1.2e+00
4.1e+00
1.0e+50
2.7e+00
1.3e+00
1.6e+00
cases:4.24%
controls:2.10%
cases:2.47%
controls:0.72%
cases:4.41%
controls:0.08%
cases:0.44%
controls:0.00%
cases:1.31%
controls:0.09%
cases:3.09%
controls:0.89%
cases:10.89%
controls:2.40%
48
238
1085
11084
28
82
1105
11240
50
9
1083
11313
5
0
1128
11322
13
10
981
11299
19
99
595
11008
11
218
90
8857
Emergency Medicine
93 [38004510]
1.0e-01
3.9e-01
2.9e+00
3.3e+00
2.4e+00
1.6e+00
1.0e+00
cases:13.95%
controls:12.75%
cases:9.89%
controls:6.94%
cases:15.53%
controls:1.00%
cases:1.68%
controls:0.06%
cases:9.36%
controls:0.91%
cases:28.66%
controls:7.66%
cases:42.57%
controls:21.43%
158
1444
975
9878
112
786
1021
10536
176
113
957
11209
19
7
1114
11315
93
103
901
11206
176
851
438
10256
43
1945
58
7130
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
-4.7e-01
7.5e-01
3.9e+00
—
3.4e+00
2.2e+00
2.2e+00
cases:0.71%
controls:1.12%
cases:0.97%
controls:0.46%
cases:2.12%
controls:0.04%
—
—
cases:1.51%
controls:0.05%
cases:4.23%
controls:0.50%
cases:11.88%
controls:1.50%
8
127
1125
11195
11
52
1122
11270
24
5
1109
11317
—
15
6
979
11303
26
56
588
11051
12
136
89
8939
Short blood count panel - Blood
55429-5 [40758558]
3.8e-01
9.0e-01
3.2e+00
1.0e+50
3.5e+00
2.2e+00
1.7e+00
cases:6.00%
controls:4.18%
cases:4.85%
controls:2.04%
cases:6.80%
controls:0.30%
cases:1.06%
controls:0.00%
cases:11.47%
controls:0.37%
cases:16.78%
controls:2.12%
cases:27.72%
controls:6.64%
68
473
1065
10849
55
231
1078
11091
77
34
1056
11288
12
0
1121
11322
114
42
880
11267
103
235
511
10872
28
603
73
8472
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.0e-02
3.5e-01
2.4e+00
4.3e+00
2.6e+00
1.0e+00
8.8e-01
cases:35.30%
controls:34.84%
cases:34.95%
controls:27.42%
cases:35.75%
controls:5.03%
cases:11.21%
controls:0.17%
cases:39.84%
controls:4.76%
cases:54.40%
controls:29.58%
cases:69.31%
controls:48.31%
400
3945
733
7377
396
3105
737
8217
405
570
728
10752
127
19
1006
11303
396
538
598
10771
334
3285
280
7822
70
4384
31
4691
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.1e-02
3.5e-01
2.3e+00
4.3e+00
2.6e+00
1.0e+00
8.7e-01
cases:35.48%
controls:35.01%
cases:35.30%
controls:27.76%
cases:35.66%
controls:5.13%
cases:11.12%
controls:0.17%
cases:39.84%
controls:4.90%
cases:54.40%
controls:29.93%
cases:69.31%
controls:48.51%
402
3964
731
7358
400
3143
733
8179
404
581
729
10741
126
19
1007
11303
396
554
598
10755
334
3324
280
7783
70
4402
31
4673
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
3.0e-01
8.2e-01
3.2e+00
—
3.6e+00
2.3e+00
1.4e+00
cases:11.39%
controls:8.73%
cases:9.62%
controls:4.47%
cases:14.21%
controls:0.65%
—
—
cases:19.32%
controls:0.65%
cases:33.88%
controls:4.82%
cases:37.62%
controls:12.87%
129
988
1004
10334
109
506
1024
10816
161
74
972
11248
—
192
73
802
11236
208
535
406
10572
38
1168
63
7907
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
4.2e-02
3.5e-01
2.4e+00
3.9e+00
2.4e+00
1.1e+00
1.0e+00
cases:25.07%
controls:24.29%
cases:27.01%
controls:20.72%
cases:31.16%
controls:3.97%
cases:5.91%
controls:0.12%
cases:30.99%
controls:3.78%
cases:47.56%
controls:23.25%
cases:65.35%
controls:39.83%
284
2750
849
8572
306
2346
827
8976
353
450
780
10872
67
14
1066
11308
308
428
686
10881
292
2582
322
8525
66
3615
35
5460
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
2.5e-01
7.9e-01
3.2e+00
—
3.5e+00
2.2e+00
1.5e+00
cases:11.92%
controls:9.53%
cases:10.41%
controls:5.02%
cases:15.18%
controls:0.75%
—
—
cases:21.03%
controls:0.76%
cases:35.83%
controls:5.58%
cases:43.56%
controls:14.90%
135
1079
998
10243
118
568
1015
10754
172
85
961
11237
—
209
86
785
11223
220
620
394
10487
44
1352
57
7723
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
-3.8e-03
3.4e-01
2.4e+00
4.1e+00
2.5e+00
9.1e-01
9.1e-01
cases:36.72%
controls:36.80%
cases:37.69%
controls:30.07%
cases:40.51%
controls:5.86%
cases:11.03%
controls:0.20%
cases:43.06%
controls:5.60%
cases:54.72%
controls:32.76%
cases:71.29%
controls:50.10%
416
4167
717
7155
427
3404
706
7918
459
664
674
10658
125
23
1008
11299
428
633
566
10676
336
3639
278
7468
72
4547
29
4528
Pneumonia, unspecified
J18.9 [45601123]
4.4e-01
1.4e+00
3.4e+00
—
3.0e+00
2.4e+00
9.1e-01
cases:5.91%
controls:3.88%
cases:6.80%
controls:1.73%
cases:7.24%
controls:0.25%
—
—
cases:4.83%
controls:0.25%
cases:16.61%
controls:1.80%
cases:17.82%
controls:8.01%
67
439
1066
10883
77
196
1056
11126
82
28
1051
11294
—
48
28
946
11281
102
200
512
10907
18
727
83
8348
Differential panel, method unspecified - Blood
69738-3 [42870588]
4.1e-01
9.1e-01
3.2e+00
—
2.8e+00
2.1e+00
1.7e+00
cases:8.65%
controls:5.93%
cases:8.30%
controls:3.52%
cases:13.50%
controls:0.63%
—
—
cases:10.06%
controls:0.68%
cases:24.92%
controls:3.81%
cases:32.67%
controls:8.23%
98
671
1035
10651
94
398
1039
10924
153
71
980
11251
—
100
77
894
11232
153
423
461
10684
33
747
68
8328
erdosteine; oral
R05CB15 [21603394]
7.4e-01
1.5e+00
2.7e+00
—
2.6e+00
1.9e+00
1.7e+00
cases:5.38%
controls:2.65%
cases:3.88%
controls:0.92%
cases:2.21%
controls:0.15%
—
—
cases:1.71%
controls:0.12%
cases:6.35%
controls:1.04%
cases:18.81%
controls:4.08%
61
300
1072
11022
44
104
1089
11218
25
17
1108
11305
—
17
14
977
11295
39
116
575
10991
19
370
82
8705
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-6.0e-03
2.8e-01
2.3e+00
4.3e+00
2.5e+00
8.9e-01
8.3e-01
cases:37.95%
controls:38.09%
cases:37.86%
controls:31.43%
cases:41.22%
controls:6.45%
cases:14.12%
controls:0.22%
cases:42.96%
controls:5.96%
cases:55.54%
controls:33.89%
cases:70.30%
controls:50.90%
430
4313
703
7009
429
3558
704
7764
467
730
666
10592
160
25
973
11297
427
674
567
10635
341
3764
273
7343
71
4619
30
4456
Platelets [#/volume] in Blood
26515-7 [3007461]
-1.1e-05
2.8e-01
2.3e+00
4.3e+00
2.5e+00
8.9e-01
8.3e-01
cases:37.86%
controls:37.86%
cases:37.60%
controls:31.33%
cases:41.22%
controls:6.45%
cases:14.12%
controls:0.22%
cases:42.96%
controls:5.96%
cases:55.54%
controls:33.90%
cases:70.30%
controls:50.83%
429
4287
704
7035
426
3547
707
7775
467
730
666
10592
160
25
973
11297
427
674
567
10635
341
3765
273
7342
71
4613
30
4462
MCH [Entitic mass]
28539-5 [3035941]
-4.5e-03
2.7e-01
2.3e+00
4.3e+00
2.5e+00
8.9e-01
8.3e-01
cases:37.86%
controls:37.97%
cases:37.51%
controls:31.38%
cases:41.22%
controls:6.43%
cases:14.12%
controls:0.22%
cases:42.96%
controls:5.95%
cases:55.54%
controls:33.92%
cases:70.30%
controls:50.84%
429
4299
704
7023
425
3553
708
7769
467
728
666
10594
160
25
973
11297
427
673
567
10636
341
3768
273
7339
71
4614
30
4461
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
3.4e-01
8.0e-01
2.9e+00
—
3.3e+00
2.2e+00
1.6e+00
cases:10.86%
controls:7.98%
cases:8.56%
controls:4.05%
cases:9.53%
controls:0.60%
—
—
cases:15.39%
controls:0.67%
cases:28.50%
controls:4.38%
cases:41.58%
controls:12.09%
123
904
1010
10418
97
459
1036
10863
108
68
1025
11254
—
153
76
841
11233
175
487
439
10620
42
1097
59
7978
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-7.1e-03
2.7e-01
2.3e+00
4.3e+00
2.5e+00
8.9e-01
8.3e-01
cases:37.86%
controls:38.03%
cases:37.60%
controls:31.43%
cases:41.22%
controls:6.46%
cases:14.12%
controls:0.22%
cases:42.96%
controls:5.96%
cases:55.54%
controls:33.97%
cases:70.30%
controls:50.89%
429
4306
704
7016
426
3558
707
7764
467
731
666
10591
160
25
973
11297
427
674
567
10635
341
3773
273
7334
71
4618
30
4457
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-7.5e-03
2.7e-01
2.3e+00
4.3e+00
2.5e+00
8.9e-01
8.3e-01
cases:37.86%
controls:38.04%
cases:37.60%
controls:31.43%
cases:41.22%
controls:6.47%
cases:14.12%
controls:0.22%
cases:42.96%
controls:5.96%
cases:55.54%
controls:33.98%
cases:70.30%
controls:50.89%
429
4307
704
7015
426
3558
707
7764
467
732
666
10590
160
25
973
11297
427
674
567
10635
341
3774
273
7333
71
4618
30
4457
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-4.5e-03
2.7e-01
2.3e+00
4.3e+00
2.5e+00
8.9e-01
8.2e-01
cases:37.95%
controls:38.06%
cases:37.51%
controls:31.43%
cases:41.22%
controls:6.47%
cases:14.12%
controls:0.22%
cases:42.96%
controls:5.97%
cases:55.54%
controls:34.00%
cases:70.30%
controls:50.92%
430
4309
703
7013
425
3559
708
7763
467
733
666
10589
160
25
973
11297
427
675
567
10634
341
3776
273
7331
71
4621
30
4454
Thorax extensive CT-examination
GD1BD [2001303621]
1.3e+00
1.8e+00
1.0e+50
1.0e+50
1.0e+50
4.2e+00
3.8e+00
cases:1.68%
controls:0.48%
cases:0.71%
controls:0.11%
cases:2.03%
controls:0.00%
cases:0.44%
controls:0.00%
cases:0.60%
controls:0.00%
cases:4.40%
controls:0.07%
cases:10.89%
controls:0.26%
19
54
1114
11268
8
13
1125
11309
23
0
1110
11322
5
0
1128
11322
6
0
988
11309
27
8
587
11099
11
24
90
9051
Bacteria identified in Blood by Culture
600-7 [3023368]
2.4e-01
8.2e-01
3.1e+00
—
3.1e+00
2.7e+00
1.3e+00
cases:5.30%
controls:4.22%
cases:5.03%
controls:2.27%
cases:5.83%
controls:0.26%
—
—
cases:6.24%
controls:0.29%
cases:23.45%
controls:2.09%
cases:22.77%
controls:7.50%
60
478
1073
10844
57
257
1076
11065
66
30
1067
11292
—
62
33
932
11276
144
232
470
10875
23
681
78
8394
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-7.1e-03
2.7e-01
2.3e+00
4.3e+00
2.5e+00
8.9e-01
8.3e-01
cases:37.86%
controls:38.03%
cases:37.51%
controls:31.41%
cases:41.22%
controls:6.47%
cases:14.03%
controls:0.23%
cases:42.96%
controls:5.97%
cases:55.54%
controls:33.94%
cases:70.30%
controls:50.85%
429
4306
704
7016
425
3556
708
7766
467
732
666
10590
159
26
974
11296
427
675
567
10634
341
3770
273
7337
71
4615
30
4460
Emergency Room and Inpatient Visit
ERIP [262]
1.9e-01
8.2e-01
3.8e+00
—
3.1e+00
2.2e+00
1.2e+00
cases:4.32%
controls:3.61%
cases:5.74%
controls:2.61%
cases:12.71%
controls:0.34%
—
—
cases:6.94%
controls:0.34%
cases:23.78%
controls:3.37%
cases:28.71%
controls:11.27%
49
409
1084
10913
65
295
1068
11027
144
38
989
11284
—
69
38
925
11271
146
374
468
10733
29
1023
72
8052
INR in Blood by Coagulation assay
34714-6 [3032080]
2.8e-01
7.2e-01
2.4e+00
3.5e+00
1.7e+00
1.5e+00
1.1e+00
cases:14.65%
controls:11.46%
cases:13.06%
controls:6.81%
cases:22.86%
controls:2.62%
cases:6.18%
controls:0.20%
cases:12.07%
controls:2.52%
cases:23.29%
controls:6.45%
cases:35.64%
controls:15.23%
166
1297
967
10025
148
771
985
10551
259
297
874
11025
70
23
1063
11299
120
285
874
11024
143
716
471
10391
36
1382
65
7693
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
1.4e-01
8.0e-01
4.0e+00
1.0e+50
3.1e+00
1.7e+00
1.2e+00
cases:5.30%
controls:4.62%
cases:4.68%
controls:2.16%
cases:11.65%
controls:0.24%
cases:4.06%
controls:0.00%
cases:4.83%
controls:0.22%
cases:9.93%
controls:2.07%
cases:18.81%
controls:6.24%
60
523
1073
10799
53
245
1080
11077
132
27
1001
11295
46
0
1087
11322
48
25
946
11284
61
230
553
10877
19
566
82
8509
Internal Medicine
11 [38004456]
2.2e-01
5.5e-01
2.7e+00
3.5e+00
2.4e+00
1.5e+00
5.4e-01
cases:31.42%
controls:26.82%
cases:17.74%
controls:11.06%
cases:21.36%
controls:1.75%
cases:1.94%
controls:0.06%
cases:16.00%
controls:1.72%
cases:37.13%
controls:11.16%
cases:40.59%
controls:28.54%
356
3036
777
8286
201
1252
932
10070
242
198
891
11124
22
7
1111
11315
159
194
835
11115
228
1239
386
9868
41
2590
60
6485
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
—
—
—
—
1.0e+50
6.2e+00
4.4e+00
—
—
—
—
—
—
—
—
cases:16.80%
controls:0.00%
cases:27.20%
controls:0.07%
cases:16.83%
controls:0.24%
—
—
—
—
167
0
827
11309
167
8
447
11099
17
22
84
9053
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
2.5e-01
7.2e-01
3.0e+00
—
3.2e+00
2.2e+00
1.3e+00
cases:14.92%
controls:11.99%
cases:11.65%
controls:6.03%
cases:15.53%
controls:0.87%
—
—
cases:14.08%
controls:0.67%
cases:36.97%
controls:6.39%
cases:43.56%
controls:17.56%
169
1358
964
9964
132
683
1001
10639
176
99
957
11223
—
140
76
854
11233
227
710
387
10397
44
1594
57
7481
Inpatient Visit
IP [9201]
5.9e-02
5.5e-01
2.9e+00
—
3.7e+00
2.1e+00
1.2e+00
cases:9.80%
controls:9.29%
cases:5.30%
controls:3.12%
cases:5.38%
controls:0.32%
—
—
cases:9.96%
controls:0.28%
cases:20.20%
controls:3.04%
cases:23.76%
controls:8.66%
111
1052
1022
10270
60
353
1073
10969
61
36
1072
11286
—
99
32
895
11277
124
338
490
10769
24
786
77
8289
Medical Oncology
90 [38004507]
3.5e+00
—
—
1.0e+50
—
—
6.8e+00
cases:3.80%
controls:0.11%
—
—
—
—
cases:1.41%
controls:0.00%
—
—
—
—
cases:57.43%
controls:0.14%
43
13
1090
11309
—
—
16
0
1117
11322
—
—
58
13
43
9062
Gas panel - Capillary blood
24337-8 [3022313]
4.5e-01
1.1e+00
3.3e+00
—
3.5e+00
2.4e+00
—
cases:1.32%
controls:0.85%
cases:1.15%
controls:0.37%
cases:2.03%
controls:0.08%
—
—
cases:2.82%
controls:0.09%
cases:4.72%
controls:0.44%
—
—
15
96
1118
11226
13
42
1120
11280
23
9
1110
11313
—
28
10
966
11299
29
49
585
11058
—
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
1.1e+00
1.2e+00
3.4e+00
—
2.0e+00
2.7e+00
8.7e-01
cases:1.68%
controls:0.56%
cases:1.68%
controls:0.53%
cases:2.47%
controls:0.09%
—
—
cases:1.21%
controls:0.17%
cases:8.31%
controls:0.62%
cases:4.95%
controls:2.14%
19
63
1114
11259
19
60
1114
11262
28
10
1105
11312
—
12
19
982
11290
51
69
563
11038
5
194
96
8881
Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.0 [45601131]
1.4e+00
1.5e+00
3.3e+00
—
2.2e+00
1.1e+00
1.8e+00
cases:3.18%
controls:0.77%
cases:1.77%
controls:0.39%
cases:1.59%
controls:0.06%
—
—
cases:0.80%
controls:0.09%
cases:1.63%
controls:0.53%
cases:9.90%
controls:1.73%
36
87
1097
11235
20
44
1113
11278
18
7
1115
11315
—
8
10
986
11299
10
59
604
11048
10
157
91
8918
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
3.8e-01
1.1e+00
3.5e+00
—
3.3e+00
2.3e+00
1.2e+00
cases:1.50%
controls:1.03%
cases:1.59%
controls:0.54%
cases:2.65%
controls:0.08%
—
—
cases:3.22%
controls:0.12%
cases:6.19%
controls:0.64%
cases:5.94%
controls:1.93%
17
117
1116
11205
18
61
1115
11261
30
9
1103
11313
—
32
14
962
11295
38
71
576
11036
6
175
95
8900
pH of Capillary blood
2745-8 [3009343]
3.8e-01
1.1e+00
3.5e+00
—
3.3e+00
2.3e+00
1.2e+00
cases:1.50%
controls:1.03%
cases:1.59%
controls:0.53%
cases:2.56%
controls:0.08%
—
—
cases:3.12%
controls:0.12%
cases:6.03%
controls:0.62%
cases:5.94%
controls:1.87%
17
117
1116
11205
18
60
1115
11262
29
9
1104
11313
—
31
14
963
11295
37
69
577
11038
6
170
95
8905
Pulmonary embolism without mention of acute cor pulmonale
I26.9 [45552785]
—
—
2.6e+00
—
2.4e+00
2.6e+00
2.5e+00
—
—
—
—
cases:0.62%
controls:0.04%
—
—
cases:0.50%
controls:0.04%
cases:3.75%
controls:0.28%
cases:10.89%
controls:1.01%
—
—
7
5
1126
11317
—
5
5
989
11304
23
31
591
11076
11
92
90
8983
Monocytes/Leukocytes in Blood
26485-3 [3019069]
2.7e-01
9.3e-01
3.1e+00
—
2.7e+00
2.1e+00
1.4e+00
cases:11.39%
controls:8.89%
cases:11.74%
controls:5.00%
cases:17.21%
controls:0.89%
—
—
cases:12.07%
controls:0.95%
cases:30.94%
controls:5.30%
cases:35.64%
controls:12.45%
129
1007
1004
10315
133
566
1000
10756
195
101
938
11221
—
120
107
874
11202
190
589
424
10518
36
1130
65
7945
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
3.1e-01
9.3e-01
3.1e+00
—
2.7e+00
2.1e+00
1.4e+00
cases:11.65%
controls:8.86%
cases:11.74%
controls:5.01%
cases:17.21%
controls:0.89%
—
—
cases:12.07%
controls:0.94%
cases:30.46%
controls:5.25%
cases:35.64%
controls:12.44%
132
1003
1001
10319
133
567
1000
10755
195
101
938
11221
—
120
106
874
11203
187
583
427
10524
36
1129
65
7946
Basophils/Leukocytes in Blood
30180-4 [3022096]
3.1e-01
9.3e-01
3.1e+00
—
2.6e+00
2.0e+00
1.4e+00
cases:11.65%
controls:8.83%
cases:11.74%
controls:4.99%
cases:17.12%
controls:0.89%
—
—
cases:11.87%
controls:0.95%
cases:30.13%
controls:5.29%
cases:36.63%
controls:12.45%
132
1000
1001
10322
133
565
1000
10757
194
101
939
11221
—
118
107
876
11202
185
588
429
10519
37
1130
64
7945
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
3.8e-01
9.8e-01
2.9e+00
—
3.6e+00
2.7e+00
7.9e-01
cases:3.44%
controls:2.38%
cases:1.77%
controls:0.67%
cases:1.24%
controls:0.07%
—
—
cases:2.41%
controls:0.07%
cases:9.12%
controls:0.66%
cases:6.93%
controls:3.26%
39
269
1094
11053
20
76
1113
11246
14
8
1119
11314
—
24
8
970
11301
56
73
558
11034
7
296
94
8779
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
2.7e-01
9.2e-01
3.1e+00
—
2.6e+00
2.1e+00
1.4e+00
cases:11.47%
controls:9.04%
cases:11.92%
controls:5.13%
cases:17.12%
controls:0.89%
—
—
cases:12.07%
controls:1.00%
cases:31.11%
controls:5.46%
cases:36.63%
controls:12.87%
130
1024
1003
10298
135
581
998
10741
194
101
939
11221
—
120
113
874
11196
191
606
423
10501
37
1168
64
7907
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
-6.7e-02
2.9e-01
2.3e+00
4.4e+00
2.3e+00
7.7e-01
6.5e-01
cases:21.45%
controls:22.59%
cases:22.95%
controls:18.19%
cases:28.33%
controls:3.86%
cases:9.36%
controls:0.12%
cases:27.57%
controls:3.71%
cases:35.50%
controls:20.39%
cases:49.50%
controls:33.94%
243
2558
890
8764
260
2060
873
9262
321
437
812
10885
106
14
1027
11308
274
419
720
10890
218
2265
396
8842
50
3080
51
5995
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
3.9e-01
1.2e+00
3.2e+00
—
3.2e+00
2.3e+00
1.4e+00
cases:1.50%
controls:1.02%
cases:1.59%
controls:0.49%
cases:1.94%
controls:0.08%
—
—
cases:2.72%
controls:0.11%
cases:5.21%
controls:0.52%
cases:5.94%
controls:1.49%
17
116
1116
11206
18
55
1115
11267
22
9
1111
11313
—
27
13
967
11296
32
58
582
11049
6
135
95
8940
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
2.3e-01
8.9e-01
3.1e+00
—
2.6e+00
1.9e+00
1.4e+00
cases:10.94%
controls:8.91%
cases:11.47%
controls:5.06%
cases:16.50%
controls:0.90%
—
—
cases:11.57%
controls:0.95%
cases:28.34%
controls:5.44%
cases:36.63%
controls:12.60%
124
1009
1009
10313
130
573
1003
10749
187
102
946
11220
—
115
108
879
11201
174
604
440
10503
37
1143
64
7932
CBC panel - Blood by Automated count
58410-2 [40761511]
2.3e-02
3.3e-01
2.2e+00
4.1e+00
2.3e+00
9.2e-01
5.9e-01
cases:32.74%
controls:32.25%
cases:28.07%
controls:21.83%
cases:28.77%
controls:4.11%
cases:9.62%
controls:0.18%
cases:26.56%
controls:3.55%
cases:41.86%
controls:22.28%
cases:53.47%
controls:38.91%
371
3651
762
7671
318
2472
815
8850
326
465
807
10857
109
20
1024
11302
264
401
730
10908
257
2475
357
8632
54
3531
47
5544
Monocytes [#/volume] in Blood
26484-6 [3001604]
2.6e-01
8.9e-01
3.1e+00
—
2.6e+00
1.8e+00
1.4e+00
cases:11.74%
controls:9.31%
cases:11.83%
controls:5.20%
cases:17.39%
controls:0.98%
—
—
cases:11.97%
controls:0.99%
cases:27.69%
controls:5.80%
cases:38.61%
controls:13.45%
133
1054
1000
10268
134
589
999
10733
197
111
936
11211
—
119
112
875
11197
170
644
444
10463
39
1221
62
7854
Laboratory Visit
OMOP4822461 [32036]
-2.4e-02
2.0e-01
1.8e+00
4.6e+00
1.9e+00
6.6e-01
7.9e-01
cases:40.34%
controls:40.90%
cases:42.01%
controls:37.18%
cases:44.48%
controls:11.39%
cases:36.36%
controls:0.57%
cases:45.07%
controls:11.03%
cases:56.19%
controls:39.92%
cases:71.29%
controls:53.02%
457
4631
676
6691
476
4209
657
7113
504
1290
629
10032
412
64
721
11258
448
1247
546
10062
345
4434
269
6673
72
4812
29
4263
Basophils [#/volume] in Blood
26444-0 [3006315]
2.8e-01
8.9e-01
3.1e+00
—
2.6e+00
1.8e+00
1.4e+00
cases:12.09%
controls:9.40%
cases:11.83%
controls:5.23%
cases:17.39%
controls:0.98%
—
—
cases:11.97%
controls:1.00%
cases:27.69%
controls:5.83%
cases:38.61%
controls:13.54%
137
1064
996
10258
134
592
999
10730
197
111
936
11211
—
119
113
875
11196
170
647
444
10460
39
1229
62
7846
Eosinophils [#/volume] in Blood
26449-9 [3013115]
2.4e-01
8.8e-01
3.1e+00
—
2.6e+00
1.8e+00
1.4e+00
cases:12.44%
controls:10.03%
cases:12.18%
controls:5.43%
cases:17.65%
controls:1.00%
—
—
cases:12.37%
controls:1.02%
cases:27.69%
controls:6.02%
cases:39.60%
controls:13.93%
141
1136
992
10186
138
615
995
10707
200
113
933
11209
—
123
115
871
11194
170
669
444
10438
40
1264
61
7811
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
2.8e-01
8.7e-01
3.1e+00
—
2.6e+00
1.8e+00
1.4e+00
cases:12.62%
controls:9.80%
cases:12.09%
controls:5.45%
cases:17.65%
controls:0.99%
—
—
cases:12.07%
controls:1.03%
cases:28.50%
controls:5.97%
cases:38.61%
controls:13.91%
143
1110
990
10212
137
617
996
10705
200
112
933
11210
—
120
117
874
11192
175
663
439
10444
39
1262
62
7813
pH of Specimen
17433-4 [3019225]
4.6e-01
1.4e-01
2.9e+00
—
3.5e+00
1.8e+00
1.4e+00
cases:3.44%
controls:2.21%
cases:1.32%
controls:1.15%
cases:2.65%
controls:0.15%
—
—
cases:4.02%
controls:0.12%
cases:6.51%
controls:1.09%
cases:9.90%
controls:2.56%
39
250
1094
11072
15
130
1118
11192
30
17
1103
11305
—
40
14
954
11295
40
121
574
10986
10
232
91
8843
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
5.5e-01
1.2e+00
2.8e+00
—
3.2e+00
2.5e+00
—
cases:1.32%
controls:0.77%
cases:1.24%
controls:0.38%
cases:1.24%
controls:0.08%
—
—
cases:2.31%
controls:0.10%
cases:3.75%
controls:0.31%
—
—
15
87
1118
11235
14
43
1119
11279
14
9
1119
11313
—
23
11
971
11298
23
34
591
11073
—
Cathetrisation of vein
TPH04 [2001309597]
1.9e-02
8.8e-01
3.2e+00
—
3.4e+00
2.2e+00
1.1e+00
cases:2.74%
controls:2.69%
cases:2.12%
controls:0.89%
cases:2.38%
controls:0.10%
—
—
cases:2.52%
controls:0.09%
cases:8.14%
controls:1.01%
cases:9.90%
controls:3.46%
31
304
1102
11018
24
101
1109
11221
27
11
1106
11311
—
25
10
969
11299
50
112
564
10995
10
314
91
8761
Bacterial pneumonia, unspecified
J15.9 [45557621]
3.9e-01
9.5e-01
3.6e+00
—
2.9e+00
2.2e+00
1.1e+00
cases:1.94%
controls:1.32%
cases:1.59%
controls:0.62%
cases:1.94%
controls:0.05%
—
—
cases:1.51%
controls:0.09%
cases:4.72%
controls:0.54%
cases:6.93%
controls:2.49%
22
150
1111
11172
18
70
1115
11252
22
6
1111
11316
—
15
10
979
11299
29
60
585
11047
7
226
94
8849
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
9.1e-01
1.1e+00
3.2e+00
—
1.7e+00
2.6e+00
1.0e+00
cases:1.68%
controls:0.68%
cases:1.94%
controls:0.63%
cases:2.65%
controls:0.11%
—
—
cases:1.01%
controls:0.19%
cases:8.79%
controls:0.72%
cases:5.94%
controls:2.24%
19
77
1114
11245
22
71
1111
11251
30
12
1103
11310
—
10
21
984
11288
54
80
560
11027
6
203
95
8872
ethylmorphine; oral
R05DA01 [21603397]
1.1e-01
1.1e+00
2.3e+00
—
2.6e+00
1.9e+00
1.7e+00
cases:3.18%
controls:2.84%
cases:1.85%
controls:0.62%
cases:0.71%
controls:0.07%
—
—
cases:0.80%
controls:0.06%
cases:4.72%
controls:0.74%
cases:9.90%
controls:1.99%
36
322
1097
11000
21
70
1112
11252
8
8
1125
11314
—
8
7
986
11302
29
82
585
11025
10
181
91
8894
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
3.1e-01
1.0e+00
3.8e+00
1.0e+50
3.0e+00
1.6e+00
9.9e-01
cases:3.62%
controls:2.67%
cases:2.91%
controls:1.04%
cases:5.83%
controls:0.14%
cases:1.50%
controls:0.00%
cases:2.52%
controls:0.12%
cases:4.89%
controls:0.98%
cases:8.91%
controls:3.50%
41
302
1092
11020
33
118
1100
11204
66
16
1067
11306
17
0
1116
11322
25
14
969
11295
30
109
584
10998
9
318
92
8757
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
5.5e-01
8.9e-01
3.0e+00
—
3.8e+00
2.6e+00
1.3e+00
cases:1.94%
controls:1.13%
cases:1.41%
controls:0.58%
cases:1.94%
controls:0.10%
—
—
cases:4.63%
controls:0.11%
cases:7.65%
controls:0.59%
cases:6.93%
controls:1.99%
22
128
1111
11194
16
66
1117
11256
22
11
1111
11311
—
46
12
948
11297
47
65
567
11042
7
181
94
8894
General Practice
1 [38004446]
3.1e-02
3.4e-01
2.2e+00
2.7e+00
2.5e+00
1.9e+00
6.8e-01
cases:16.42%
controls:16.00%
cases:10.33%
controls:7.54%
cases:9.53%
controls:1.12%
cases:0.79%
controls:0.05%
cases:12.37%
controls:1.12%
cases:36.64%
controls:7.80%
cases:37.62%
controls:23.38%
186
1811
947
9511
117
854
1016
10468
108
127
1025
11195
9
6
1124
11316
123
127
871
11182
225
866
389
10241
38
2122
63
6953
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
9.3e-01
1.1e+00
3.1e+00
—
1.6e+00
2.6e+00
1.0e+00
cases:1.59%
controls:0.64%
cases:1.77%
controls:0.60%
cases:2.38%
controls:0.11%
—
—
cases:0.91%
controls:0.19%
cases:8.14%
controls:0.68%
cases:5.94%
controls:2.19%
18
72
1115
11250
20
68
1113
11254
27
12
1106
11310
—
9
21
985
11288
50
76
564
11031
6
199
95
8876
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
1.1e+00
2.7e+00
—
1.0e+50
—
3.6e+00
1.8e+00
cases:2.82%
controls:0.96%
cases:6.27%
controls:0.44%
—
—
cases:9.89%
controls:0.00%
—
—
cases:10.75%
controls:0.32%
cases:6.93%
controls:1.17%
32
109
1101
11213
71
50
1062
11272
—
112
0
1021
11322
—
66
36
548
11071
7
106
94
8969
prednisolone; oral, parenteral
H02AB06 [21602734]
4.3e-01
8.9e-01
2.1e+00
—
2.8e+00
1.8e+00
1.3e+00
cases:17.21%
controls:11.89%
cases:12.36%
controls:5.48%
cases:7.94%
controls:1.05%
—
—
cases:13.68%
controls:0.98%
cases:26.38%
controls:5.59%
cases:34.65%
controls:13.10%
195
1346
938
9976
140
621
993
10701
90
119
1043
11203
—
136
111
858
11198
162
621
452
10486
35
1189
66
7886
prednisolone
A07EA01 [21600653]
4.4e-01
8.8e-01
2.1e+00
—
2.8e+00
1.8e+00
1.3e+00
cases:17.30%
controls:11.91%
cases:12.36%
controls:5.50%
cases:7.94%
controls:1.05%
—
—
cases:13.68%
controls:0.98%
cases:26.38%
controls:5.61%
cases:34.65%
controls:13.12%
196
1349
937
9973
140
623
993
10699
90
119
1043
11203
—
136
111
858
11198
162
623
452
10484
35
1191
66
7884
Other interstitial pulmonary diseases with fibrosis
J84.1 [45557630]
1.7e+00
2.3e+00
3.4e+00
—
—
1.9e+00
-1.0e+50
cases:1.06%
controls:0.20%
cases:1.50%
controls:0.16%
cases:1.32%
controls:0.04%
—
—
—
—
cases:1.30%
controls:0.20%
cases:0.00%
controls:0.30%
12
23
1121
11299
17
18
1116
11304
15
5
1118
11317
—
—
8
22
606
11085
0
27
101
9048
Teaching
WZC30 [2001310891]
3.2e-01
8.8e-01
—
1.0e+50
4.1e+00
3.1e+00
2.0e+00
cases:1.68%
controls:1.23%
cases:1.41%
controls:0.59%
—
—
cases:0.79%
controls:0.00%
cases:3.12%
controls:0.05%
cases:10.91%
controls:0.52%
cases:12.87%
controls:2.03%
19
139
1114
11183
16
67
1117
11255
—
9
0
1124
11322
31
6
963
11303
67
58
547
11049
13
184
88
8891
Immunohistochemistry procedure
117617002 [4035726]
1.3e+00
1.7e+00
1.0e+50
1.0e+50
1.0e+50
2.8e+00
3.3e+00
cases:1.50%
controls:0.42%
cases:0.79%
controls:0.14%
cases:1.77%
controls:0.00%
cases:19.15%
controls:0.00%
cases:3.72%
controls:0.00%
cases:2.93%
controls:0.18%
cases:8.91%
controls:0.35%
17
47
1116
11275
9
16
1124
11306
20
0
1113
11322
217
0
916
11322
37
0
957
11309
18
20
596
11087
9
32
92
9043
Extensive CT of head and brain
AA1BD [2001300110]
—
—
1.0e+50
—
1.0e+50
4.8e+00
4.4e+00
—
—
—
—
cases:0.53%
controls:0.00%
—
—
cases:1.41%
controls:0.00%
cases:5.05%
controls:0.05%
cases:7.92%
controls:0.11%
—
—
6
0
1127
11322
—
14
0
980
11309
31
5
583
11102
8
10
93
9065
pH of Arterial blood
2744-1 [3019977]
7.6e-01
6.4e-01
3.4e+00
1.0e+50
3.6e+00
1.3e+00
6.6e-01
cases:3.09%
controls:1.47%
cases:1.59%
controls:0.85%
cases:3.35%
controls:0.11%
cases:1.06%
controls:0.00%
cases:1.61%
controls:0.04%
cases:3.58%
controls:0.98%
cases:5.94%
controls:3.15%
35
166
1098
11156
18
96
1115
11226
38
13
1095
11309
12
0
1121
11322
16
5
978
11304
22
109
592
10998
6
286
95
8789
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
4.4e-01
1.0e+00
3.2e+00
1.0e+50
2.9e+00
2.0e+00
8.6e-01
cases:3.44%
controls:2.25%
cases:1.94%
controls:0.69%
cases:1.85%
controls:0.08%
cases:0.71%
controls:0.00%
cases:1.61%
controls:0.09%
cases:4.72%
controls:0.69%
cases:5.94%
controls:2.60%
39
255
1094
11067
22
78
1111
11244
21
9
1112
11313
8
0
1125
11322
16
10
978
11299
29
77
585
11030
6
236
95
8839
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-1.7e-01
1.2e-01
2.0e+00
4.3e+00
2.2e+00
5.4e-01
5.3e-01
cases:24.45%
controls:27.72%
cases:23.83%
controls:21.67%
cases:26.57%
controls:4.49%
cases:9.27%
controls:0.13%
cases:26.76%
controls:4.03%
cases:33.71%
controls:22.79%
cases:49.50%
controls:36.63%
277
3138
856
8184
270
2453
863
8869
301
508
832
10814
105
15
1028
11307
266
456
728
10853
207
2531
407
8576
50
3324
51
5751
Dyspnoea
R06.0 [45558449]
4.8e-01
1.1e+00
3.7e+00
—
2.4e+00
1.4e+00
6.4e-01
cases:5.65%
controls:3.59%
cases:3.88%
controls:1.30%
cases:7.15%
controls:0.19%
—
—
cases:2.11%
controls:0.20%
cases:6.03%
controls:1.61%
cases:9.90%
controls:5.50%
64
406
1069
10916
44
147
1089
11175
81
22
1052
11300
—
21
23
973
11286
37
179
577
10928
10
499
91
8576
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.6e-01
3.7e-01
2.8e+00
—
3.3e+00
1.6e+00
1.3e+00
cases:7.24%
controls:6.23%
cases:3.62%
controls:2.52%
cases:4.59%
controls:0.29%
—
—
cases:6.14%
controls:0.25%
cases:12.21%
controls:2.74%
cases:23.76%
controls:8.07%
82
705
1051
10617
41
285
1092
11037
52
33
1081
11289
—
61
28
933
11281
75
304
539
10803
24
732
77
8343
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
3.8e-01
8.6e-01
3.7e+00
—
2.5e+00
1.7e+00
3.0e-01
cases:2.21%
controls:1.52%
cases:1.94%
controls:0.83%
cases:2.91%
controls:0.07%
—
—
cases:1.21%
controls:0.10%
cases:5.54%
controls:1.07%
cases:4.95%
controls:3.71%
25
172
1108
11150
22
94
1111
11228
33
8
1100
11314
—
12
11
982
11298
34
119
580
10988
5
337
96
8738
tiotropium bromide; inhalant
R03BB04 [21603296]
1.2e+00
1.4e+00
1.4e+00
—
1.8e+00
1.3e+00
1.7e+00
cases:9.89%
controls:3.14%
cases:9.89%
controls:2.60%
cases:3.44%
controls:0.88%
—
—
cases:4.73%
controls:0.80%
cases:9.45%
controls:2.82%
cases:22.77%
controls:5.15%
112
356
1021
10966
112
294
1021
11028
39
100
1094
11222
—
47
90
947
11219
58
313
556
10794
23
467
78
8608
Outpatient Visit
OP [9202]
7.5e-02
2.1e-01
1.3e+00
3.6e+00
2.2e+00
1.5e+00
9.8e-01
cases:70.79%
controls:69.22%
cases:54.90%
controls:49.54%
cases:29.13%
controls:9.88%
cases:13.59%
controls:0.42%
cases:48.09%
controls:9.44%
cases:81.92%
controls:51.22%
cases:91.09%
controls:79.32%
802
7837
331
3485
622
5609
511
5713
330
1119
803
10203
154
47
979
11275
478
1068
516
10241
503
5689
111
5418
92
7198
9
1877
Palliative care
Z51.5 [45547323]
-1.0e+50
—
—
—
—
5.0e+00
3.8e+00
cases:0.00%
controls:0.04%
—
—
—
—
—
—
—
—
cases:18.89%
controls:0.15%
cases:18.81%
controls:0.53%
0
5
1133
11317
—
—
—
—
116
17
498
11090
19
48
82
9027
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
3.3e-01
6.7e-01
3.2e+00
—
3.5e+00
2.1e+00
—
cases:2.47%
controls:1.79%
cases:1.50%
controls:0.78%
cases:2.03%
controls:0.09%
—
—
cases:2.31%
controls:0.07%
cases:6.84%
controls:0.87%
—
—
28
203
1105
11119
17
88
1116
11234
23
10
1110
11312
—
23
8
971
11301
42
97
572
11010
—
Fever, unspecified
R50.9 [45582716]
2.5e-01
-7.1e-04
2.7e+00
—
3.1e+00
2.9e+00
1.3e+00
cases:1.59%
controls:1.24%
cases:0.44%
controls:0.44%
cases:0.79%
controls:0.05%
—
—
cases:1.01%
controls:0.04%
cases:6.19%
controls:0.35%
cases:6.93%
controls:1.91%
18
140
1115
11182
5
50
1128
11272
9
6
1124
11316
—
10
5
984
11304
38
39
576
11068
7
173
94
8902
Enolase.neuron specific [Mass/volume] in Serum or Plasma
15060-7 [3028531]
—
3.1e+00
1.0e+50
1.0e+50
1.0e+50
—
5.7e+00
—
—
cases:1.15%
controls:0.05%
cases:9.27%
controls:0.00%
cases:2.21%
controls:0.00%
cases:13.98%
controls:0.00%
—
—
cases:24.75%
controls:0.11%
—
13
6
1120
11316
105
0
1028
11322
25
0
1108
11322
139
0
855
11309
—
25
10
76
9065
Normoblasts [#/volume] in Blood
715-3 [3021589]
2.2e-01
6.4e-01
2.8e+00
—
2.5e+00
1.4e+00
1.4e+00
cases:9.09%
controls:7.41%
cases:10.68%
controls:5.91%
cases:16.33%
controls:1.12%
—
—
cases:13.78%
controls:1.34%
cases:24.27%
controls:7.05%
cases:39.60%
controls:14.20%
103
839
1030
10483
121
669
1012
10653
185
127
948
11195
—
137
152
857
11157
149
783
465
10324
40
1289
61
7786
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
1.9e-01
1.0e+00
1.8e+00
—
2.4e+00
1.8e+00
1.6e+00
cases:7.15%
controls:6.01%
cases:4.50%
controls:1.64%
cases:1.41%
controls:0.24%
—
—
cases:2.72%
controls:0.26%
cases:9.61%
controls:1.81%
cases:23.76%
controls:5.82%
81
680
1052
10642
51
186
1082
11136
16
27
1117
11295
—
27
29
967
11280
59
201
555
10906
24
528
77
8547
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
3.5e-01
1.0e+00
3.8e+00
—
2.4e+00
1.3e+00
—
cases:1.50%
controls:1.06%
cases:1.68%
controls:0.61%
cases:1.94%
controls:0.04%
—
—
cases:0.80%
controls:0.07%
cases:3.42%
controls:0.95%
—
—
17
120
1116
11202
19
69
1114
11253
22
5
1111
11317
—
8
8
986
11301
21
106
593
11001
—
Blasts/Leukocytes in Blood
26446-5 [3025159]
8.8e-01
1.0e+00
3.2e+00
—
1.9e+00
2.4e+00
1.2e+00
cases:1.41%
controls:0.59%
cases:1.59%
controls:0.59%
cases:2.47%
controls:0.11%
—
—
cases:1.21%
controls:0.18%
cases:7.98%
controls:0.76%
cases:6.93%
controls:2.20%
16
67
1117
11255
18
67
1115
11255
28
12
1105
11310
—
12
20
982
11289
49
84
565
11023
7
200
94
8875
Office Visit
OMOP4822458 [581477]
1.1e-01
4.2e-01
3.0e+00
—
3.6e+00
1.9e+00
2.2e-01
cases:8.38%
controls:7.60%
cases:3.53%
controls:2.35%
cases:4.77%
controls:0.25%
—
—
cases:7.85%
controls:0.24%
cases:13.52%
controls:2.21%
cases:8.91%
controls:7.28%
95
860
1038
10462
40
266
1093
11056
54
28
1079
11294
—
78
27
916
11282
83
246
531
10861
9
661
92
8414
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
7.1e-02
5.8e-01
2.8e+00
—
2.6e+00
1.5e+00
1.0e+00
cases:6.35%
controls:5.94%
cases:4.32%
controls:2.47%
cases:4.94%
controls:0.30%
—
—
cases:3.02%
controls:0.24%
cases:9.93%
controls:2.49%
cases:19.80%
controls:8.09%
72
673
1061
10649
49
280
1084
11042
56
34
1077
11288
—
30
27
964
11282
61
277
553
10830
20
734
81
8341
enoxaparin; parenteral
B01AB05 [21600976]
2.4e-01
-7.2e-04
1.8e+00
—
3.4e+00
1.9e+00
1.4e+00
cases:6.00%
controls:4.80%
cases:1.32%
controls:1.32%
cases:0.97%
controls:0.16%
—
—
cases:4.23%
controls:0.15%
cases:6.84%
controls:1.10%
cases:13.86%
controls:3.87%
68
544
1065
10778
15
150
1118
11172
11
18
1122
11304
—
42
17
952
11292
42
122
572
10985
14
351
87
8724
ECG with 12 standard connections
XF400 [2001303368]
1.6e-01
7.7e-01
3.7e+00
—
2.9e+00
1.8e+00
7.1e-01
cases:3.00%
controls:2.56%
cases:1.77%
controls:0.82%
cases:2.74%
controls:0.07%
—
—
cases:1.61%
controls:0.09%
cases:4.89%
controls:0.81%
cases:5.94%
controls:3.00%
34
290
1099
11032
20
93
1113
11229
31
8
1102
11314
—
16
10
978
11299
30
90
584
11017
6
272
95
8803
Cytology report of Tissue fine needle aspirate Cyto stain
33718-8 [3043109]
6.9e-01
2.3e+00
1.0e+50
1.0e+50
1.0e+50
2.9e+00
3.2e+00
cases:0.44%
controls:0.22%
cases:0.53%
controls:0.05%
cases:1.15%
controls:0.00%
cases:5.47%
controls:0.00%
cases:1.21%
controls:0.00%
cases:1.14%
controls:0.06%
cases:4.95%
controls:0.21%
5
25
1128
11297
6
6
1127
11316
13
0
1120
11322
62
0
1071
11322
12
0
982
11309
7
7
607
11100
5
19
96
9056
Thorax CT examination
GD1AD [2001303618]
7.0e-01
1.8e+00
—
1.0e+50
—
3.7e+00
2.9e+00
cases:0.62%
controls:0.31%
cases:1.06%
controls:0.18%
—
—
cases:0.44%
controls:0.00%
—
—
cases:7.00%
controls:0.19%
cases:11.88%
controls:0.73%
7
35
1126
11287
12
20
1121
11302
—
5
0
1128
11322
—
43
21
571
11086
12
66
89
9009
Malaise and fatigue
R53 [45553741]
-6.1e-01
2.6e-01
2.8e+00
—
3.1e+00
1.4e+00
1.0e+00
cases:1.41%
controls:2.57%
cases:1.50%
controls:1.17%
cases:1.59%
controls:0.10%
—
—
cases:1.31%
controls:0.06%
cases:5.05%
controls:1.24%
cases:13.86%
controls:5.59%
16
291
1117
11031
17
132
1116
11190
18
11
1115
11311
—
13
7
981
11302
31
138
583
10969
14
507
87
8568
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
1.2e-01
1.5e-01
1.8e+00
3.2e+00
2.4e+00
9.4e-01
-2.5e-02
cases:8.38%
controls:7.49%
cases:4.50%
controls:3.90%
cases:3.71%
controls:0.61%
cases:1.24%
controls:0.05%
cases:5.33%
controls:0.53%
cases:10.75%
controls:4.51%
cases:10.89%
controls:11.14%
95
848
1038
10474
51
442
1082
10880
42
69
1091
11253
14
6
1119
11316
53
60
941
11249
66
501
548
10606
11
1011
90
8064
Flexible bronchoscopy
UGC12 [2001303610]
7.6e-01
3.1e+00
—
—
—
3.1e+00
2.1e+00
cases:1.41%
controls:0.66%
cases:3.97%
controls:0.19%
—
—
—
—
—
—
cases:4.23%
controls:0.20%
cases:5.94%
controls:0.76%
16
75
1117
11247
45
22
1088
11300
—
—
—
26
22
588
11085
6
69
95
9006
Physiotherapy
R4110 [2001310233]
2.4e-01
6.5e-01
2.7e+00
—
2.2e+00
1.5e+00
1.2e+00
cases:5.21%
controls:4.13%
cases:2.91%
controls:1.54%
cases:3.09%
controls:0.21%
—
—
cases:1.61%
controls:0.19%
cases:5.05%
controls:1.20%
cases:12.87%
controls:4.28%
59
468
1074
10854
33
174
1100
11148
35
24
1098
11298
—
16
21
978
11288
31
133
583
10974
13
388
88
8687
ABO and Rh group [Type] in Blood
882-1 [3003694]
1.3e-01
7.5e-01
3.1e+00
—
3.0e+00
1.3e+00
4.6e-01
cases:4.06%
controls:3.58%
cases:2.29%
controls:1.10%
cases:1.85%
controls:0.09%
—
—
cases:2.11%
controls:0.11%
cases:4.40%
controls:1.20%
cases:6.93%
controls:4.47%
46
405
1087
10917
26
124
1107
11198
21
10
1112
11312
—
21
12
973
11297
27
133
587
10974
7
406
94
8669
Monitored bed care
WX892 [2001310850]
1.6e-01
1.5e+00
—
1.0e+50
2.8e+00
1.8e+00
1.9e+00
cases:0.97%
controls:0.83%
cases:1.06%
controls:0.24%
—
—
cases:1.94%
controls:0.00%
cases:0.70%
controls:0.04%
cases:1.30%
controls:0.21%
cases:5.94%
controls:0.93%
11
94
1122
11228
12
27
1121
11295
—
22
0
1111
11322
7
5
987
11304
8
23
606
11084
6
84
95
8991
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
7.2e-01
2.1e+00
—
1.0e+50
—
3.1e+00
2.8e+00
cases:1.77%
controls:0.87%
cases:2.56%
controls:0.34%
—
—
cases:2.29%
controls:0.00%
—
—
cases:7.65%
controls:0.37%
cases:14.85%
controls:1.00%
20
98
1113
11224
29
38
1104
11284
—
26
0
1107
11322
—
47
41
567
11066
15
91
86
8984
Body CT examination
JN4AD [2001310897]
1.2e+00
—
—
1.0e+50
—
4.6e+00
3.4e+00
cases:0.97%
controls:0.28%
—
—
—
—
cases:0.53%
controls:0.00%
—
—
cases:16.94%
controls:0.21%
cases:18.81%
controls:0.79%
11
32
1122
11290
—
—
6
0
1127
11322
—
104
23
510
11084
19
72
82
9003
fenoterol and ipratropium bromide
R03AL01 [43534843]
8.5e-01
1.2e+00
2.1e+00
—
2.2e+00
1.5e+00
1.1e+00
cases:3.97%
controls:1.74%
cases:3.71%
controls:1.12%
cases:2.65%
controls:0.32%
—
—
cases:2.82%
controls:0.32%
cases:5.37%
controls:1.22%
cases:7.92%
controls:2.84%
45
197
1088
11125
42
127
1091
11195
30
36
1103
11286
—
28
36
966
11273
33
136
581
10971
8
258
93
8817
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
2.8e-01
8.0e-01
3.3e+00
1.0e+50
3.0e+00
1.5e+00
—
cases:1.32%
controls:1.01%
cases:1.06%
controls:0.48%
cases:2.21%
controls:0.08%
cases:0.88%
controls:0.00%
cases:1.11%
controls:0.05%
cases:2.61%
controls:0.57%
—
—
15
114
1118
11208
12
54
1121
11268
25
9
1108
11313
10
0
1123
11322
11
6
983
11303
16
63
598
11044
—
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
8.2e-02
6.6e-01
3.1e+00
—
2.6e+00
1.5e+00
4.2e-01
cases:8.91%
controls:8.27%
cases:7.77%
controls:4.19%
cases:10.06%
controls:0.49%
—
—
cases:5.94%
controls:0.46%
cases:16.94%
controls:4.27%
cases:17.82%
controls:12.52%
101
936
1032
10386
88
474
1045
10848
114
56
1019
11266
—
59
52
935
11257
104
474
510
10633
18
1136
83
7939
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
2.1e-01
8.7e-01
3.1e+00
—
2.2e+00
1.6e+00
6.1e-01
cases:3.97%
controls:3.23%
cases:3.71%
controls:1.59%
cases:6.27%
controls:0.29%
—
—
cases:2.52%
controls:0.29%
cases:9.12%
controls:1.91%
cases:8.91%
controls:5.06%
45
366
1088
10956
42
180
1091
11142
71
33
1062
11289
—
25
33
969
11276
56
212
558
10895
9
459
92
8616
Chronic obstructive pulmonary disease, unspecified
J44.9 [45548115]
1.2e+00
1.3e+00
—
1.0e+50
3.4e+00
1.9e+00
1.0e+00
cases:3.00%
controls:0.94%
cases:1.68%
controls:0.45%
—
—
cases:0.44%
controls:0.00%
cases:1.51%
controls:0.05%
cases:3.58%
controls:0.53%
cases:4.95%
controls:1.85%
34
106
1099
11216
19
51
1114
11271
—
5
0
1128
11322
15
6
979
11303
22
59
592
11048
5
168
96
8907
Microorganisms panel - Urine sediment
58435-9 [40761536]
5.7e-01
9.3e-01
2.2e+00
—
2.6e+00
2.1e+00
1.2e+00
cases:2.47%
controls:1.41%
cases:1.85%
controls:0.74%
cases:1.06%
controls:0.12%
—
—
cases:1.71%
controls:0.12%
cases:5.21%
controls:0.68%
cases:4.95%
controls:1.58%
28
160
1105
11162
21
84
1112
11238
12
14
1121
11308
—
17
14
977
11295
32
76
582
11031
5
143
96
8932
Bacteria identified in Isolate by Culture
43409-2 [3042936]
4.3e-01
8.8e-01
3.2e+00
1.0e+50
2.0e+00
1.7e+00
7.6e-01
cases:3.62%
controls:2.38%
cases:2.21%
controls:0.93%
cases:1.94%
controls:0.08%
cases:1.50%
controls:0.00%
cases:0.80%
controls:0.11%
cases:4.40%
controls:0.86%
cases:5.94%
controls:2.88%
41
270
1092
11052
25
105
1108
11217
22
9
1111
11313
17
0
1116
11322
8
12
986
11297
27
95
587
11012
6
261
95
8814
Essential (primary) hypertension
I10 [45591453]
4.6e-02
3.2e-01
1.6e+00
3.2e+00
1.8e+00
7.4e-01
1.0e-01
cases:22.51%
controls:21.71%
cases:14.56%
controls:11.01%
cases:8.47%
controls:1.81%
cases:2.74%
controls:0.11%
cases:9.66%
controls:1.67%
cases:21.17%
controls:11.39%
cases:31.68%
controls:29.50%
255
2458
878
8864
165
1246
968
10076
96
205
1037
11117
31
13
1102
11309
96
189
898
11120
130
1265
484
9842
32
2677
69
6398
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
6.3e-01
7.3e-01
2.2e+00
—
1.7e+00
9.0e-01
1.5e+00
cases:4.41%
controls:2.39%
cases:2.82%
controls:1.38%
cases:1.94%
controls:0.22%
—
—
cases:2.01%
controls:0.37%
cases:3.42%
controls:1.42%
cases:11.88%
controls:2.92%
50
271
1083
11051
32
156
1101
11166
22
25
1111
11297
—
20
42
974
11267
21
158
593
10949
12
265
89
8810
Periodontitis pronounced
K05.31 [2000502729]
1.0e+00
6.7e-01
2.2e+00
—
2.8e+00
1.7e+00
1.4e+00
cases:4.24%
controls:1.53%
cases:1.24%
controls:0.64%
cases:0.53%
controls:0.06%
—
—
cases:1.51%
controls:0.10%
cases:2.93%
controls:0.55%
cases:6.93%
controls:1.76%
48
173
1085
11149
14
72
1119
11250
6
7
1127
11315
—
15
11
979
11298
18
61
596
11046
7
160
94
8915
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
2.2e-01
1.8e+00
—
—
4.0e+00
1.8e+00
—
cases:0.71%
controls:0.57%
cases:1.59%
controls:0.26%
—
—
—
—
cases:2.41%
controls:0.04%
cases:1.30%
controls:0.22%
—
—
8
64
1125
11258
18
30
1115
11292
—
—
24
5
970
11304
8
24
606
11083
—
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
4.5e-01
9.7e-01
3.3e+00
—
2.2e+00
1.2e+00
—
cases:1.94%
controls:1.25%
cases:2.12%
controls:0.81%
cases:2.03%
controls:0.08%
—
—
cases:0.91%
controls:0.11%
cases:3.75%
controls:1.17%
—
—
22
141
1111
11181
24
92
1109
11230
23
9
1110
11313
—
9
12
985
11297
23
130
591
10977
—
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
—
—
-1.0e+50
—
3.4e+00
4.1e+00
—
—
—
—
—
cases:0.00%
controls:0.05%
—
—
cases:1.61%
controls:0.05%
cases:7.33%
controls:0.13%
—
—
—
—
0
6
1133
11316
—
16
6
978
11303
45
14
569
11093
—
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
3.5e-01
6.5e-01
2.6e+00
—
2.5e+00
1.8e+00
8.0e-01
cases:7.41%
controls:5.35%
cases:3.88%
controls:2.08%
cases:3.71%
controls:0.29%
—
—
cases:2.31%
controls:0.19%
cases:11.24%
controls:1.97%
cases:13.86%
controls:6.77%
84
606
1049
10716
44
235
1089
11087
42
33
1091
11289
—
23
22
971
11287
69
219
545
10888
14
614
87
8461
Oxygen saturation in Arterial blood
2708-6 [3016502]
5.9e-01
5.9e-01
3.4e+00
1.0e+50
2.9e+00
1.3e+00
7.4e-01
cases:2.21%
controls:1.24%
cases:1.24%
controls:0.69%
cases:2.74%
controls:0.10%
cases:0.62%
controls:0.00%
cases:0.80%
controls:0.04%
cases:2.93%
controls:0.85%
cases:5.94%
controls:2.93%
25
140
1108
11182
14
78
1119
11244
31
11
1102
11311
7
0
1126
11322
8
5
986
11304
18
94
596
11013
6
266
95
8809
X-ray examination of the lungs in one projection
GD1PA [2001303645]
2.3e-01
8.1e-01
—
1.0e+50
3.2e+00
2.3e+00
1.9e+00
cases:1.32%
controls:1.05%
cases:0.79%
controls:0.35%
—
—
cases:1.68%
controls:0.00%
cases:1.51%
controls:0.06%
cases:3.42%
controls:0.34%
cases:10.89%
controls:1.73%
15
119
1118
11203
9
40
1124
11282
—
19
0
1114
11322
15
7
979
11302
21
38
593
11069
11
157
90
8918
Tissue Pathology biopsy report
66121-5 [40768804]
3.7e-01
9.4e-01
2.4e+00
1.0e+50
3.1e+00
9.2e-01
5.7e-01
cases:8.47%
controls:5.99%
cases:5.12%
controls:2.07%
cases:2.21%
controls:0.19%
cases:17.30%
controls:0.00%
cases:3.32%
controls:0.15%
cases:4.40%
controls:1.79%
cases:9.90%
controls:5.84%
96
678
1037
10644
58
234
1075
11088
25
22
1108
11300
196
0
937
11322
33
17
961
11292
27
199
587
10908
10
530
91
8545
Osmolality of Urine
2695-5 [3026782]
6.6e-02
7.5e-01
2.8e+00
—
2.1e+00
1.8e+00
6.9e-01
cases:4.59%
controls:4.31%
cases:3.62%
controls:1.75%
cases:4.06%
controls:0.26%
—
—
cases:2.41%
controls:0.31%
cases:8.31%
controls:1.55%
cases:7.92%
controls:4.14%
52
488
1081
10834
41
198
1092
11124
46
29
1087
11293
—
24
35
970
11274
51
172
563
10935
8
376
93
8699
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
1.2e-01
6.4e-01
2.2e+00
—
2.1e+00
1.5e+00
8.9e-01
cases:6.18%
controls:5.52%
cases:5.21%
controls:2.83%
cases:3.88%
controls:0.43%
—
—
cases:3.62%
controls:0.45%
cases:13.03%
controls:3.24%
cases:20.79%
controls:9.76%
70
625
1063
10697
59
320
1074
11002
44
49
1089
11273
—
36
51
958
11258
80
360
534
10747
21
886
80
8189
Medical doctor
Z2221 [2001311556]
6.1e-01
7.3e-01
2.7e+00
—
2.8e+00
1.2e+00
—
cases:6.35%
controls:3.54%
cases:1.77%
controls:0.86%
cases:1.77%
controls:0.11%
—
—
cases:1.71%
controls:0.11%
cases:2.61%
controls:0.81%
—
—
72
401
1061
10921
20
97
1113
11225
20
13
1113
11309
—
17
12
977
11297
16
90
598
11017
—
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
-6.0e-02
7.2e-01
2.8e+00
1.0e+50
1.7e+00
1.1e+00
1.0e+00
cases:3.62%
controls:3.83%
cases:3.88%
controls:1.93%
cases:4.59%
controls:0.29%
cases:0.79%
controls:0.00%
cases:1.61%
controls:0.29%
cases:5.86%
controls:2.11%
cases:14.85%
controls:5.88%
41
434
1092
10888
44
219
1089
11103
52
33
1081
11289
9
0
1124
11322
16
33
978
11276
36
234
578
10873
15
534
86
8541
Atrial fibrillation and flutter
I48 [45596206]
1.5e-01
5.1e-01
1.7e+00
3.1e+00
2.0e+00
4.7e-01
2.0e-01
cases:9.97%
controls:8.67%
cases:7.86%
controls:4.85%
cases:4.59%
controls:0.87%
cases:1.15%
controls:0.05%
cases:5.73%
controls:0.80%
cases:7.65%
controls:4.92%
cases:14.85%
controls:12.46%
113
982
1020
10340
89
549
1044
10773
52
98
1081
11224
13
6
1120
11316
57
91
937
11218
47
547
567
10560
15
1131
86
7944
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
5.7e-02
6.6e-01
2.2e+00
—
2.1e+00
1.5e+00
9.3e-01
cases:7.33%
controls:6.95%
cases:6.09%
controls:3.23%
cases:4.06%
controls:0.48%
—
—
cases:4.02%
controls:0.53%
cases:13.52%
controls:3.51%
cases:21.78%
controls:9.94%
83
787
1050
10535
69
366
1064
10956
46
54
1087
11268
—
40
60
954
11249
83
390
531
10717
22
902
79
8173
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
-5.6e-02
6.9e-01
2.9e+00
—
3.0e+00
1.3e+00
—
cases:1.59%
controls:1.68%
cases:1.41%
controls:0.72%
cases:1.24%
controls:0.07%
—
—
cases:1.11%
controls:0.05%
cases:1.95%
controls:0.52%
—
—
18
190
1115
11132
16
81
1117
11241
14
8
1119
11314
—
11
6
983
11303
12
58
602
11049
—
Supine thorax X-ray examination
GD1QA [2001303648]
2.4e-01
6.0e-01
2.7e+00
—
2.7e+00
1.8e+00
7.4e-01
cases:2.82%
controls:2.23%
cases:1.59%
controls:0.87%
cases:2.12%
controls:0.14%
—
—
cases:1.71%
controls:0.11%
cases:6.51%
controls:1.14%
cases:8.91%
controls:4.47%
32
253
1101
11069
18
99
1115
11223
24
16
1109
11306
—
17
13
977
11296
40
127
574
10980
9
406
92
8669
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
1.7e-01
4.5e-01
2.7e+00
—
2.8e+00
1.2e+00
6.1e-01
cases:15.18%
controls:13.17%
cases:9.09%
controls:6.01%
cases:9.00%
controls:0.64%
—
—
cases:10.06%
controls:0.68%
cases:18.40%
controls:6.17%
cases:25.74%
controls:15.90%
172
1491
961
9831
103
680
1030
10642
102
72
1031
11250
—
100
77
894
11232
113
685
501
10422
26
1443
75
7632
roxithromycin; oral
J01FA06 [21602974]
4.0e-01
1.2e+00
2.8e+00
—
2.1e+00
1.1e+00
4.9e-01
cases:5.03%
controls:3.44%
cases:3.88%
controls:1.15%
cases:1.68%
controls:0.11%
—
—
cases:0.70%
controls:0.09%
cases:3.42%
controls:1.22%
cases:5.94%
controls:3.74%
57
389
1076
10933
44
130
1089
11192
19
12
1114
11310
—
7
10
987
11299
21
135
593
10972
6
339
95
8736
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
2.1e-01
6.6e-01
2.5e+00
—
2.3e+00
1.7e+00
5.7e-01
cases:4.77%
controls:3.90%
cases:3.09%
controls:1.63%
cases:2.74%
controls:0.23%
—
—
cases:2.11%
controls:0.21%
cases:8.14%
controls:1.66%
cases:8.91%
controls:5.25%
54
442
1079
10880
35
184
1098
11138
31
26
1102
11296
—
21
24
973
11285
50
184
564
10923
9
476
92
8599
salbutamol; inhalant
R03AC02 [21603256]
3.9e-01
9.1e-01
2.0e+00
—
1.9e+00
1.1e+00
8.7e-01
cases:17.74%
controls:12.76%
cases:15.09%
controls:6.65%
cases:8.83%
controls:1.32%
—
—
cases:8.05%
controls:1.33%
cases:19.22%
controls:7.40%
cases:29.70%
controls:15.03%
201
1445
932
9877
171
753
962
10569
100
150
1033
11172
—
80
150
914
11159
118
822
496
10285
30
1364
71
7711
amoxicillin; oral, parenteral
J01CA04 [21602823]
3.0e-01
7.2e-01
2.0e+00
—
2.2e+00
9.4e-01
9.5e-01
cases:21.80%
controls:17.13%
cases:9.80%
controls:5.01%
cases:4.24%
controls:0.57%
—
—
cases:3.82%
controls:0.46%
cases:12.38%
controls:5.22%
cases:34.65%
controls:16.97%
247
1940
886
9382
111
567
1022
10755
48
65
1085
11257
—
38
52
956
11257
76
580
538
10527
35
1540
66
7535
doxycycline; oral, parenteral
J01AA02 [21602800]
3.1e-01
1.0e+00
2.8e+00
—
1.5e+00
7.4e-01
7.9e-01
cases:22.42%
controls:17.54%
cases:12.62%
controls:5.00%
cases:7.15%
controls:0.49%
—
—
cases:2.11%
controls:0.50%
cases:10.10%
controls:5.07%
cases:27.72%
controls:14.84%
254
1986
879
9336
143
566
990
10756
81
55
1052
11267
—
21
56
973
11253
62
563
552
10544
28
1347
73
7728
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
2.9e-01
6.8e-01
2.6e+00
—
2.3e+00
1.4e+00
6.0e-01
cases:9.89%
controls:7.59%
cases:6.00%
controls:3.14%
cases:5.47%
controls:0.42%
—
—
cases:3.12%
controls:0.32%
cases:12.05%
controls:3.12%
cases:16.83%
controls:10.01%
112
859
1021
10463
68
355
1065
10967
62
47
1071
11275
—
31
36
963
11273
74
346
540
10761
17
908
84
8167
Base excess in Venous blood by calculation
1927-3 [3002032]
4.9e-01
8.4e-01
3.0e+00
—
2.1e+00
1.2e+00
—
cases:2.03%
controls:1.25%
cases:1.85%
controls:0.81%
cases:1.85%
controls:0.10%
—
—
cases:0.91%
controls:0.11%
cases:3.58%
controls:1.13%
—
—
23
142
1110
11180
21
92
1112
11230
21
11
1112
11311
—
9
13
985
11296
22
126
592
10981
—
Respiratory and circulatory monitoring
WX700 [2001310817]
2.8e-01
9.0e-01
2.5e+00
—
3.1e+00
1.4e+00
—
cases:2.56%
controls:1.95%
cases:1.50%
controls:0.62%
cases:1.32%
controls:0.11%
—
—
cases:1.21%
controls:0.05%
cases:1.95%
controls:0.47%
—
—
29
221
1104
11101
17
70
1116
11252
15
13
1118
11309
—
12
6
982
11303
12
52
602
11055
—
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
7.3e-02
5.3e-01
2.6e+00
—
1.9e+00
9.7e-01
9.9e-01
cases:6.80%
controls:6.35%
cases:4.24%
controls:2.53%
cases:3.35%
controls:0.25%
—
—
cases:1.51%
controls:0.23%
cases:6.51%
controls:2.57%
cases:19.80%
controls:8.40%
77
719
1056
10603
48
286
1085
11036
38
28
1095
11294
—
15
26
979
11283
40
285
574
10822
20
762
81
8313
pH of Venous blood
2746-6 [3012544]
4.1e-01
8.5e-01
2.9e+00
—
2.1e+00
1.1e+00
—
cases:1.94%
controls:1.30%
cases:1.94%
controls:0.84%
cases:1.77%
controls:0.10%
—
—
cases:0.91%
controls:0.11%
cases:3.42%
controls:1.16%
—
—
22
147
1111
11175
22
95
1111
11227
20
11
1113
11311
—
9
13
985
11296
21
129
593
10978
—
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
1.8e-01
5.3e-01
3.1e+00
—
1.6e+00
1.0e+00
1.2e+00
cases:3.88%
controls:3.27%
cases:2.03%
controls:1.21%
cases:3.53%
controls:0.16%
—
—
cases:0.80%
controls:0.16%
cases:3.75%
controls:1.40%
cases:12.87%
controls:4.40%
44
370
1089
10952
23
137
1110
11185
40
18
1093
11304
—
8
18
986
11291
23
155
591
10952
13
399
88
8676
Anaemia, unspecified
D64.9 [45600610]
7.3e-01
2.7e-01
2.2e+00
—
2.2e+00
1.8e+00
—
cases:2.65%
controls:1.30%
cases:0.71%
controls:0.54%
cases:0.62%
controls:0.07%
—
—
cases:0.70%
controls:0.08%
cases:3.91%
controls:0.68%
—
—
30
147
1103
11175
8
61
1125
11261
7
8
1126
11314
—
7
9
987
11300
24
76
590
11031
—
nystatin; oral
A07AA02 [21600604]
1.2e+00
1.4e+00
—
—
2.8e+00
2.9e+00
—
cases:2.12%
controls:0.65%
cases:0.71%
controls:0.17%
—
—
—
—
cases:0.70%
controls:0.04%
cases:3.75%
controls:0.22%
—
—
24
74
1109
11248
8
19
1125
11303
—
—
7
5
987
11304
23
24
591
11083
—
codeine; oral
R05DA04 [21603399]
3.1e-01
1.1e+00
—
—
3.5e+00
2.3e+00
—
cases:3.80%
controls:2.82%
cases:1.41%
controls:0.49%
—
—
—
—
cases:1.71%
controls:0.05%
cases:4.23%
controls:0.46%
—
—
43
319
1090
11003
16
56
1117
11266
—
—
17
6
977
11303
26
51
588
11056
—
moxifloxacin; oral, parenteral
J01MA14 [21603021]
6.9e-01
1.6e+00
—
—
—
2.9e+00
2.3e+00
cases:1.59%
controls:0.80%
cases:1.50%
controls:0.31%
—
—
—
—
—
—
cases:4.07%
controls:0.23%
cases:9.90%
controls:1.11%
18
91
1115
11231
17
35
1116
11287
—
—
—
25
26
589
11081
10
101
91
8974
SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
94759-8 [586526]
4.4e-01
7.0e-01
2.7e+00
—
—
2.3e+00
1.7e+00
cases:0.62%
controls:0.40%
cases:0.79%
controls:0.40%
cases:1.32%
controls:0.09%
—
—
—
—
cases:4.23%
controls:0.45%
cases:6.93%
controls:1.34%
7
45
1126
11277
9
45
1124
11277
15
10
1118
11312
—
—
26
50
588
11057
7
122
94
8953
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
3.9e-01
5.1e-01
2.5e+00
—
2.6e+00
1.6e+00
9.8e-01
cases:5.12%
controls:3.52%
cases:2.56%
controls:1.55%
cases:2.65%
controls:0.23%
—
—
cases:1.71%
controls:0.12%
cases:6.84%
controls:1.49%
cases:12.87%
controls:5.25%
58
399
1075
10923
29
176
1104
11146
30
26
1103
11296
—
17
14
977
11295
42
165
572
10942
13
476
88
8599
Bacteria [Presence] in Urine
87829-8 [36304419]
2.1e-01
6.2e-01
2.4e+00
—
2.1e+00
1.6e+00
8.8e-01
cases:5.38%
controls:4.42%
cases:4.24%
controls:2.33%
cases:3.44%
controls:0.34%
—
—
cases:2.82%
controls:0.35%
cases:11.24%
controls:2.50%
cases:15.84%
controls:7.24%
61
500
1072
10822
48
264
1085
11058
39
38
1094
11284
—
28
40
966
11269
69
278
545
10829
16
657
85
8418
oxycodone and naloxone; oral
N02AA55 [21604265]
4.0e-01
5.2e-01
2.6e+00
—
2.9e+00
1.1e+00
7.2e-01
cases:2.56%
controls:1.72%
cases:1.50%
controls:0.90%
cases:1.06%
controls:0.08%
—
—
cases:2.11%
controls:0.11%
cases:3.26%
controls:1.12%
cases:6.93%
controls:3.48%
29
195
1104
11127
17
102
1116
11220
12
9
1121
11313
—
21
13
973
11296
20
124
594
10983
7
316
94
8759
Interstitial pulmonary disease, unspecified
J84.9 [45543277]
2.2e+00
2.4e+00
—
—
—
2.0e+00
-1.0e+50
cases:1.15%
controls:0.12%
cases:1.41%
controls:0.13%
—
—
—
—
—
—
cases:1.30%
controls:0.18%
cases:0.00%
controls:0.35%
13
14
1120
11308
16
15
1117
11307
—
—
—
8
20
606
11087
0
32
101
9043
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
1.5e-01
5.9e-01
2.3e+00
—
2.1e+00
1.5e+00
7.8e-01
cases:5.38%
controls:4.69%
cases:4.32%
controls:2.45%
cases:3.53%
controls:0.37%
—
—
cases:3.12%
controls:0.40%
cases:11.40%
controls:2.73%
cases:15.84%
controls:7.92%
61
531
1072
10791
49
277
1084
11045
40
42
1093
11280
—
31
45
963
11264
70
303
544
10804
16
719
85
8356
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
-1.9e-01
2.3e-01
2.3e+00
—
1.9e+00
1.3e+00
1.0e+00
cases:4.32%
controls:5.20%
cases:4.32%
controls:3.48%
cases:4.85%
controls:0.52%
—
—
cases:3.22%
controls:0.50%
cases:13.03%
controls:4.02%
cases:29.70%
controls:13.18%
49
589
1084
10733
49
394
1084
10928
55
59
1078
11263
—
32
56
962
11253
80
447
534
10660
30
1196
71
7879
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
1.1e-01
5.8e-01
3.0e+00
1.0e+50
2.2e+00
7.7e-01
2.1e-01
cases:6.27%
controls:5.65%
cases:6.00%
controls:3.45%
cases:7.24%
controls:0.40%
cases:0.44%
controls:0.00%
cases:3.32%
controls:0.40%
cases:8.47%
controls:4.12%
cases:13.86%
controls:11.52%
71
640
1062
10682
68
391
1065
10931
82
45
1051
11277
5
0
1128
11322
33
45
961
11264
52
458
562
10649
14
1045
87
8030
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
2.9e-01
7.6e-01
—
—
1.0e+50
3.5e+00
2.7e+00
cases:0.88%
controls:0.66%
cases:0.53%
controls:0.25%
—
—
—
—
cases:1.11%
controls:0.00%
cases:5.05%
controls:0.15%
cases:6.93%
controls:0.47%
10
75
1123
11247
6
28
1127
11294
—
—
11
0
983
11309
31
17
583
11090
7
43
94
9032
Leukocytes [#/volume] in Urine
30405-5 [3018095]
6.2e-02
5.9e-01
2.3e+00
—
2.1e+00
1.4e+00
7.6e-01
cases:6.62%
controls:6.24%
cases:5.83%
controls:3.31%
cases:4.15%
controls:0.45%
—
—
cases:3.72%
controls:0.50%
cases:13.36%
controls:3.76%
cases:20.79%
controls:10.90%
75
707
1058
10615
66
375
1067
10947
47
51
1086
11271
—
37
56
957
11253
82
418
532
10689
21
989
80
8086
prednisone; oral
H02AB07 [21602735]
4.4e-01
1.2e+00
2.2e+00
—
1.4e+00
1.4e+00
1.1e+00
cases:3.09%
controls:2.00%
cases:2.65%
controls:0.80%
cases:0.79%
controls:0.09%
—
—
cases:1.01%
controls:0.24%
cases:3.09%
controls:0.81%
cases:4.95%
controls:1.76%
35
227
1098
11095
30
91
1103
11231
9
10
1124
11312
—
10
27
984
11282
19
90
595
11017
5
160
96
8915
prednisone
A07EA03 [21600655]
4.4e-01
1.2e+00
2.2e+00
—
1.4e+00
1.4e+00
1.1e+00
cases:3.09%
controls:2.00%
cases:2.65%
controls:0.80%
cases:0.79%
controls:0.09%
—
—
cases:1.01%
controls:0.24%
cases:3.09%
controls:0.81%
cases:4.95%
controls:1.76%
35
227
1098
11095
30
91
1103
11231
9
10
1124
11312
—
10
27
984
11282
19
90
595
11017
5
160
96
8915
Case Management Agency
251B00000X [38004193]
1.8e-02
1.3e-01
1.2e+00
2.6e+00
1.5e+00
8.3e-01
5.2e-01
cases:61.87%
controls:61.45%
cases:55.25%
controls:51.91%
cases:45.28%
controls:20.55%
cases:15.09%
controls:1.26%
cases:53.22%
controls:20.25%
cases:73.94%
controls:55.42%
cases:80.20%
controls:70.70%
701
6957
432
4365
626
5877
507
5445
513
2327
620
8995
171
143
962
11179
529
2290
465
9019
454
6156
160
4951
81
6416
20
2659
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
1.5e-01
7.3e-02
1.9e+00
—
3.4e+00
8.0e-01
6.2e-01
cases:7.59%
controls:6.61%
cases:2.03%
controls:1.89%
cases:1.24%
controls:0.19%
—
—
cases:4.73%
controls:0.17%
cases:3.75%
controls:1.72%
cases:9.90%
controls:5.58%
86
748
1047
10574
23
214
1110
11108
14
22
1119
11300
—
47
19
947
11290
23
191
591
10916
10
506
91
8569
Gas panel - Venous blood
24339-4 [3000991]
5.7e-01
8.0e-01
2.8e+00
—
2.1e+00
1.0e+00
—
cases:1.59%
controls:0.90%
cases:1.32%
controls:0.60%
cases:1.50%
controls:0.09%
—
—
cases:0.60%
controls:0.07%
cases:2.12%
controls:0.77%
—
—
18
102
1115
11220
15
68
1118
11254
17
10
1116
11312
—
6
8
988
11301
13
85
601
11022
—
Abdominal CT examination
JN3AD [2001305554]
6.4e-02
6.7e-01
3.0e+00
—
3.0e+00
1.1e+00
—
cases:0.71%
controls:0.66%
cases:0.71%
controls:0.36%
cases:1.85%
controls:0.10%
—
—
cases:1.11%
controls:0.05%
cases:1.63%
controls:0.52%
—
—
8
75
1125
11247
8
41
1125
11281
21
11
1112
11311
—
11
6
983
11303
10
58
604
11049
—
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
1.0e+00
2.2e+00
—
—
—
3.8e+00
—
cases:0.53%
controls:0.19%
cases:0.62%
controls:0.07%
—
—
—
—
—
—
cases:2.44%
controls:0.05%
—
—
6
22
1127
11300
7
8
1126
11314
—
—
—
15
6
599
11101
—
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
-3.1e-02
3.9e-01
2.0e+00
—
2.1e+00
1.5e+00
7.1e-01
cases:14.30%
controls:14.68%
cases:10.77%
controls:7.56%
cases:7.24%
controls:1.04%
—
—
cases:8.05%
controls:1.06%
cases:26.87%
controls:7.47%
cases:32.67%
controls:19.34%
162
1662
971
9660
122
856
1011
10466
82
118
1051
11204
—
80
120
914
11189
165
830
449
10277
33
1755
68
7320
Shortness of breath/dyspnoea
R02 [2002000883]
9.3e-01
1.4e+00
3.7e+00
—
—
8.2e-01
1.0e+00
cases:3.71%
controls:1.50%
cases:1.85%
controls:0.46%
cases:2.03%
controls:0.05%
—
—
—
—
cases:1.30%
controls:0.58%
cases:5.94%
controls:2.24%
42
170
1091
11152
21
52
1112
11270
23
6
1110
11316
—
—
8
64
606
11043
6
203
95
8872
Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
62424-7 [40765161]
1.1e+00
2.2e+00
—
—
—
3.8e+00
—
cases:0.44%
controls:0.15%
cases:0.53%
controls:0.06%
—
—
—
—
—
—
cases:1.95%
controls:0.05%
—
—
5
17
1128
11305
6
7
1127
11315
—
—
—
12
5
602
11102
—
codeine and paracetamol
N02AJ06 [1123647]
2.1e-01
4.5e-01
1.6e+00
—
1.6e+00
1.3e+00
9.4e-01
cases:14.47%
controls:12.04%
cases:7.68%
controls:5.03%
cases:4.41%
controls:0.93%
—
—
cases:4.33%
controls:0.91%
cases:14.82%
controls:4.72%
cases:24.75%
controls:11.38%
164
1363
969
9959
87
569
1046
10753
50
105
1083
11217
—
43
103
951
11206
91
524
523
10583
25
1033
76
8042
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
4.7e-01
7.9e-01
2.2e+00
—
2.3e+00
1.3e+00
9.0e-01
cases:1.94%
controls:1.23%
cases:1.24%
controls:0.57%
cases:0.97%
controls:0.11%
—
—
cases:0.70%
controls:0.07%
cases:2.28%
controls:0.65%
cases:5.94%
controls:2.51%
22
139
1111
11183
14
64
1119
11258
11
12
1122
11310
—
7
8
987
11301
14
72
600
11035
6
228
95
8847
pantoprazole; oral, parenteral
A02BC02 [21600097]
2.5e-01
5.1e-01
6.6e-01
—
1.9e+00
1.9e+00
8.8e-01
cases:20.56%
controls:16.84%
cases:16.33%
controls:10.50%
cases:4.77%
controls:2.52%
—
—
cases:14.49%
controls:2.54%
cases:44.46%
controls:10.94%
cases:38.61%
controls:20.69%
233
1907
900
9415
185
1189
948
10133
54
285
1079
11037
—
144
287
850
11022
273
1215
341
9892
39
1878
62
7197
Neutrophils [#/volume] in Blood
26499-4 [3017732]
-1.8e-01
5.3e-01
2.6e+00
—
1.7e+00
1.4e+00
9.3e-01
cases:0.88%
controls:1.05%
cases:0.79%
controls:0.47%
cases:1.06%
controls:0.08%
—
—
cases:0.70%
controls:0.12%
cases:3.26%
controls:0.82%
cases:6.93%
controls:2.84%
10
119
1123
11203
9
53
1124
11269
12
9
1121
11313
—
7
14
987
11295
20
91
594
11016
7
258
94
8817
Cancer Ag 125 [Units/volume] in Serum or Plasma
10334-1 [3037551]
2.7e-01
—
3.3e+00
—
1.0e+50
2.4e+00
—
cases:0.53%
controls:0.41%
—
—
cases:1.24%
controls:0.04%
—
—
cases:0.60%
controls:0.00%
cases:1.14%
controls:0.11%
—
—
6
46
1127
11276
—
14
5
1119
11317
—
6
0
988
11309
7
12
607
11095
—
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
1.1e+00
2.0e+00
—
—
—
3.7e+00
—
cases:0.53%
controls:0.19%
cases:0.53%
controls:0.07%
—
—
—
—
—
—
cases:2.12%
controls:0.05%
—
—
6
21
1127
11301
6
8
1127
11314
—
—
—
13
6
601
11101
—
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
4.6e-01
5.4e-01
2.1e+00
—
2.2e+00
1.3e+00
8.1e-01
cases:3.09%
controls:1.97%
cases:1.50%
controls:0.88%
cases:1.24%
controls:0.15%
—
—
cases:0.91%
controls:0.10%
cases:3.58%
controls:0.97%
cases:6.93%
controls:3.21%
35
223
1098
11099
17
100
1116
11222
14
17
1119
11305
—
9
11
985
11298
22
108
592
10999
7
291
94
8784
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
J44.1 [45601132]
1.6e+00
2.3e+00
—
—
—
7.7e-01
1.8e+00
cases:2.21%
controls:0.46%
cases:1.68%
controls:0.18%
—
—
—
—
—
—
cases:0.81%
controls:0.38%
cases:5.94%
controls:1.02%
25
52
1108
11270
19
20
1114
11302
—
—
—
5
42
609
11065
6
93
95
8982
High resolution CT examination of lungs
GD1DD [2001303632]
1.0e+00
2.4e+00
—
—
—
2.2e+00
-1.0e+50
cases:1.41%
controls:0.50%
cases:1.24%
controls:0.11%
—
—
—
—
—
—
cases:1.14%
controls:0.13%
cases:0.00%
controls:0.34%
16
57
1117
11265
14
13
1119
11309
—
—
—
7
14
607
11093
0
31
101
9044
Cough
R05 [45606792]
-1.3e-01
8.0e-01
3.2e+00
—
2.4e+00
3.3e-02
—
cases:2.38%
controls:2.70%
cases:1.68%
controls:0.76%
cases:2.91%
controls:0.12%
—
—
cases:0.70%
controls:0.06%
cases:0.98%
controls:0.95%
—
—
27
306
1106
11016
19
86
1114
11236
33
14
1100
11308
—
7
7
987
11302
6
105
608
11002
—
Intravenous
ZX120 [2001311495]
4.0e-01
7.8e-01
—
—
—
3.5e+00
2.1e+00
cases:1.24%
controls:0.83%
cases:0.44%
controls:0.20%
—
—
—
—
—
—
cases:8.14%
controls:0.27%
cases:6.93%
controls:0.88%
14
94
1119
11228
5
23
1128
11299
—
—
—
50
30
564
11077
7
80
94
8995
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
-4.3e-02
2.2e-01
1.9e+00
—
2.1e+00
1.5e+00
8.3e-01
cases:2.74%
controls:2.85%
cases:1.41%
controls:1.14%
cases:0.79%
controls:0.11%
—
—
cases:0.80%
controls:0.10%
cases:4.23%
controls:0.94%
cases:6.93%
controls:3.14%
31
323
1102
10999
16
129
1117
11193
9
13
1124
11309
—
8
11
986
11298
26
104
588
11003
7
285
94
8790
Atherosclerotic heart disease
I25.1 [45596196]
1.9e-01
3.2e-01
1.3e+00
2.6e+00
1.7e+00
3.9e-01
-2.2e-01
cases:8.91%
controls:7.52%
cases:5.21%
controls:3.85%
cases:2.47%
controls:0.72%
cases:0.97%
controls:0.07%
cases:3.72%
controls:0.69%
cases:6.51%
controls:4.51%
cases:9.90%
controls:12.08%
101
851
1032
10471
59
436
1074
10886
28
81
1105
11241
11
8
1122
11314
37
78
957
11231
40
501
574
10606
10
1096
91
7979
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
8.9e-02
3.7e-01
1.9e+00
—
2.3e+00
1.3e+00
6.8e-01
cases:8.47%
controls:7.81%
cases:3.97%
controls:2.77%
cases:3.35%
controls:0.50%
—
—
cases:4.73%
controls:0.49%
cases:9.93%
controls:2.83%
cases:13.86%
controls:7.52%
96
884
1037
10438
45
314
1088
11008
38
57
1095
11265
—
47
55
947
11254
61
314
553
10793
14
682
87
8393
Asthma, unspecified
J45.9 [45562456]
3.7e-01
6.8e-01
1.9e+00
—
2.0e+00
9.7e-01
8.6e-01
cases:4.85%
controls:3.40%
cases:3.18%
controls:1.63%
cases:1.85%
controls:0.28%
—
—
cases:2.21%
controls:0.31%
cases:4.56%
controls:1.78%
cases:9.90%
controls:4.45%
55
385
1078
10937
36
185
1097
11137
21
32
1112
11290
—
22
35
972
11274
28
198
586
10909
10
404
91
8671
Base excess in Arterial blood by calculation
1925-7 [3003396]
7.5e-01
6.5e-01
3.4e+00
1.0e+50
—
1.4e+00
6.6e-01
cases:3.09%
controls:1.48%
cases:1.59%
controls:0.84%
cases:3.09%
controls:0.11%
cases:1.06%
controls:0.00%
—
—
cases:3.75%
controls:0.97%
cases:5.94%
controls:3.15%
35
168
1098
11154
18
95
1115
11227
35
12
1098
11310
12
0
1121
11322
—
23
108
591
10999
6
286
95
8789
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
3.5e-02
3.2e-01
2.4e+00
—
2.1e+00
1.0e+00
1.1e+00
cases:2.29%
controls:2.22%
cases:1.41%
controls:1.02%
cases:1.68%
controls:0.16%
—
—
cases:1.11%
controls:0.13%
cases:2.93%
controls:1.07%
cases:5.94%
controls:2.03%
26
251
1107
11071
16
116
1117
11206
19
18
1114
11304
—
11
15
983
11294
18
119
596
10988
6
184
95
8891
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
7.6e-01
5.4e-01
3.4e+00
1.0e+50
—
1.4e+00
6.7e-01
cases:3.09%
controls:1.48%
cases:1.41%
controls:0.83%
cases:3.27%
controls:0.11%
cases:1.06%
controls:0.00%
—
—
cases:3.75%
controls:0.98%
cases:5.94%
controls:3.14%
35
167
1098
11155
16
94
1117
11228
37
13
1096
11309
12
0
1121
11322
—
23
109
591
10998
6
285
95
8790
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
7.6e-01
5.3e-01
3.4e+00
1.0e+50
—
1.4e+00
6.7e-01
cases:3.09%
controls:1.48%
cases:1.41%
controls:0.84%
cases:3.27%
controls:0.11%
cases:1.06%
controls:0.00%
—
—
cases:3.75%
controls:0.98%
cases:5.94%
controls:3.14%
35
167
1098
11155
16
95
1117
11227
37
13
1096
11309
12
0
1121
11322
—
23
109
591
10998
6
285
95
8790
EKG study
11524-6 [3013512]
2.0e-02
3.6e-01
2.2e+00
—
2.4e+00
8.5e-01
2.6e-01
cases:8.47%
controls:8.32%
cases:6.18%
controls:4.38%
cases:5.30%
controls:0.59%
—
—
cases:5.53%
controls:0.53%
cases:11.40%
controls:5.19%
cases:15.84%
controls:12.72%
96
942
1037
10380
70
496
1063
10826
60
67
1073
11255
—
55
60
939
11249
70
577
544
10530
16
1154
85
7921
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
1.2e-01
4.0e-01
2.2e+00
—
1.9e+00
1.3e+00
9.5e-01
cases:2.21%
controls:1.97%
cases:2.03%
controls:1.37%
cases:1.85%
controls:0.21%
—
—
cases:1.41%
controls:0.20%
cases:6.03%
controls:1.66%
cases:12.87%
controls:5.41%
25
223
1108
11099
23
155
1110
11167
21
24
1112
11298
—
14
23
980
11286
37
184
577
10923
13
491
88
8584
Atherosclerosis of arteries of extremities
I70.2 [45538421]
8.3e-01
1.1e+00
1.8e+00
—
1.7e+00
7.1e-01
5.4e-01
cases:6.53%
controls:2.95%
cases:4.50%
controls:1.49%
cases:2.03%
controls:0.34%
—
—
cases:2.11%
controls:0.39%
cases:3.42%
controls:1.71%
cases:7.92%
controls:4.79%
74
334
1059
10988
51
169
1082
11153
23
39
1110
11283
—
21
44
973
11265
21
190
593
10917
8
435
93
8640
Dentistry
C5 [903277]
5.0e-01
6.0e-01
—
—
3.4e+00
2.0e+00
—
cases:2.38%
controls:1.47%
cases:0.88%
controls:0.49%
—
—
—
—
cases:2.41%
controls:0.08%
cases:3.75%
controls:0.51%
—
—
27
166
1106
11156
10
55
1123
11267
—
—
24
9
970
11300
23
57
591
11050
—
vilanterol, umeclidinium bromide and fluticasone furoate
R03AL08 [1501769]
1.8e+00
1.9e+00
-1.0e+50
—
—
1.8e+00
—
cases:0.79%
controls:0.13%
cases:0.97%
controls:0.15%
cases:0.00%
controls:0.06%
—
—
—
—
cases:1.14%
controls:0.20%
—
—
9
15
1124
11307
11
17
1122
11305
0
7
1133
11315
—
—
7
22
607
11085
—
vilanterol and umeclidinium bromide
R03AL03 [43534845]
1.9e+00
2.5e+00
—
—
—
2.9e+00
—
cases:0.53%
controls:0.08%
cases:0.97%
controls:0.08%
—
—
—
—
—
—
cases:1.14%
controls:0.06%
—
—
6
9
1127
11313
11
9
1122
11313
—
—
—
7
7
607
11100
—
Upper gastrointestinal surgery
106 [44777669]
3.2e-01
5.6e-01
1.9e+00
1.0e+50
1.9e+00
9.8e-01
6.8e-01
cases:11.30%
controls:8.47%
cases:5.38%
controls:3.14%
cases:3.53%
controls:0.52%
cases:0.88%
controls:0.00%
cases:2.72%
controls:0.41%
cases:8.14%
controls:3.21%
cases:16.83%
controls:9.31%
128
959
1005
10363
61
355
1072
10967
40
59
1093
11263
10
0
1123
11322
27
46
967
11263
50
356
564
10751
17
845
84
8230
Thorax and upper abdomen combined extensive CT examination of
GD5BD [2001303656]
—
—
1.0e+50
1.0e+50
—
—
5.4e+00
—
—
—
—
cases:2.47%
controls:0.00%
cases:0.71%
controls:0.00%
—
—
—
—
cases:10.89%
controls:0.06%
—
—
28
0
1105
11322
8
0
1125
11322
—
—
11
5
90
9070
sulfadiazine and trimethoprim
J01EE02 [21602962]
3.2e-01
8.7e-01
2.6e+00
—
1.9e+00
1.8e-01
3.4e-01
cases:4.50%
controls:3.29%
cases:2.65%
controls:1.13%
cases:1.06%
controls:0.08%
—
—
cases:0.70%
controls:0.11%
cases:1.47%
controls:1.22%
cases:4.95%
controls:3.57%
51
373
1082
10949
30
128
1103
11194
12
9
1121
11313
—
7
12
987
11297
9
136
605
10971
5
324
96
8751
Multidisciplinary treatment meeting
WZC20 [2001310890]
2.0e+00
—
—
—
1.0e+50
3.4e+00
—
cases:0.71%
controls:0.10%
—
—
—
—
—
—
cases:0.70%
controls:0.00%
cases:1.79%
controls:0.06%
—
—
8
11
1125
11311
—
—
—
7
0
987
11309
11
7
603
11100
—
magnesium hydroxide; oral
A02AA04 [21600052]
7.2e-01
9.2e-01
—
—
—
2.9e+00
2.4e+00
cases:0.79%
controls:0.39%
cases:0.44%
controls:0.18%
—
—
—
—
—
—
cases:4.89%
controls:0.27%
cases:5.94%
controls:0.58%
9
44
1124
11278
5
20
1128
11302
—
—
—
30
30
584
11077
6
53
95
9022
magnesium hydroxide; oral
G04BX01 [21602658]
7.2e-01
9.2e-01
—
—
—
2.9e+00
2.4e+00
cases:0.79%
controls:0.39%
cases:0.44%
controls:0.18%
—
—
—
—
—
—
cases:4.89%
controls:0.27%
cases:5.94%
controls:0.58%
9
44
1124
11278
5
20
1128
11302
—
—
—
30
30
584
11077
6
53
95
9022
lactulose; oral
A06AD11 [21600571]
1.4e-01
3.2e-01
1.2e+00
—
2.1e+00
2.1e+00
7.5e-01
cases:2.91%
controls:2.54%
cases:2.03%
controls:1.48%
cases:1.15%
controls:0.36%
—
—
cases:3.12%
controls:0.41%
cases:12.05%
controls:1.73%
cases:8.91%
controls:4.43%
33
288
1100
11034
23
168
1110
11154
13
41
1120
11281
—
31
46
963
11263
74
192
540
10915
9
402
92
8673
One hour or less
ZXE00 [2001311394]
3.0e-01
5.0e-01
1.9e+00
—
2.4e+00
1.0e+00
6.1e-01
cases:7.33%
controls:5.56%
cases:2.21%
controls:1.35%
cases:0.71%
controls:0.11%
—
—
cases:1.11%
controls:0.11%
cases:3.42%
controls:1.27%
cases:6.93%
controls:3.89%
83
629
1050
10693
25
153
1108
11169
8
12
1125
11310
—
11
12
983
11297
21
141
593
10966
7
353
94
8722
12 lead EKG panel
34534-8 [3044889]
1.5e-02
4.1e-01
2.5e+00
—
1.9e+00
4.5e-01
3.1e-01
cases:19.33%
controls:19.10%
cases:14.39%
controls:10.07%
cases:11.74%
controls:1.07%
—
—
cases:7.34%
controls:1.19%
cases:15.15%
controls:10.22%
cases:30.69%
controls:24.58%
219
2162
914
9160
163
1140
970
10182
133
121
1000
11201
—
73
135
921
11174
93
1135
521
9972
31
2231
70
6844
Bacteria identified in Urine by Culture
630-4 [3026008]
1.3e-01
5.1e-01
1.9e+00
—
2.0e+00
1.3e+00
6.1e-01
cases:5.56%
controls:4.93%
cases:4.41%
controls:2.69%
cases:2.38%
controls:0.35%
—
—
cases:2.92%
controls:0.40%
cases:9.61%
controls:2.85%
cases:14.85%
controls:8.66%
63
558
1070
10764
50
304
1083
11018
27
40
1106
11282
—
29
45
965
11264
59
317
555
10790
15
786
86
8289
Hypo-osmolality and hyponatraemia
E87.1 [45542779]
1.1e+00
2.2e+00
—
—
1.0e+50
3.0e+00
—
cases:0.97%
controls:0.34%
cases:1.24%
controls:0.14%
—
—
—
—
cases:2.11%
controls:0.00%
cases:3.26%
controls:0.16%
—
—
11
38
1122
11284
14
16
1119
11306
—
—
21
0
973
11309
20
18
594
11089
—
Osmolality of Serum or Plasma
2692-2 [3008295]
—
2.3e+00
—
—
—
2.9e+00
-1.0e+50
—
—
cases:0.62%
controls:0.06%
—
—
—
—
—
—
cases:0.81%
controls:0.05%
cases:0.00%
controls:0.19%
—
7
7
1126
11315
—
—
—
5
5
609
11102
0
17
101
9058
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
7.9e-02
6.7e-01
2.9e+00
—
1.6e+00
2.8e-01
5.1e-01
cases:20.04%
controls:18.80%
cases:17.03%
controls:9.51%
cases:17.12%
controls:1.16%
—
—
cases:6.24%
controls:1.28%
cases:12.54%
controls:9.77%
cases:33.66%
controls:23.35%
227
2128
906
9194
193
1077
940
10245
194
131
939
11191
—
62
145
932
11164
77
1085
537
10022
34
2119
67
6956
Mycobacterium sp identified in Specimen by Organism specific culture
543-9 [3005702]
1.1e+00
2.5e+00
1.0e+50
1.0e+50
—
2.7e+00
—
cases:0.71%
controls:0.23%
cases:1.68%
controls:0.14%
cases:2.47%
controls:0.00%
cases:8.83%
controls:0.00%
—
—
cases:1.14%
controls:0.08%
—
—
8
26
1125
11296
19
16
1114
11306
28
0
1105
11322
100
0
1033
11322
—
7
9
607
11098
—
Atherosclerotic cardiovascular disease, so described
I25.0 [45552783]
2.3e-02
6.5e-01
2.6e+00
—
2.5e+00
1.1e+00
-1.0e+50
cases:1.15%
controls:1.12%
cases:0.71%
controls:0.37%
cases:0.71%
controls:0.05%
—
—
cases:1.01%
controls:0.08%
cases:1.47%
controls:0.50%
cases:0.00%
controls:1.56%
13
127
1120
11195
8
42
1125
11280
8
6
1125
11316
—
10
9
984
11300
9
56
605
11051
0
142
101
8933
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
-7.8e-02
2.7e-01
1.8e+00
—
2.0e+00
1.2e+00
3.6e-02
cases:5.38%
controls:5.79%
cases:4.32%
controls:3.33%
cases:2.38%
controls:0.39%
—
—
cases:3.32%
controls:0.46%
cases:11.24%
controls:3.54%
cases:9.90%
controls:9.59%
61
656
1072
10666
49
377
1084
10945
27
44
1106
11278
—
33
52
961
11257
69
393
545
10714
10
870
91
8205
Addiction caused by tobacco UNS
F17.29 [2000501845]
1.8e+00
—
1.0e+50
—
1.0e+50
3.3e+00
—
cases:1.06%
controls:0.18%
—
—
cases:0.53%
controls:0.00%
—
—
cases:0.60%
controls:0.00%
cases:1.63%
controls:0.06%
—
—
12
20
1121
11302
—
6
0
1127
11322
—
6
0
988
11309
10
7
604
11100
—
tinzaparin; parenteral
B01AB10 [21600981]
6.6e-01
5.5e-01
2.1e+00
—
—
3.3e+00
1.7e+00
cases:0.88%
controls:0.46%
cases:0.44%
controls:0.26%
cases:0.44%
controls:0.05%
—
—
—
—
cases:6.35%
controls:0.24%
cases:6.93%
controls:1.31%
10
52
1123
11270
5
29
1128
11293
5
6
1128
11316
—
—
39
27
575
11080
7
119
94
8956
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
5.4e-02
5.7e-01
2.2e+00
—
2.8e+00
7.3e-01
—
cases:2.56%
controls:2.43%
cases:1.68%
controls:0.95%
cases:0.88%
controls:0.10%
—
—
cases:1.41%
controls:0.09%
cases:2.28%
controls:1.11%
—
—
29
275
1104
11047
19
108
1114
11214
10
11
1123
11311
—
14
10
980
11299
14
123
600
10984
—
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
7.4e-02
5.1e-01
1.8e+00
—
1.8e+00
1.3e+00
1.1e+00
cases:2.38%
controls:2.22%
cases:2.21%
controls:1.33%
cases:1.32%
controls:0.21%
—
—
cases:1.41%
controls:0.23%
cases:5.86%
controls:1.63%
cases:12.87%
controls:4.74%
27
251
1106
11071
25
151
1108
11171
15
24
1118
11298
—
14
26
980
11283
36
181
578
10926
13
430
88
8645
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
-8.3e-02
4.5e-01
1.7e+00
—
1.7e+00
1.1e+00
4.0e-01
cases:15.00%
controls:16.09%
cases:12.71%
controls:8.50%
cases:5.91%
controls:1.17%
—
—
cases:6.24%
controls:1.25%
cases:21.99%
controls:8.35%
cases:27.72%
controls:20.45%
170
1822
963
9500
144
962
989
10360
67
133
1066
11189
—
62
141
932
11168
135
927
479
10180
28
1856
73
7219
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
8.5e-01
1.1e+00
3.1e+00
—
—
1.8e+00
1.5e+00
cases:1.41%
controls:0.61%
cases:0.88%
controls:0.30%
cases:1.15%
controls:0.05%
—
—
—
—
cases:2.12%
controls:0.36%
cases:5.94%
controls:1.39%
16
69
1117
11253
10
34
1123
11288
13
6
1120
11316
—
—
13
40
601
11067
6
126
95
8949
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
4.2e-01
9.4e-01
3.1e+00
1.0e+50
1.7e+00
1.8e+00
—
cases:1.68%
controls:1.11%
cases:1.32%
controls:0.52%
cases:0.97%
controls:0.04%
cases:0.53%
controls:0.00%
cases:0.50%
controls:0.09%
cases:3.26%
controls:0.57%
—
—
19
126
1114
11196
15
59
1118
11263
11
5
1122
11317
6
0
1127
11322
5
10
989
11299
20
63
594
11044
—
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
-7.8e-03
1.3e-01
7.5e-01
2.5e+00
1.2e+00
4.9e-01
3.5e-01
cases:26.13%
controls:26.28%
cases:12.00%
controls:10.71%
cases:3.35%
controls:1.62%
cases:0.62%
controls:0.05%
cases:5.13%
controls:1.66%
cases:16.61%
controls:10.88%
cases:28.71%
controls:22.13%
296
2975
837
8347
136
1213
997
10109
38
183
1095
11139
7
6
1126
11316
51
188
943
11121
102
1208
512
9899
29
2008
72
7067
ibuprofen
R02AX02 [1588667]
-7.8e-03
1.3e-01
7.5e-01
2.5e+00
1.2e+00
4.9e-01
3.5e-01
cases:26.13%
controls:26.28%
cases:12.00%
controls:10.71%
cases:3.35%
controls:1.62%
cases:0.62%
controls:0.05%
cases:5.13%
controls:1.66%
cases:16.61%
controls:10.88%
cases:28.71%
controls:22.13%
296
2975
837
8347
136
1213
997
10109
38
183
1095
11139
7
6
1126
11316
51
188
943
11121
102
1208
512
9899
29
2008
72
7067
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
5.4e-01
8.8e-01
2.3e+00
—
1.7e+00
9.0e-01
8.4e-01
cases:2.65%
controls:1.56%
cases:2.29%
controls:0.96%
cases:1.50%
controls:0.16%
—
—
cases:1.21%
controls:0.23%
cases:2.44%
controls:1.01%
cases:4.95%
controls:2.19%
30
177
1103
11145
26
109
1107
11213
17
18
1116
11304
—
12
26
982
11283
15
112
599
10995
5
199
96
8876
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
4.1e-01
1.1e+00
3.7e+00
1.0e+50
1.8e+00
6.7e-01
—
cases:2.03%
controls:1.36%
cases:1.77%
controls:0.61%
cases:3.18%
controls:0.08%
cases:1.06%
controls:0.00%
cases:0.50%
controls:0.08%
cases:0.98%
controls:0.50%
—
—
23
154
1110
11168
20
69
1113
11253
36
9
1097
11313
12
0
1121
11322
5
9
989
11300
6
56
608
11051
—
Gas panel - Arterial blood
24336-0 [3019060]
5.9e-01
9.8e-01
3.2e+00
1.0e+50
—
1.6e+00
—
cases:2.03%
controls:1.13%
cases:1.24%
controls:0.47%
cases:1.85%
controls:0.08%
cases:0.79%
controls:0.00%
—
—
cases:2.93%
controls:0.62%
—
—
23
128
1110
11194
14
53
1119
11269
21
9
1112
11313
9
0
1124
11322
—
18
69
596
11038
—
formoterol, glycopyrronium bromide and budesonide
R03AL11 [715850]
-2.9e-01
5.8e-01
2.5e+00
—
2.2e+00
8.4e-01
—
cases:0.97%
controls:1.30%
cases:1.15%
controls:0.64%
cases:0.97%
controls:0.08%
—
—
cases:1.21%
controls:0.13%
cases:1.79%
controls:0.78%
—
—
11
147
1122
11175
13
73
1120
11249
11
9
1122
11313
—
12
15
982
11294
11
87
603
11020
—
Cells panel - Urine sediment
58434-2 [40761535]
-1.4e-01
6.0e-02
2.6e+00
—
2.1e+00
6.2e-01
—
cases:1.94%
controls:2.23%
cases:1.06%
controls:1.00%
cases:0.62%
controls:0.04%
—
—
cases:0.70%
controls:0.09%
cases:1.79%
controls:0.97%
—
—
22
253
1111
11069
12
113
1121
11209
7
5
1126
11317
—
7
10
987
11299
11
108
603
10999
—
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
-8.3e-02
5.9e-01
2.6e+00
—
2.0e+00
3.8e-01
9.8e-01
cases:2.65%
controls:2.87%
cases:1.68%
controls:0.94%
cases:1.24%
controls:0.09%
—
—
cases:0.80%
controls:0.11%
cases:1.47%
controls:1.01%
cases:7.92%
controls:3.14%
30
325
1103
10997
19
106
1114
11216
14
10
1119
11312
—
8
12
986
11297
9
112
605
10995
8
285
93
8790
Vascular Surgery
77 [38004496]
7.9e-01
1.0e+00
1.9e+00
—
1.2e+00
9.0e-01
3.4e-01
cases:6.97%
controls:3.30%
cases:3.80%
controls:1.39%
cases:1.59%
controls:0.24%
—
—
cases:1.01%
controls:0.29%
cases:2.93%
controls:1.22%
cases:5.94%
controls:4.31%
79
374
1054
10948
43
157
1090
11165
18
27
1115
11295
—
10
33
984
11276
18
135
596
10972
6
391
95
8684
Assessment of need for services (elderly/care support)
SPAT1217 [2001700318]
-2.6e-01
-5.9e-02
—
—
2.9e+00
1.7e+00
—
cases:0.71%
controls:0.91%
cases:0.44%
controls:0.47%
—
—
—
—
cases:0.80%
controls:0.04%
cases:2.61%
controls:0.49%
—
—
8
103
1125
11219
5
53
1128
11269
—
—
8
5
986
11304
16
54
598
11053
—
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
—
—
1.0e+50
—
2.6e+00
2.0e+00
—
—
—
—
—
cases:0.88%
controls:0.00%
—
—
cases:0.70%
controls:0.05%
cases:1.79%
controls:0.24%
—
—
—
—
10
0
1123
11322
—
7
6
987
11303
11
27
603
11080
—
oxazepam; oral
N05BA04 [21604569]
1.2e-01
1.4e-01
1.2e+00
2.3e+00
2.0e+00
1.4e+00
6.4e-01
cases:5.21%
controls:4.66%
cases:3.71%
controls:3.24%
cases:2.74%
controls:0.87%
cases:0.44%
controls:0.04%
cases:5.73%
controls:0.80%
cases:12.38%
controls:3.36%
cases:10.89%
controls:6.04%
59
528
1074
10794
42
367
1091
10955
31
99
1102
11223
5
5
1128
11317
57
91
937
11218
76
373
538
10734
11
548
90
8527
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
1.9e-01
2.0e-01
1.9e+00
—
2.7e+00
4.1e-01
2.7e-01
cases:7.41%
controls:6.24%
cases:3.18%
controls:2.62%
cases:1.41%
controls:0.22%
—
—
cases:3.62%
controls:0.26%
cases:3.91%
controls:2.63%
cases:8.91%
controls:6.98%
84
706
1049
10616
36
297
1097
11025
16
25
1117
11297
—
36
29
958
11280
24
292
590
10815
9
633
92
8442
ipratropium bromide; inhalant
R03BB01 [21603293]
9.6e-01
9.7e-01
1.1e+00
—
1.5e+00
1.2e+00
-1.0e+50
cases:3.71%
controls:1.46%
cases:2.65%
controls:1.02%
cases:0.88%
controls:0.29%
—
—
cases:1.31%
controls:0.31%
cases:3.58%
controls:1.15%
cases:0.00%
controls:1.62%
42
165
1091
11157
30
115
1103
11207
10
33
1123
11289
—
13
35
981
11274
22
128
592
10979
0
147
101
8928
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
-1.4e-01
3.2e-01
1.8e+00
—
1.7e+00
1.0e+00
8.5e-02
cases:8.03%
controls:9.09%
cases:7.24%
controls:5.35%
cases:3.80%
controls:0.64%
—
—
cases:4.33%
controls:0.84%
cases:14.50%
controls:5.81%
cases:17.82%
controls:16.62%
91
1029
1042
10293
82
606
1051
10716
43
72
1090
11250
—
43
95
951
11214
89
645
525
10462
18
1508
83
7567
vilanterol and fluticasone furoate
R03AK10 [43534841]
7.8e-01
1.4e+00
1.3e+00
—
1.2e+00
1.2e+00
1.9e+00
cases:1.41%
controls:0.65%
cases:1.94%
controls:0.49%
cases:0.53%
controls:0.15%
—
—
cases:0.60%
controls:0.18%
cases:1.95%
controls:0.59%
cases:6.93%
controls:1.10%
16
74
1117
11248
22
56
1111
11266
6
17
1127
11305
—
6
20
988
11289
12
65
602
11042
7
100
94
8975
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
-1.4e-01
3.0e-01
1.8e+00
—
1.7e+00
9.9e-01
1.3e-01
cases:8.21%
controls:9.35%
cases:7.24%
controls:5.46%
cases:3.88%
controls:0.66%
—
—
cases:4.43%
controls:0.85%
cases:14.66%
controls:6.00%
cases:18.81%
controls:16.87%
93
1059
1040
10263
82
618
1051
10704
44
75
1089
11247
—
44
96
950
11213
90
666
524
10441
19
1531
82
7544
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
-8.8e-02
2.8e-01
1.8e+00
—
1.7e+00
1.0e+00
1.3e-01
cases:8.74%
controls:9.47%
cases:7.24%
controls:5.57%
cases:3.88%
controls:0.68%
—
—
cases:4.53%
controls:0.88%
cases:15.15%
controls:6.02%
cases:18.81%
controls:16.90%
99
1072
1034
10250
82
631
1051
10691
44
77
1089
11245
—
45
99
949
11210
93
669
521
10438
19
1534
82
7541
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
5.1e-03
3.3e-01
9.4e-01
1.2e+00
1.4e+00
8.3e-01
9.3e-01
cases:31.33%
controls:31.22%
cases:23.57%
controls:18.16%
cases:8.38%
controls:3.45%
cases:0.53%
controls:0.17%
cases:13.28%
controls:3.56%
cases:35.02%
controls:18.99%
cases:61.39%
controls:38.56%
355
3535
778
7787
267
2056
866
9266
95
391
1038
10931
6
19
1127
11303
132
403
862
10906
215
2109
399
8998
62
3499
39
5576
macrogol; oral
A06AD15 [21600575]
4.1e-01
3.4e-01
—
—
2.4e+00
2.1e+00
—
cases:1.59%
controls:1.06%
cases:0.88%
controls:0.63%
—
—
—
—
cases:2.01%
controls:0.19%
cases:5.70%
controls:0.74%
—
—
18
120
1115
11202
10
71
1123
11251
—
—
20
22
974
11287
35
82
579
11025
—
Urgent procedure
ZXD05 [2001311386]
2.9e-01
4.3e-01
2.2e+00
—
2.3e+00
9.5e-01
-1.0e+50
cases:5.12%
controls:3.88%
cases:1.50%
controls:0.98%
cases:0.71%
controls:0.08%
—
—
cases:1.01%
controls:0.11%
cases:2.28%
controls:0.89%
cases:0.00%
controls:3.54%
58
439
1075
10883
17
111
1116
11211
8
9
1125
11313
—
10
12
984
11297
14
99
600
11008
0
321
101
8754
More than one and less than three hours
ZXE10 [2001311401]
3.1e-01
5.5e-01
2.3e+00
—
2.1e+00
9.0e-01
—
cases:6.97%
controls:5.21%
cases:2.29%
controls:1.33%
cases:1.32%
controls:0.13%
—
—
cases:0.80%
controls:0.10%
cases:2.61%
controls:1.08%
—
—
79
590
1054
10732
26
151
1107
11171
15
15
1118
11307
—
8
11
986
11298
16
120
598
10987
—
Heart failure, unspecified
I50.9 [45576879]
3.8e-01
7.3e-01
2.4e+00
—
1.3e+00
4.8e-01
-1.3e-01
cases:3.88%
controls:2.69%
cases:3.00%
controls:1.48%
cases:3.44%
controls:0.33%
—
—
cases:1.21%
controls:0.33%
cases:3.09%
controls:1.94%
cases:4.95%
controls:5.61%
44
305
1089
11017
34
167
1099
11155
39
37
1094
11285
—
12
37
982
11272
19
216
595
10891
5
509
96
8566
salmeterol and fluticasone
R03AK06 [21603280]
6.9e-01
8.2e-01
8.8e-01
-1.0e+50
1.3e+00
7.3e-01
9.5e-01
cases:6.80%
controls:3.53%
cases:6.09%
controls:2.76%
cases:2.29%
controls:0.96%
cases:0.00%
controls:0.06%
cases:3.22%
controls:0.92%
cases:6.03%
controls:3.01%
cases:11.88%
controls:4.96%
77
400
1056
10922
69
313
1064
11009
26
109
1107
11213
0
7
1133
11315
32
104
962
11205
37
334
577
10773
12
450
89
8625
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
1.7e-01
4.1e-01
2.9e+00
—
—
1.5e+00
1.4e+00
cases:1.68%
controls:1.42%
cases:0.97%
controls:0.64%
cases:1.59%
controls:0.09%
—
—
—
—
cases:2.61%
controls:0.61%
cases:7.92%
controls:1.98%
19
161
1114
11161
11
73
1122
11249
18
10
1115
11312
—
—
16
68
598
11039
8
180
93
8895
Pharmacy visit
OMOP4822462 [581458]
-1.1e-01
3.2e-01
8.5e-01
9.5e-01
1.2e+00
1.3e+00
2.4e-01
cases:89.76%
controls:90.70%
cases:90.11%
controls:86.88%
cases:73.52%
controls:54.23%
cases:6.35%
controls:2.56%
cases:80.38%
controls:54.04%
cases:96.74%
controls:88.78%
cases:97.03%
controls:96.26%
1017
10269
116
1053
1021
9837
112
1485
833
6140
300
5182
72
290
1061
11032
799
6111
195
5198
594
9861
20
1246
98
8736
3
339
Spirometry study
18759-1 [3000492]
5.8e-01
1.4e+00
2.9e+00
—
—
—
—
cases:3.18%
controls:1.80%
cases:1.94%
controls:0.47%
cases:1.15%
controls:0.06%
—
—
—
—
—
—
—
—
36
204
1097
11118
22
53
1111
11269
13
7
1120
11315
—
—
—
—
Band form neutrophils/Leukocytes in Blood
26508-2 [3004809]
1.5e+00
1.8e+00
1.0e+50
—
—
4.4e+00
—
cases:0.53%
controls:0.11%
cases:0.44%
controls:0.07%
cases:0.62%
controls:0.00%
—
—
—
—
cases:4.72%
controls:0.06%
—
—
6
13
1127
11309
5
8
1128
11314
7
0
1126
11322
—
—
29
7
585
11100
—
Haemoptysis
R04.2 [45577777]
—
1.8e+00
1.0e+50
—
—
2.5e+00
—
—
—
cases:0.88%
controls:0.14%
cases:2.47%
controls:0.00%
—
—
—
—
cases:1.30%
controls:0.11%
—
—
—
10
16
1123
11306
28
0
1105
11322
—
—
8
12
606
11095
—
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
1.8e-02
5.2e-01
1.4e+00
—
1.7e+00
1.2e+00
2.9e-01
cases:5.03%
controls:4.95%
cases:4.24%
controls:2.56%
cases:1.68%
controls:0.42%
—
—
cases:2.52%
controls:0.46%
cases:8.47%
controls:2.68%
cases:9.90%
controls:7.59%
57
560
1076
10762
48
290
1085
11032
19
47
1114
11275
—
25
52
969
11257
52
298
562
10809
10
689
91
8386
pH of Urine
2756-5 [3015736]
-1.6e-01
3.2e-01
1.9e+00
—
1.6e+00
8.1e-01
-3.8e-02
cases:6.44%
controls:7.49%
cases:5.65%
controls:4.15%
cases:2.91%
controls:0.43%
—
—
cases:2.82%
controls:0.59%
cases:9.12%
controls:4.29%
cases:11.88%
controls:12.29%
73
848
1060
10474
64
470
1069
10852
33
49
1100
11273
—
28
67
966
11242
56
476
558
10631
12
1115
89
7960
varenicline; oral
N07BA03 [21604819]
1.9e+00
2.4e+00
—
—
—
1.9e+00
—
cases:3.80%
controls:0.59%
cases:1.32%
controls:0.12%
—
—
—
—
—
—
cases:0.81%
controls:0.13%
—
—
43
67
1090
11255
15
14
1118
11308
—
—
—
5
14
609
11093
—
Cough
R05 [2002000886]
2.2e-01
1.1e+00
3.2e+00
—
-1.0e+50
—
—
cases:4.50%
controls:3.65%
cases:2.47%
controls:0.87%
cases:1.50%
controls:0.06%
—
—
cases:0.00%
controls:0.14%
—
—
—
—
51
413
1082
10909
28
99
1105
11223
17
7
1116
11315
—
0
16
994
11293
—
—
loperamide; oral
A07DA03 [21600646]
6.0e-01
1.2e+00
—
—
—
2.3e+00
1.9e+00
cases:1.06%
controls:0.58%
cases:0.97%
controls:0.29%
—
—
—
—
—
—
cases:2.93%
controls:0.29%
cases:5.94%
controls:0.93%
12
66
1121
11256
11
33
1122
11289
—
—
—
18
32
596
11075
6
84
95
8991
loperamide oxide; oral
A07DA05 [21600648]
6.0e-01
1.2e+00
—
—
—
2.3e+00
1.9e+00
cases:1.06%
controls:0.58%
cases:0.97%
controls:0.29%
—
—
—
—
—
—
cases:2.93%
controls:0.29%
cases:5.94%
controls:0.93%
12
66
1121
11256
11
33
1122
11289
—
—
—
18
32
596
11075
6
84
95
8991
Chron obstructive pulmonary disease
R95 [2002000960]
1.9e+00
2.4e+00
—
—
—
—
—
cases:2.21%
controls:0.35%
cases:1.41%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
25
40
1108
11282
16
15
1117
11307
—
—
—
—
—
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
-1.4e-01
3.4e-01
1.6e+00
—
1.6e+00
9.8e-01
-2.0e-02
cases:7.15%
controls:8.13%
cases:6.18%
controls:4.47%
cases:2.82%
controls:0.56%
—
—
cases:3.32%
controls:0.69%
cases:11.07%
controls:4.47%
cases:11.88%
controls:12.09%
81
921
1052
10401
70
506
1063
10816
32
63
1101
11259
—
33
78
961
11231
68
497
546
10610
12
1097
89
7978
Thorax and upper abdomen combined CT examination of
GD5AD [2001303655]
—
—
—
1.0e+50
—
—
4.2e+00
—
—
—
—
—
—
cases:0.44%
controls:0.00%
—
—
—
—
cases:9.90%
controls:0.17%
—
—
—
5
0
1128
11322
—
—
10
15
91
9060
Cerebral aneurysm, nonruptured
I67.1 [45538401]
1.6e+00
1.7e+00
—
—
1.0e+50
2.6e+00
-1.0e+50
cases:0.88%
controls:0.18%
cases:0.62%
controls:0.11%
—
—
—
—
cases:0.50%
controls:0.00%
cases:0.81%
controls:0.06%
cases:0.00%
controls:0.12%
10
20
1123
11302
7
13
1126
11309
—
—
5
0
989
11309
5
7
609
11100
0
11
101
9064
zopiclone; oral
N05CF01 [21604654]
1.0e-01
2.2e-01
1.1e+00
—
1.8e+00
1.4e+00
7.7e-01
cases:10.24%
controls:9.33%
cases:7.77%
controls:6.31%
cases:4.59%
controls:1.64%
—
—
cases:8.65%
controls:1.61%
cases:20.85%
controls:6.32%
cases:20.79%
controls:10.82%
116
1056
1017
10266
88
714
1045
10608
52
186
1081
11136
—
86
182
908
11127
128
702
486
10405
21
982
80
8093
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
—
—
—
—
—
2.4e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:4.23%
controls:0.40%
cases:10.89%
controls:2.09%
—
—
—
—
—
26
44
588
11063
11
190
90
8885
Physiotherapist
Z3226 [2001311560]
3.2e-01
6.0e-01
2.1e+00
—
—
2.1e+00
—
cases:2.47%
controls:1.80%
cases:0.71%
controls:0.39%
cases:0.62%
controls:0.08%
—
—
—
—
cases:2.12%
controls:0.27%
—
—
28
204
1105
11118
8
44
1125
11278
7
9
1126
11313
—
—
13
30
601
11077
—
Overnight pulse oximetry
252568001 [4091874]
4.2e-01
2.0e+00
—
—
—
2.1e+00
—
cases:0.62%
controls:0.41%
cases:0.71%
controls:0.10%
—
—
—
—
—
—
cases:1.14%
controls:0.14%
—
—
7
46
1126
11276
8
11
1125
11311
—
—
—
7
15
607
11092
—
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
2.8e-01
7.1e-01
2.0e+00
—
2.4e+00
1.7e+00
—
cases:2.91%
controls:2.22%
cases:1.06%
controls:0.52%
cases:0.44%
controls:0.06%
—
—
cases:0.60%
controls:0.05%
cases:2.44%
controls:0.47%
—
—
33
251
1100
11071
12
59
1121
11263
5
7
1128
11315
—
6
6
988
11303
15
52
599
11055
—
Creatine kinase.MB [Mass/volume] in Serum or Plasma
13969-1 [3005785]
9.3e-02
1.2e-01
2.9e+00
—
—
1.2e+00
—
cases:2.21%
controls:2.01%
cases:0.88%
controls:0.79%
cases:1.41%
controls:0.08%
—
—
—
—
cases:2.12%
controls:0.64%
—
—
25
228
1108
11094
10
89
1123
11233
16
9
1117
11313
—
—
13
71
601
11036
—
Otolaryngology
4 [38004449]
1.3e-01
7.3e-01
1.8e+00
—
1.5e+00
4.2e-01
6.3e-01
cases:12.62%
controls:11.27%
cases:8.12%
controls:4.07%
cases:3.80%
controls:0.64%
—
—
cases:2.82%
controls:0.62%
cases:6.35%
controls:4.27%
cases:21.78%
controls:12.96%
143
1276
990
10046
92
461
1041
10861
43
73
1090
11249
—
28
70
966
11239
39
474
575
10633
22
1176
79
7899
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
D38.1 [45605357]
—
—
—
1.0e+50
—
—
4.1e+00
—
—
—
—
—
—
cases:6.00%
controls:0.00%
—
—
—
—
cases:4.95%
controls:0.09%
—
—
—
68
0
1065
11322
—
—
5
8
96
9067
formoterol and budesonide
R03AK07 [21603281]
-2.1e-01
7.8e-01
2.0e+00
—
2.1e+00
8.0e-01
—
cases:1.24%
controls:1.52%
cases:1.68%
controls:0.78%
cases:1.24%
controls:0.17%
—
—
cases:1.31%
controls:0.17%
cases:2.12%
controls:0.96%
—
—
14
172
1119
11150
19
88
1114
11234
14
19
1119
11303
—
13
19
981
11290
13
107
601
11000
—
Emphysema, unspecified
J43.9 [45567264]
1.8e+00
1.6e+00
—
—
—
2.2e+00
—
cases:0.79%
controls:0.13%
cases:0.44%
controls:0.09%
—
—
—
—
—
—
cases:0.98%
controls:0.11%
—
—
9
15
1124
11307
5
10
1128
11312
—
—
—
6
12
608
11095
—
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
7.0e-01
1.3e+00
2.7e+00
—
2.1e+00
1.1e+00
—
cases:1.15%
controls:0.57%
cases:1.15%
controls:0.32%
cases:0.88%
controls:0.06%
—
—
cases:0.50%
controls:0.06%
cases:1.63%
controls:0.52%
—
—
13
65
1120
11257
13
36
1120
11286
10
7
1123
11315
—
5
7
989
11302
10
58
604
11049
—
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
-1.3e-01
4.6e-02
2.0e+00
—
2.0e+00
4.2e-01
—
cases:4.06%
controls:4.59%
cases:2.38%
controls:2.28%
cases:2.03%
controls:0.29%
—
—
cases:1.71%
controls:0.24%
cases:2.61%
controls:1.72%
—
—
46
520
1087
10802
27
258
1106
11064
23
33
1110
11289
—
17
27
977
11282
16
191
598
10916
—
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
-2.4e-01
-1.2e-02
—
—
1.3e+00
2.0e+00
1.9e+00
cases:0.88%
controls:1.12%
cases:0.79%
controls:0.80%
—
—
—
—
cases:0.91%
controls:0.24%
cases:6.68%
controls:0.93%
cases:8.91%
controls:1.43%
10
127
1123
11195
9
91
1124
11231
—
—
9
27
985
11282
41
103
573
11004
9
130
92
8945
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
2.6e-01
—
—
—
—
2.1e+00
1.9e+00
cases:1.15%
controls:0.88%
—
—
—
—
—
—
—
—
cases:1.79%
controls:0.23%
cases:5.94%
controls:0.96%
13
100
1120
11222
—
—
—
—
11
26
603
11081
6
87
95
8988
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
1.2e-01
1.9e-01
1.1e+00
—
1.6e+00
8.8e-01
1.4e+00
cases:3.35%
controls:2.98%
cases:1.77%
controls:1.47%
cases:0.79%
controls:0.26%
—
—
cases:1.71%
controls:0.36%
cases:3.58%
controls:1.51%
cases:10.89%
controls:2.79%
38
337
1095
10985
20
166
1113
11156
9
30
1124
11292
—
17
41
977
11268
22
168
592
10939
11
253
90
8822
ambroxol; oral
R05CB06 [21603385]
3.2e-01
1.1e+00
2.8e+00
—
—
6.0e-01
1.0e+00
cases:4.15%
controls:3.05%
cases:2.29%
controls:0.78%
cases:0.97%
controls:0.06%
—
—
—
—
cases:1.30%
controls:0.72%
cases:6.93%
controls:2.64%
47
345
1086
10977
26
88
1107
11234
11
7
1122
11315
—
—
8
80
606
11027
7
240
94
8835
General Surgery
2 [38004447]
-2.8e-02
3.3e-01
1.6e+00
—
1.6e+00
6.3e-01
-2.4e-01
cases:20.65%
controls:21.11%
cases:9.00%
controls:6.67%
cases:4.32%
controls:0.90%
—
—
cases:4.53%
controls:0.94%
cases:11.07%
controls:6.22%
cases:15.84%
controls:19.32%
234
2390
899
8932
102
755
1031
10567
49
102
1084
11220
—
45
106
949
11203
68
691
546
10416
16
1753
85
7322
Clinic/Center
261Q00000X [38004207]
3.9e-01
7.4e-01
-1.0e+50
—
—
3.8e+00
—
cases:0.97%
controls:0.66%
cases:0.44%
controls:0.21%
cases:0.00%
controls:0.05%
—
—
—
—
cases:5.05%
controls:0.12%
—
—
11
75
1122
11247
5
24
1128
11298
0
6
1133
11316
—
—
31
13
583
11094
—
Neurology
13 [38004458]
-1.2e-01
1.2e-01
1.8e+00
1.0e+50
1.2e+00
7.6e-01
2.4e-01
cases:10.41%
controls:11.55%
cases:5.74%
controls:5.13%
cases:4.15%
controls:0.69%
cases:0.62%
controls:0.00%
cases:2.92%
controls:0.88%
cases:9.77%
controls:4.83%
cases:17.82%
controls:14.59%
118
1308
1015
10014
65
581
1068
10741
47
78
1086
11244
7
0
1126
11322
29
100
965
11209
60
536
554
10571
18
1324
83
7751

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
291
183
21.05
307.65
1.3
1.2
—
—
—
0
0
264
416
7.97
167.77
2.1
1.4
32.34
2.91
ug/l
2.54
242
316
93
112
8.96
72.45
1.5
2.7
—
—
—
0
0
323
1263
3.18
61.67
4.3
2.3
0.77
0.83
mmol/l
11.94
313
1153
78
2928
0.21
44.94
1.7
2.0
1.60
1.29
mmol/l
1.09
65
2394
453
6971
0.42
44.10
6.3
7.4
41.81
40.89
mmol/mol
1.14
395
6401
487
7159
0.44
39.48
4.5
6.5
2.53
2.48
mmol/l
0.63
425
6529
462
6921
0.44
39.20
4.2
5.5
1.32
1.41
mmol/l
4.50
402
6281
469
6981
0.44
39.02
4.1
5.6
4.36
4.34
mmol/l
0.21
412
6393
447
6685
0.45
35.91
4.3
4.9
1.84
2.06
mu/l
2.65
391
5990
494
7115
0.46
35.64
4.7
5.7
6.37
6.14
mmol/l
2.48
427
6373
32
25
13.14
33.26
1.3
1.6
—
—
—
0
0
456
6646
0.48
31.91
3.8
4.7
1.44
1.27
mmol/l
4.47
396
5967
580
7744
0.49
30.63
40.6
25.0
124.92
134.25
g/l
40.05
572
7577
580
7742
0.49
30.56
40.3
24.8
4.13
4.42
e12/l
32.08
561
7457
580
7742
0.49
30.56
40.1
24.7
30.72
30.55
pg
1.45
572
7577
580
7742
0.49
30.56
40.7
25.3
37.63
39.97
%
26.10
571
7570
580
7741
0.49
30.53
40.4
24.9
255.29
234.94
e9/l
7.66
564
7492
580
7741
0.49
30.53
40.2
24.8
92.58
91.92
fl
2.64
572
7574
581
7745
0.49
30.36
40.3
24.9
7.94
6.95
e9/l
16.01
562
7462
581
7702
0.50
28.92
36.5
22.5
77.45
86.82
umol/l
7.47
570
7539
351
5416
0.49
26.43
3.6
3.9
15.48
15.08
pmol/l
1.62
302
4813
67
159
4.42
26.14
1.5
1.3
75.62
59.24
mmol/l
2.09
61
126
581
7612
0.51
26.06
32.6
21.3
4.02
4.03
mmol/l
0.27
569
7390
220
3990
0.44
25.92
1.9
2.3
88.10
92.87
pmol/l
0.78
124
2139
581
7603
0.52
25.78
32.8
21.2
137.10
139.76
mmol/l
35.30
570
7395
573
7502
0.52
24.92
17.8
10.6
28.05
25.09
u/l
2.06
561
7139
546
7251
0.52
24.80
24.4
15.6
—
—
—
0
0
223
3950
0.46
24.10
4.1
4.3
1.88
2.29
ug/l
1.87
193
3498
49
97
5.23
23.71
1.5
1.4
—
—
—
0
0
37
60
6.34
22.01
1.4
1.2
12.41
14.73
u/l
1.21
37
55
400
5723
0.53
21.64
36.0
22.0
331.25
331.75
g/l
0.50
393
5673
181
3358
0.45
21.47
1.8
2.3
71.11
78.15
nmol/l
2.91
157
2907
51
117
4.52
20.75
1.3
1.4
3545.11
1277.98
e6/l
1.36
45
82
376
2373
1.87
20.42
4.8
5.2
—
—
—
0
0
36
63
5.87
19.86
1.2
1.2
11.06
10.00
u/l
0.23
36
55
132
2655
0.43
18.79
1.6
1.8
17.36
19.55
nmol/l
0.97
120
2212
536
3837
1.75
18.67
9.6
3.8
10.84
12.69
umol/l
2.28
526
3604
45
104
4.46
18.15
1.3
1.4
24801.06
35473.98
e6/l
0.21
36
57
36
69
5.36
18.05
1.2
1.6
258.30
271.87
mosm/kgh2o
1.70
27
47
45
105
4.42
17.94
1.2
1.4
—
—
—
0
0
326
2039
1.84
17.79
2.2
1.7
—
—
—
0
0
385
2537
1.78
17.64
4.4
4.2
—
—
—
0
0
106
2250
0.42
16.98
2.6
3.0
0.79
0.77
ug/l
0.09
73
1584
175
3043
0.50
16.10
3.1
3.4
6.96
7.47
mmol/l
1.02
137
2542
24
13
18.83
16.04
1.0
1.0
—
—
—
0
0
529
3905
1.66
15.48
14.0
5.8
4.79
4.53
e9/l
1.38
482
3314
420
5638
0.59
15.31
35.4
20.4
14.74
13.81
%
28.22
415
5522
108
2198
0.44
15.31
3.4
3.8
—
—
—
0
0
198
3268
0.52
15.28
2.7
3.0
281.54
144.15
ug/l
5.50
182
2969
178
3009
0.52
14.70
3.0
3.5
74.19
49.80
mg/l
0.66
122
1982
185
3086
0.52
14.63
4.0
4.2
21.57
8.80
mg/mmol
1.01
117
1975
581
7168
0.61
14.53
29.7
16.9
32.38
27.74
mg/l
3.02
561
5979
271
3947
0.59
12.77
3.7
4.0
0.00
0.00
estimate
-0.00
81
829
277
4007
0.59
12.68
3.7
4.0
0.00
2.07
estimate
0.50
83
845
119
596
2.11
12.12
2.7
3.7
1.17
0.84
%
0.79
87
135
25
29
8.79
12.04
1.1
1.2
100.94
1.97
ug/l
—
20
10
283
4032
0.60
11.97
3.7
4.0
0.00
0.03
estimate
2.07
81
785
36
100
3.69
11.40
1.4
1.5
—
—
—
0
0
447
3339
1.56
11.38
5.7
5.5
8.86
9.15
%
1.07
441
3066
24
49
4.98
11.24
1.8
1.5
58.08
22.76
ng/l
1.38
24
49
34
93
3.74
11.01
1.4
1.8
73.93
29.04
u/ml
1.13
27
82
338
2383
1.60
10.97
5.1
3.2
7.40
7.40
ph
1.11
261
1735
438
3336
1.51
9.81
5.7
5.4
1.72
2.99
%
40.09
432
3064
220
3169
0.62
9.06
3.2
3.5
6.18
6.27
ph
0.62
126
1769
412
5200
0.67
9.02
4.0
4.5
—
2.94
—
0
7
107
574
1.95
9.01
2.7
3.5
0.82
0.67
%
0.33
79
135
106
578
1.92
8.51
2.7
3.7
0.23
0.05
%
0.87
75
119
209
3008
0.63
8.45
4.0
4.0
0.00
0.02
estimate
1.87
72
678
154
2344
0.60
7.79
2.5
2.3
3.27
2.85
mg/l
1.64
137
1980
85
444
1.99
7.74
4.8
3.6
—
—
—
0
0
114
1871
0.57
7.71
4.2
4.2
1.02
1.02
kg/l
0.40
90
1226
40
152
2.69
7.61
1.8
1.9
122.17
47.70
u/ml
0.37
35
116
45
182
2.53
7.57
4.0
4.6
2.82
2.57
mmol/l
0.26
34
116
457
3644
1.43
7.54
5.1
5.3
0.70
0.63
e9/l
4.50
407
3068
458
3661
1.42
7.42
5.1
5.3
0.04
0.04
e9/l
0.02
410
3086
112
653
1.79
7.29
4.5
3.6
5.37
5.16
kpa
1.50
106
616
461
3703
1.41
7.21
5.3
5.4
1.77
1.76
e9/l
0.02
415
3203
108
628
1.80
7.09
2.5
1.7
514.17
371.69
nmol/l
3.26
103
569
109
638
1.78
7.00
4.6
3.6
7.43
7.41
ph
1.50
99
530
464
3766
1.39
6.69
5.3
5.4
0.15
0.21
e9/l
12.40
414
3221
437
3518
1.39
6.59
6.0
3.7
32.03
34.86
g/l
17.76
413
3206
333
2582
1.41
6.17
5.6
2.0
2.37
2.34
mmol/l
3.15
311
2233
456
3728
1.37
6.14
7.2
5.4
1.21
1.20
mmol/l
0.52
445
3352
101
603
1.74
6.08
2.8
3.8
0.07
0.02
%
0.76
71
114
123
1869
0.62
6.01
1.7
1.8
1084.76
1138.03
nmol/l
0.28
97
1414
131
1955
0.63
5.91
1.7
1.8
434.10
24567449.76
pmol/l
1.46
109
1559
496
4132
1.36
5.84
7.5
5.7
1.21
1.21
mmol/l
0.59
426
3507
65
1131
0.55
5.32
1.3
1.3
23.86
11.78
u/ml
0.57
21
394
43
201
2.18
5.31
3.8
4.1
—
—
—
0
0
6
265
0.22
5.26
1.2
1.1
—
121.00
—
0
6
30
120
2.54
5.24
1.8
2.4
—
—
—
0
0
72
1184
0.58
4.80
1.3
1.3
121.17
39.65
iu/ml
1.17
25
353
219
1650
1.41
4.65
5.5
2.1
2.54
2.45
mmol/l
16.70
201
1442
14
401
0.34
4.26
2.0
2.0
—
—
—
0
0
92
1375
0.64
4.11
1.1
1.3
0.82
1.55
u/ml
1.63
18
366
14
35
4.04
4.10
3.6
3.3
0.86
1.06
index
0.55
14
35
176
2320
0.71
4.06
3.7
4.0
0.00
0.00
estimate
0.50
65
735
258
3198
0.75
3.97
2.8
3.3
1640.27
1889.61
ng/l
0.24
237
2782
224
2827
0.74
3.89
2.3
2.3
273.85
263.82
u/l
0.04
208
2640
90
600
1.54
3.58
4.0
4.3
—
—
—
0
0
154
2018
0.73
3.38
3.7
3.6
0.00
0.01
estimate
1.15
64
630
69
1044
0.64
3.27
1.4
1.2
—
—
—
0
0
35
184
1.93
3.27
2.0
2.5
33.03
33.63
umol/l
0.07
29
166
478
4195
1.24
3.16
12.4
19.9
1.23
1.41
inr
10.04
400
3539
105
747
1.45
3.08
2.0
1.6
65.25
66.35
g/l
0.86
95
664
205
1631
1.31
3.02
2.4
2.8
530.25
538.16
mosm/kgh2o
0.21
176
1422
167
2116
0.75
2.90
2.8
2.6
340.79
368.37
umol/l
1.77
145
1771
15
58
2.61
2.88
1.0
1.1
—
—
—
0
0
379
4336
0.81
2.80
5.1
3.1
103.83
51.53
u/l
5.06
351
3937
22
107
2.08
2.58
2.1
2.0
88.80
89.72
%
0.34
22
107
456
5093
0.82
2.58
4.2
4.7
35.33
3660.86
e6/l
—
9
109
21
405
0.51
2.50
1.2
1.4
—
60.99
—
0
26
208
2512
0.79
2.46
2.8
3.3
—
—
—
0
0
40
634
0.62
2.38
2.5
2.9
6.19
6.05
ph
0.40
32
466
87
1177
0.72
2.33
1.1
1.3
3.07
2.84
g/l
0.35
49
671
105
788
1.37
2.31
4.3
3.5
7.36
7.36
ph
0.10
98
516
12
274
0.43
2.30
10.2
11.4
—
—
—
0
0
23
418
0.54
2.29
2.5
2.4
—
—
—
0
0
7
19
3.70
2.15
1.6
1.5
1689.71
58.47
nmol/24h
—
7
19
31
509
0.60
2.15
1.7
2.2
11.41
15.28
nmol/l
2.59
24
453
0
57
0.00
2.05
0.0
1.2
—
—
—
0
0
5
148
0.33
2.00
2.0
1.8
183.80
209.28
pmol/l
—
5
139
5
11
4.56
1.94
1.0
1.0
—
—
—
0
0
143
1157
1.27
1.88
1.7
2.0
—
—
—
0
0
116
1452
0.78
1.84
2.1
2.5
11.29
12.15
umol/l
0.61
109
1320
5
12
4.18
1.82
1.0
1.2
34.00
18.00
u/l
—
5
6
20
108
1.87
1.82
3.4
2.6
5.40
4.73
e9/l
0.45
20
108
78
584
1.36
1.79
1.7
1.6
—
—
—
0
0
8
29
2.77
1.79
1.8
2.3
—
—
—
0
0
11
233
0.47
1.79
2.5
4.3
—
—
—
0
0
71
944
0.74
1.75
2.4
2.5
4.00
6.88
ug/l
3.18
60
815
135
1096
1.26
1.74
5.6
6.4
7.42
7.41
ph
0.22
87
648
108
1346
0.78
1.67
2.1
2.5
2.18
2.23
g/l
0.37
97
1222
6
19
3.17
1.66
4.0
1.9
0.59
0.61
mmol/l
—
6
19
10
209
0.47
1.59
1.4
1.3
—
—
—
0
0
134
1100
1.25
1.58
5.6
6.4
1.73
1.11
mmol/l
0.78
107
887
19
320
0.59
1.52
1.4
1.2
112.63
97.79
u/ml
—
6
118
70
905
0.76
1.45
1.2
1.3
378.95
559.45
titre
1.04
19
220
5
16
3.13
1.44
2.4
1.1
—
—
—
0
0
133
1106
1.23
1.41
5.6
6.4
5.10
5.07
kpa
0.09
122
1060
133
1106
1.23
1.41
5.6
6.4
10.22
11.10
kpa
1.57
122
1060
12
223
0.53
1.37
3.4
3.1
7.46
7.76
mmol/l
0.15
12
214
15
82
1.84
1.36
1.5
1.4
—
—
—
0
0
15
82
1.84
1.36
1.5
1.4
—
—
—
0
0
15
82
1.84
1.36
1.5
1.4
—
—
—
0
0
15
82
1.84
1.36
1.5
1.4
—
—
—
0
0
164
1399
1.20
1.36
4.0
4.1
—
—
—
0
0
0
37
0.00
1.34
0.0
1.4
—
5.33
—
0
6
74
578
1.30
1.33
4.1
3.9
—
—
—
0
0
11
54
2.05
1.33
1.3
1.2
—
—
—
0
0
0
40
0.00
1.32
0.0
1.3
—
156.60
—
0
40
326
3586
0.87
1.30
4.0
4.5
26.84
143.41
ng/l
1.61
285
2857
21
130
1.63
1.27
4.6
2.5
58.81
60.26
%
0.12
21
130
15
254
0.59
1.26
3.3
3.1
1.40
1.72
mmol/l
1.29
15
245
20
315
0.63
1.26
3.8
1.8
—
—
—
0
0
38
270
1.42
1.25
5.4
5.1
1.34
1.40
mmol/l
0.20
28
240
53
693
0.75
1.22
1.3
1.3
—
—
—
0
0
32
221
1.46
1.22
4.3
3.6
6.57
1.55
index
1.43
23
114
5
19
2.64
1.21
1.0
1.0
—
—
—
0
0
5
20
2.51
1.15
1.6
2.3
—
—
—
0
0
105
1244
0.83
1.07
2.3
2.6
20.94
21.91
%
0.30
98
1135
29
406
0.71
1.05
1.0
1.2
755.67
298.14
u/ml
0.48
24
375
129
1107
1.19
1.03
4.0
4.5
1.07
1.02
mmol/l
0.61
121
992
20
298
0.67
1.02
1.6
1.5
50.01
36.42
mg/l
0.57
14
250
20
298
0.67
1.02
1.6
1.5
59.38
52.82
mg/l
0.18
15
249
270
2962
0.88
1.01
3.5
3.9
35.14
129.60
e6/l
6.17
211
2168
95
795
1.21
1.00
3.3
2.2
12.50
8.49
umol/l
0.91
80
700
49
625
0.77
0.98
3.1
3.8
98.44
95.98
ng/l
0.05
42
527
0
30
0.00
0.97
0.0
1.1
—
1.51
—
0
15
0
31
0.00
0.96
0.0
1.2
—
28.20
—
0
26
0
31
0.00
0.96
0.0
1.2
—
138.65
—
0
26
234
2115
1.13
0.95
11.3
4.6
—
—
—
0
0
0
32
0.00
0.95
0.0
1.4
—
135.30
—
0
23
18
269
0.66
0.94
1.6
1.4
1.43
1.37
ratio
0.17
11
158
6
28
2.15
0.91
1.3
1.1
—
—
—
0
0
99
1154
0.84
0.87
2.7
2.0
2.05
1.74
%
1.75
90
1014
16
240
0.66
0.86
1.0
1.3
—
—
—
0
0
60
488
1.24
0.85
1.2
1.1
—
—
—
0
0
161
1804
0.87
0.84
3.6
4.5
166.73
431.65
ng/l
2.37
137
1568
6
111
0.54
0.83
3.0
2.5
1.21
1.18
mmol/l
—
6
111
6
114
0.52
0.83
3.0
2.5
104.67
105.56
mmol/l
—
6
114
6
114
0.52
0.83
3.0
2.5
4.13
4.09
mmol/l
—
6
114
73
870
0.83
0.82
2.8
2.0
80.00
65.74
e9/l
1.60
48
663
0
24
0.00
0.79
0.0
1.1
—
96.20
—
0
24
0
25
0.00
0.79
0.0
1.1
—
1797.80
—
0
25
77
650
1.20
0.78
2.3
2.2
38.84
34.66
u/l
0.25
67
513
0
27
0.00
0.77
0.0
1.3
—
23.00
—
0
18
0
28
0.00
0.76
0.0
1.1
—
3.11
—
0
12
36
459
0.78
0.76
1.1
1.3
—
—
—
0
0
36
458
0.78
0.75
1.1
1.2
—
—
—
0
0
502
4783
1.09
0.73
6.3
4.8
6.85
6.91
mmol/l
0.30
487
4554
26
345
0.75
0.73
1.5
1.3
—
—
—
0
0
247
2278
1.11
0.72
5.2
2.5
45.52
34.99
u/l
0.71
232
2122
247
2284
1.10
0.69
2.4
2.2
—
—
—
0
0
5
28
1.79
0.66
1.8
2.6
455.80
1214.75
u/ml
—
5
28
32
250
1.29
0.66
2.4
2.3
116.82
131.50
g/l
0.99
17
202
5
29
1.73
0.64
1.6
2.4
49.88
45.12
%
—
5
29
62
526
1.19
0.63
1.3
1.4
—
—
—
0
0
89
781
1.15
0.60
5.7
5.5
11.12
11.89
mmol/l
0.29
80
731
0
20
0.00
0.60
0.0
7.5
—
5.26
—
0
20
23
176
1.31
0.56
1.2
1.2
—
—
—
0
0
5
86
0.58
0.56
1.2
1.3
186.20
340.52
nmol/l
—
5
75
57
490
1.17
0.52
7.8
8.7
15.60
15.78
%
0.20
50
478
22
281
0.78
0.51
1.0
1.2
—
—
—
0
0
22
280
0.78
0.50
2.2
2.5
522.54
344.18
mg/l
0.34
13
92
31
252
1.24
0.50
2.7
2.2
352.04
85.82
ug/min
1.09
16
141
22
172
1.28
0.48
1.1
1.2
—
—
—
0
0
108
979
1.11
0.47
3.0
3.2
5.77
5.84
kpa
0.25
103
943
56
642
0.87
0.46
1.6
1.5
—
—
—
0
0
179
1914
0.92
0.43
2.7
2.5
7.21
4.62
e6/l
1.69
169
1734
10
70
1.43
0.41
1.2
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
4.01
—
0
6
0
17
0.00
0.40
0.0
1.2
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
28
336
0.83
0.40
3.7
3.9
1.80
1.48
mmol/l
0.60
28
327
0
18
0.00
0.40
0.0
1.2
—
1.68
—
0
13
22
270
0.81
0.39
1.8
3.3
0.77
0.82
nmol/l
0.25
15
211
78
863
0.90
0.39
2.5
3.3
201.18
286.52
ng/l
1.13
71
807
5
35
1.43
0.39
1.8
2.1
58.00
54.32
umol/l
—
5
30
5
35
1.43
0.39
1.2
1.2
—
—
—
0
0
84
762
1.11
0.38
6.0
7.1
—
—
—
0
0
105
965
1.10
0.38
3.0
3.2
1.93
1.88
mmol/l
0.04
86
817
5
37
1.35
0.37
2.6
3.4
—
—
—
0
0
15
191
0.78
0.37
1.1
1.1
—
795.71
—
0
7
82
898
0.91
0.35
1.9
1.8
—
—
—
0
0
166
1760
0.93
0.34
1.3
1.3
—
—
—
0
0
15
188
0.80
0.33
3.3
3.7
31.31
28.63
mg/l
—
10
139
17
137
1.24
0.32
1.5
2.1
3.20
41.24
iu/l
—
7
63
69
629
1.10
0.31
1.3
1.5
—
—
—
0
0
11
84
1.31
0.30
1.2
1.2
1.18
1.50
nmol/l
0.78
11
76
35
308
1.14
0.28
5.3
3.4
4.26
4.36
pmol/l
0.16
30
262
30
343
0.87
0.27
1.2
1.6
—
26.90
—
0
7
49
443
1.11
0.26
1.6
2.2
10.40
11.07
g/l
0.44
41
407
5
75
0.67
0.26
3.8
3.2
39.92
43.77
mg/l
—
5
57
16
192
0.83
0.25
1.2
1.2
569.06
554.91
mg/l
0.05
16
181
9
73
1.23
0.25
1.2
1.1
—
—
—
0
0
81
869
0.93
0.25
1.5
1.4
—
—
—
0
0
235
2266
1.05
0.24
2.8
3.2
0.77
0.43
e6/l
1.28
181
1699
17
143
1.19
0.23
1.2
1.1
—
—
—
0
0
7
94
0.74
0.22
1.7
1.2
—
—
nmol/l
—
0
0
562
5715
0.97
0.21
13.8
5.5
105.03
78.26
u/l
11.34
554
5264
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
6.91
—
0
7
8
104
0.77
0.21
1.1
1.2
—
—
—
0
0
5
43
1.16
0.21
2.6
3.3
—
—
—
0
0
316
3244
0.96
0.21
2.6
2.5
—
—
estimate
—
0
0
0
13
0.00
0.21
0.0
1.5
—
42.54
—
0
13
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
254
2465
1.04
0.20
2.7
2.3
64.33
61.84
u/l
0.18
227
2251
6
49
1.23
0.20
1.2
1.1
—
—
—
0
0
6
51
1.18
0.19
3.3
1.8
87.33
95.82
umol/l
—
6
51
7
58
1.21
0.18
1.0
1.3
—
—
—
0
0
105
1002
1.05
0.17
3.0
3.2
7.39
7.38
ph
0.26
54
592
264
2709
0.97
0.17
3.0
3.3
55.29
106.81
e6/l
0.79
208
2112
8
71
1.13
0.16
1.5
1.5
16.14
16.52
%
—
8
71
6
78
0.77
0.15
3.2
1.2
—
—
—
0
0
6
80
0.75
0.15
1.5
1.5
8.00
7.81
mmol/l
—
6
80
9
81
1.11
0.15
1.8
1.3
—
—
—
0
0
27
246
1.10
0.14
1.9
1.6
25.00
22.80
u/ml
—
5
44
8
98
0.82
0.13
1.0
1.0
—
—
—
0
0
134
1383
0.96
0.13
2.5
3.1
0.88
1.07
e6/l
0.42
61
777
9
106
0.85
0.13
1.4
1.2
0.51
17.68
nmol/l
—
9
100
86
827
1.04
0.12
3.0
2.7
4.20
4.40
kpa
0.48
81
789
10
116
0.86
0.12
1.0
1.2
—
—
—
0
0
312
3172
0.98
0.11
15.6
10.7
0.00
0.00
e9/l
2.15
241
2566
32
298
1.08
0.11
1.2
1.3
—
—
—
0
0
48
506
0.95
0.11
1.4
1.4
—
—
—
0
0
131
1279
1.03
0.09
2.5
3.2
2.95
1.75
e6/l
0.47
59
667
6
56
1.07
0.08
1.2
1.1
—
—
—
0
0
6
58
1.03
0.08
1.5
1.2
68.22
30.03
iu/l
—
6
47
5
63
0.79
0.08
1.0
1.4
—
—
—
0
0
8
75
1.07
0.07
1.4
1.2
—
—
—
0
0
8
76
1.05
0.07
1.3
1.8
309.63
279.43
mu/l
—
8
68
18
194
0.93
0.07
1.2
1.1
—
—
—
0
0
28
295
0.95
0.06
1.1
1.2
—
—
—
0
0
11
99
1.11
0.06
1.0
1.4
102.80
259.80
pmol/l
—
5
84
9
103
0.87
0.06
1.0
1.0
—
—
—
0
0
10
111
0.90
0.06
1.0
1.1
36.80
111.50
iu/ml
—
5
14
65
632
1.03
0.06
6.2
6.3
25.45
24.48
mmol/l
0.77
59
611
35
364
0.96
0.05
1.2
1.3
0.86
1.22
g/l
2.01
30
336
14
132
1.06
0.02
1.1
1.1
—
—
—
0
0
11
116
0.95
0.00
2.4
2.8
—
—
—
0
0
154
1542
1.00
0.00
1.5
1.6
2.17
1.40
mg/l
0.67
129
1206
20
195
1.03
0.00
1.4
1.4
302.67
307.82
ug/g
0.04
12
125
5
54
0.93
0.00
1.2
1.1
2.04
2.53
mmol/l
—
5
48
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
5
52
0.96
-0.00
2.4
2.8
—
—
—
0
0
8
81
0.99
-0.00
1.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
28.8
—
0.24
—
0
5
5
51
0.98
-0.00
1.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
371.56
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
201.80
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
345.00
—
0
5
5
51
0.98
-0.00
1.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
2.07
—
0
6
9
99
0.91
-0.00
1.3
1.8
11.49
10.16
%
—
9
99
6
61
0.98
-0.00
1.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
100.57
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_SCLC – Small cell lung cancer

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).